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Abstract 
 
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune 
response and a critical vaccine candidate. However, Env is densely glycosylated and 
thereby substantially protected from neutralisation. Despite the importance of the HIV-
1 Env glycans, limited computational analyses have been employed to analyse these 
glycans. 
 
Here, the Env glycans of two HIV-1 wild-type subtype C isolates are examined, in 
detail, using computational approaches. These particular strains were used since in 
vitro data showed that the removal of a single glycan had a substantially different 
impact on the neutralisation sensitivity of the two strains. Molecular dynamics 
simulations, and the subsequent analyses, were carried out on the computationally 
determined, fully glycosylated, Env structures of these two wild-type strains and their 
N301A mutant counterparts.  
 
Detailed comparison of the molecular dynamics simulations demonstrated that unique 
glycan dynamics and conformations emerged and that, despite shared HXB2 
reference sequence positions, the glycans adopted distinct conformations specific to 
each wild-type model. Furthermore, different changes in conformations were observed 
for each wild-type model compared to its N301A mutant counterpart and, interestingly, 
these N301A mutant model-specific glycan conformations were directly associated 
with the protein residues ultimately found to be exposed, which may explain the varied 
resistance to neutralising antibodies observed, in vitro, for the two N301A mutant 
strains.  
 
A further detailed analysis was carried out focussing on the strain that remained 
resistant to frequently elicited neutralising antibodies, and displayed increased 
resistance to a CD4-binding site bNAb, despite the loss of glycan N301. The results 
complemented the laboratory study and revealed that, in silico, the glycan shield of 
this strain retained its ability to shield the protein residues even after the removal of 
glycan N301 from the wild-type model. Moreover, the change in the glycan landscape, 
and cascade of events, that contributed towards the maintenance of this glycan shield 
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and the increased resistance to a bNAb epitope located at the edge of the cascade, 
were discernible. 
 
This study has demonstrated that the landscape of the glycan shield contains 
immense diversity, and that glycans that share an HXB2 reference sequence position 
will not necessarily conform in shape, dynamics and function between different strains. 
These conformational differences ultimately determine whether or not the glycan 
shield can compensate for the loss of a glycan, which directly relates to the 
fundamental function of the glycans in their ability to shield and protect the virus from 
immune surveillance. Additionally, this study highlights the remarkable potential of 
molecular dynamics simulations, which can be used as a powerful predictive 
technique to facilitate, and direct, laboratory studies focussing on vaccine research. 
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 1 
Introduction  
 
The human immunodeficiency virus-1 (HIV-1) envelope (Env) glycoprotein trimer is 
extensively glycosylated with host-derived glycans. These glycans impede the 
engagement of frequently elicited neutralising antibodies, effectively shielding the 
virus from immune surveillance. However, the dense glycosylation on the Env trimer 
surface also limits the actions of the glycan-processing enzymes, which leads to an 
abundance of under-processed oligomannose glycans. Since this feature of the glycan 
shield is conserved, antibodies that target these oligomannose glycans achieve 
remarkable breadth. While glycan-targeting broadly neutralising antibodies (bNAbs) 
provide hope for the development of a vaccine, the isolation of viral isolates harbouring 
escape mutations from infected individuals who develop bNAbs, is of concern. These 
escape mutations have been related to shifted or deleted N-glycosylation sites and, 
therefore, the glycan shield is of particular interest both in its susceptibility to, and 
escape from, bNAbs. However, despite the importance of these glycans, to date, the 
computational analyses employed to analyse HIV-1 Env glycans are limited. Thus, this 
thesis explores the characteristics of the HIV-1 Env glycan shield using molecular 
dynamics simulations, with particular focus on the effect of removing a glycan from a 
wild-type model, as well as the application of various analysis techniques to this 
context. 
 
Chapter 1 is aimed at understanding both the features of HIV-1 Env glycans, as well 
as the requirements necessary to perform, and analyse, molecular dynamics 
simulations of the HIV-1 Env protein and its glycans. Therefore, a broad background 
on HIV, glycans and molecular dynamics simulations is provided. The first section 
includes an overview of the Env glycoprotein focusing on its biosynthesis and the 
experimental and computational approaches that have been employed to understand 
the HIV-1 Env glycans. The second section describes structural and conformational 
considerations relevant to the study of HIV-1 Env glycans, and the chapter concludes 
with a description of the underlying theory of molecular dynamics simulations as well 
as the requirements for applying it to molecular models. 
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In Chapter 2, the two wild-type HIV-1 subtype C isolates used throughout this thesis 
are introduced. These particular strains were of interest since in vitro data showed that 
the absence of glycan N301 had a substantially different effect on the neutralisation 
sensitivity of the two strains. Therefore, in order to understand the difference in the 
glycan shields of these two strains, and the differential impact of removing glycan 
N301, the fully glycosylated Env structures of these strains were computationally 
determined. Thus, Chapter 2 presents the computational approaches used to both 
predict the three-dimensional (3D) structures of experimentally undetermined HIV-1 
Env trimers as well as to glycosylate these trimers. Since numerous modelling options 
and parameters exist, for each of the software packages used, the prerequisites are 
described and the various features investigated. Finally, with the established 
framework for determining the HIV-1 Env glycoprotein trimer models, the preliminary 
analysis aimed at understanding the impact of removing glycan N301 by using these 
static state representations, is described.  
 
The static state representations determined in Chapter 2, however, offered relatively 
limited information since the molecules are dynamic, changing conformation over time. 
Therefore, Chapter 3 extended the analysis by comparing the molecular dynamics 
simulations of the modelled structures (two wild-type models and their N301A mutant 
counterparts). Several methods were applied to individual, or clusters of, glycan/s in 
order to describe the surroundings, conformations and potential functions of the 
glycans. These results were then compared between the wild-type models, between 
a wild-type model and its N301A mutant counterpart, and between the N301A mutant 
models. The differences between the N301A mutant model simulations are discussed 
in relation to their wild-type model counterparts, with specific focus on the integrity of 
the modelled glycan shields of the two strains. Therefore, Chapter 3 built upon Chapter 
2 and included information on the changes in glycan conformations over time for each 
model.   
 
During the analysis performed in Chapter 3, glycans that were conformational 
heterogeneous between each wild-type model and its N301A mutant counterpart were 
identified. Interestingly, some of these glycans were not in the immediate vicinity of 
the N301A mutation. The conformational heterogeneity of these glycans that are not 
located near the N301A mutation may explain why one of the strains remained 
https://etd.uwc.ac.za
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resistant to frequently elicited neutralising antibodies and displayed increased 
resistance to a CD4-binding site bNAb despite the loss of glycan N301. Therefore, in 
order to further investigate the resistant strain and directly associate the 
conformational heterogeneity of its glycans with the N301A mutation, a more detailed 
comparison between this wild-type model and its N301A mutant counterpart was 
carried out in Chapter 4. A method that determines the glycan nearest to each amino 
acid residue over time is described and used to illustrate how changes in glycan 
conformations impact their ability to protect surrounding residues of the underlying 
protein. Finally, the cascade of conformational changes that occurred after glycan 
N301 was removed is described. This analysis offers one explanation of how glycans 
further from the N301A mutation site could be impacted by the N301A mutation. 
Furthermore, results are presented that link the cascade of glycan conformational 
changes with the increased resistance to the CD4-binding site bNAb (observed in 
vitro), thereby providing a definitive hypothesis for, and connecting the computational 
analysis with, the laboratory findings.  
 
Finally, Chapter 5 provides a summary of the main findings of this thesis and presents 
clear avenues for future work.   
https://etd.uwc.ac.za
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Chapter 1 Background 
 
1.1 The Human Immunodeficiency Virus 
 
Human immunodeficiency virus (HIV) is a lentivirus of the retrovirus family that can 
cause acquired immunodeficiency syndrome (AIDS) in humans. Despite the 
development of antiretroviral therapies, HIV remains one of the greatest global health 
burdens. Approximately 1.8 million people were newly infected with HIV in 2017 and 
36.9 million people were already living with HIV at the time1. An effective prophylactic 
vaccine is therefore essential, but remains elusive despite tremendous progress in our 
understanding of HIV infection and the substantial investments in vaccine research 
and clinical trials2–10. A key scientific challenge in the field of HIV vaccine development 
is the design of immunogens that elicit antibodies capable of neutralising HIV despite 
its immense global diversity2–10. 
 
Two types of HIV have been characterised, HIV-1 and HIV-2, which originated from 
simian immunodeficiency virus (SIV) through multiple cross-species transmission 
events from non-human primates to humans11–17. Compared to HIV-1 infection, those 
infected with HIV-2 generally have longer asymptomatic stages, lower virus titers, and 
lower transmission rates; these particular differences contribute to the confinement of 
HIV-2 to West Africa18. HIV-1, on the other hand, is the cause of the majority of HIV 
infections globally and is currently the main focus for HIV researchers.  
 
HIV-1 is an assortment of genetically related, but phylogenetically diverse, viruses, 
which are classified into four groups (M, N, O, and P)19–21. Group M is responsible for 
the current worldwide pandemic and is further divided into nine major subtypes (A, B, 
C, D, F, G, H, J, and K)19–21. Superinfection or co-infection with one or more subtypes 
within an individual has led to more than 100 circulating recombinant forms (CRFs)19–
21. Subtypes A-D, and the recombinant forms CRF01_AE and CRF02_AG, cause the 
majority of HIV-1 infections; however, subtype C alone accounts for half of all HIV-1 
infections worldwide20.  
 
https://etd.uwc.ac.za
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HIV-1 is transmitted by the exchange of bodily fluids, which includes sexual contact, 
needle sharing by injecting drug users, and transmission from mother to child22. The 
main transmission route of HIV-1 infection is via sexual contact and requires that the 
virus cross a mucosal barrier22. Therefore, the first cells to encounter HIV-1 are the 
dendritic cells and macrophages located in vaginal mucosa, oral mucosa and male 
foreskin22. Both dendritic cells and macrophages express low levels of the surface 
protein, CD4, required by HIV-1 for binding and entry23–25. Following transmission, the 
progression from initial to chronic infection includes the spread of HIV-1 throughout 
the body’s CD4+ T cells, i.e. T cells that express a CD4 receptor26. The depletion of 
these cells is a hallmark of HIV-1 infection26.  
 
Like many other viruses, HIV-1 uses the cellular biosynthesis pathways of host cells 
to replicate27. This requires the virus to enter a host cell, a process initiated by the HIV-
1 surface glycoprotein, envelope (Env). Briefly, the Env glycoprotein comprises two 
subunits, gp120 and gp41, and of these, the gp120 subunit binds the CD4 receptor of 
the targeted host cell and initiates a series of conformational changes that enables 
binding to a chemokine co-receptor, either C-C chemokine receptor type 5 (CCR5) or 
CXC-chemokine receptor type 4 (CXCR4)28–30. After co-receptor binding, structural 
changes in the gp41 subunit of the HIV-1 envelope glycoprotein mediate fusion 
between the virion and host cell membranes27. 
 
Upon fusion, the HIV-1 capsid, which contains the viral RNA and enzymes, enters the 
host cell cytoplasm31; uncoating and degradation of the viral core takes place and the 
RNA is liberated from attached viral proteins and coded into complementary DNA 
(cDNA) by reverse transcriptase31,32. The cDNA forms a double-stranded viral DNA 
molecule and is transported into the cell nucleus by another viral enzyme, integrase33. 
The final step, assembly of a new HIV-1 virion, begins at the plasma membrane of the 
host cell. The polyproteins associate with the inner surface of the plasma membrane 
along with the HIV-1 RNA, after which the immature virion buds from the host cell and 
is then assembled to produce a mature HIV-1 virion capable of infecting another cell33. 
 
This HIV-1 replication cycle, where viral RNA is reverse transcribed into DNA33, is 
relatively short, lasting only approximately 2.5 days34. This process is performed by 
the viral enzyme reverse transcriptase, which is highly error-prone35 compared to other 
https://etd.uwc.ac.za
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transcription processes performed by mammalian cells where various proofreading 
and error correction mechanisms exist36. The short replication cycle and error-prone 
reverse transcription leads to diverse populations of viral particles, which are 
commonly referred to as the quasispecies37. While certain mutations may result in 
non-functioning viral particles38, others may result in increased fitness, particularly in 
the presence of a immune reaction38. As will be noted in section 1.1.1, a subset of 
individuals develop particularly broad and potent neutralising antibodies capable of 
neutralising a wide range of HIV-1 viruses39–43. However, this does not provide a 
clinical benefit for these individuals since escape mutations, present on the Env 
glycoprotein, flourish under the selection pressure leading to a “new” quasispecies, 
rendering the neutralising antibodies ineffective against the viruses expressing the 
mutated, and thus resistant, Env glycoproteins42,44. 
 
1.1.1 The HIV-1 Env glycoprotein 
 
HIV-1 Env, which mediates cell entry (as described in section 1.1), is the only surface-
exposed viral protein (Figure 1.1 A). It is, therefore, targeted by the humoral immune 
response and a good candidate for vaccine research. This has consequently led to 
extensive analyses of the Env glycoprotein (Figure 1.1 B), which, as the name 
suggests, comprises protein residues and glycans (carbohydrates; described in detail 
in section 1.2). 
 
https://etd.uwc.ac.za
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Figure 1.1: Schematic diagram of the HIV-1 virion and its surface glycoprotein 
(A) The assembled HIV-1 virion; (B) enlarged view of the surface protein, Enva; and 
(C) linear schematic of the env gene. For the Env protein structure (B) the gp41, gp120 
and variable loop (V1-V5) regions of gp120 are labelled and coloured, for the env gene 
schematic (C), these regions as well as the conserved regions (C1-C5) of gp120 are 
labelled and coloured to illustrate the order of gene sections. 
 
The Env glycoprotein is initially synthesised as a precursor gp160 molecule, which is 
cleaved by the host protease, furin, during its transportation through the trans-Golgi 
                                            
a	The	depicted	orientation,	where	the	lipid	membrane	is	located	at	the	top	and	the	V1/V2	loop	
regions	are	at	the	bottom	of	the	figure,	is	used	throughout	this	thesis.	
https://etd.uwc.ac.za
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network, into gp41 and gp12028. The surface of the gp120 subunit, in turn, consists of 
5 variable loop (V1-V5) and 5 conserved (C1-C5) regions (Figure 1.1 C). Prior to 
protein folding, cleaving and trimerisation, precursor Glc3Man9GlcNAc2 (Glc: glycose; 
Man: mannose; GlcNAc: N-acetylglucosamine; Figure 1.2 A) glycans are added, 
where possible, to the amide groups of asparagine (Asn) residues at potential N-linked 
glycosylation sites (PNGSs), determined by an Asn-X-Threonine (Thr) or Asn-X-
Serine (Ser) motif, where X is any amino acid except proline45. The gp120 subunit has, 
depending on the viral strain, 20-30 PNGSs, while the gp41 subunit has 4-5 PNGSs, 
and HIV-1 Env is one of the most heavily glycosylated molecules known to date46,47.  
 
After the precursor glycans are attached to the PNGSs, they are trimmed by the 
endoplasmic reticulum (ER) α-glucosidase I and II to yield monoglucosylated N-linked 
glycans, GlcMan9GlcNAc2, that interact with the folding chaperones calnexin and 
calreticulin45,48 (Figure 1.2 A). Once gp160 has correctly folded, the ER α-glucosidase 
II further trims the GlcMan9GlcNAc2 glycans into Man9GlcNAc2 glycans45 (Figure 1.2 
A). These are then further processed by ER and Golgi α-mannosidases, which yields 
unprocessed, immature, oligomannose-type glycans (Man5GlcNAc2) (Figure 1.2 B). 
 
Finally, N-acetylglucosaminyltransferase I transfers an N-acetylglucosamine residue, 
which initiates complex-type glycosylation and diversification45 (Figure 1.2). It is 
important to note that the exact glycoforms of hybrid- and complex-type glycans are 
cell type and tissue-specific, which can lead to a range of different glycoforms at 
different glycan sites49,50, as well as micro-heterogeneity at a particular site49. 
Ultimately, the matured, and functional, Env glycoprotein is a metastable trimer formed 
by non-covalently associated heterodimers of gp120 and gp41, with both subunits 
extensively modified by numerous glycans comprising different glycoforms.  
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Figure 1.2: Glycosylation pathway  
(A) In the ER, Glc3Man9GlcNAc2 glycans are attached to Asn residues of PNGSs on 
the Env glycoprotein. The three terminal glucose molecules are removed by α-
glucosidases I and II. This is followed by the ER α-mannosidases I, which further trim 
the glycans to form Man8GlcNAc2 glycans. (B) These glycans are further processed 
by Golgi ( -mannosidases IA-C to yield Man5GlcNAc2 glycans. Thereafter, an N-
acetylglucosamine residue is transferred, by N-acetylglucosaminyltransferase I, to the 
Man5GlcNAc2 glycans. (C) The GlcNAcMan5GlcNAc2 glycans are the substrate for 
Golgi-resident fucosyltransferase. Alternatively, further mannose trimming by the 
Golgi α-mannosidase II can occur, which leads to GlcNAcMan3GlcNAc2 glycans. (D) 
Finally, the glycan can be further possessed into hybrid- or complex-type glycans. This 
figure was adapted from a book by Pantophlet et al.51 and glycan representations are 
shown according to the nomenclature of Harvey et al.52. 
 
This extensive glycan coating is an important feature of the HIV-1 Env glycoprotein, 
as it is used as a defence mechanism to evade recognition by neutralising antibodies. 
Since these glycans are synthesised by the host-cell glycosylation machinery, it limits 
the range of B-cell responses due to antigen self-tolerance. The shielding capacity of 
these glycans is demonstrated by observations that the removal or addition of specific 
N-linked glycans modulate the susceptibility of HIV-1 to neutralising antibodies42,44,53–
https://etd.uwc.ac.za
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55. Therefore, the HIV-1 Env glycans have often been referred to as the “glycan shield” 
56,57. 
 
It was, therefore, surprising when a breakthrough publication by Walker et al.58 
revealed not only the presence of a distinct family of antibodies with greater 
neutralisation potency and breadth, but also that the epitopes of these antibodies 
contained glycans58. Further studies of such broadly neutralising antibodies (bNAbs) 
showed that the epitopes tend to cluster around “sites of vulnerability” (Figure 1.3), 
which include the CD4-binding site59, the membrane-proximal external region of 
gp4160, the glycan outer domain61, the V1V2 apex region around glycan N16058, the 
V3 base around glycans N301 and N33262, and the gp120/gp41 interface63. However, 
despite the presence of bNAbs in the serum of HIV-1 infected individuals, circulating 
plasma viruses generally escape, resulting in continued infection64,65. In these infected 
individuals, the virus is under constant pressure from both antibodies that target 
exposed protein epitopes and antibodies that target N-linked glycans42,44. Thus, the 
glycan shield is constantly evolving and shifting in response to the host immune 
system42,44. Taken together, these observations have led to the emerging view that 
the glycosylation profiles of HIV-1 strains are homogeneous overall, but within-host 
virus populations have diminished or increased numbers of glycans, or shifted glycan 
positions, depending on the specific pressure exerted by the host immune system. 
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Figure 1.3: HIV-1 Env sites of vulnerability 
Anti-HIV-1 bNAbs target six conserved regions on the Env glycoprotein: The CD4-
binding site (CD4bs); the membrane-proximal external region (MPER); the glycan 
outer domain; the V1V2 apex region around glycan N160; the V3 base around glycan 
N301 and N332; and the gp120/gp41 interface. 
 
Due to their importance, the HIV-1 Env glycans have been extensively investigated 
using a variety of techniques. The outcomes of these techniques include, but are not 
limited to, remodelling of the glycan shield53–55,66–71, determining the glycoforms at 
each glycosylated site49,72–82, and determining the structural characteristics of 
glycans83–92, which are each described in more detail below.  
 
Glycan shield remodelling refers to a process by which one, or more, glycans are 
edited or removed from the Env surface. This involves the use of glycosidase 
inhibitors93,94 to manipulate the glycoforms on Env, and/or the addition or removal of 
glycosylation sites through site-directed mutagenesis53–55,66–71, which mutates the 
https://etd.uwc.ac.za
http://etd.uwc.ac.za/
 12 
Asn, and/or Thr or Ser, residues. These methods have allowed for the identification of 
potential escape mutations, as well as N-linked glycans, and their glycoforms, that 
form part of epitopes of particular HIV-1 Env bNAbs53–55,66–71. 
 
Although remodelling of the glycan shield presents a crude determination of the 
glycoforms necessary for antibody binding, it does not provide information regarding 
the native glycoforms. However, the native glycoforms of each site can be, and are 
commonly, determined by carrying out mass spectrometry using HIV-1 Env 
glycoproteins49,72–82. Broadly speaking, these studies have demonstrated that 
complex-type glycans are more often found on the C1, V1/V2 and V3 regions, whereas 
oligomannose-type glycans mainly reside on the C2 and C3 regions, i.e. the outer 
domain of the Env glycoprotein (Figure 1.1 C). The presence of a dense cluster of 
glycans on the gp120 outer domain is thought to decrease the accessibility for 
glycosidases, which subsequently leads to stalled, or reduced, trimming of glycans 
forming part of these clusters49,72–82. This results in an N-linked glycosylation pattern 
dominated by minimally trimmed glycans, which differs from that which is generally 
observed on human glycoproteins49,72–82. Additionally, recent studies using mass 
spectrometry have provided information on how often each PNGS is glycosylated, as 
well as quantification of the individual glycoform micro-heterogeneity at each 
glycosylated site49,95. The presence or absence of a glycan/s, as well as the specific 
glycoforms, have been shown to have a substantial impact on the binding of bNAbs95. 
 
However, in order to determine exactly how different glycoforms impact the binding of 
bNAbs, the Env glycoprotein, together with the relevant bNAbs, need to be 
characterised in detail. This requires alternative methods over and above glycan shield 
remodelling and mass spectrometry. X-ray crystallography is one such method, 
however, the structural characterisation of a stable trimer is particularly difficult. The 
reason for this is that the assembly of functional Env trimers is inefficient and leads to 
dimers, malformed trimers, and higher-order aggregates, which do not represent the 
native Env trimer96,97. Additionally, Env often sheds the gp120 component98; together, 
these features of the HIV-1 Env glycoprotein contribute to the huge challenge of 
obtaining intact crystal structures of Env. Despite these challenges, the crystal 
structures of peptide fragments, gp120 core monomers, and scaffolded gp120 and 
gp41 loops have been determined for a variety of viral strains by introducing various 
https://etd.uwc.ac.za
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stabilising mutations, and by using antibodies and/or CD4 for additional stabilisation 
(some examples are83–92). 
 
The crystal structures of the Env glycans are even more difficult to characterise using 
X-ray crystallography than the protein component99. Crystallising any glycan-part 
beyond the protein-proximal GlcNAc residues is extremely difficult due to the 
extensive conformational heterogeneity99. Nevertheless, analysis of these protein-
proximal GlcNAc residues bound to proteins has shown a strong preference for 
glycosidic linkages with specific phi and psi dihedral angles (bond between four linked 
atoms; see section 1.2.2) with minimal energy conformations99–101. Recently, the 
atomic-level details of clades A, B and G Env glycoproteins were determined by 
Stewart et al.88, with 15, 17 and 16 glycans, respectively, resolved (to different 
degrees/lengths from the base) beyond the protein-proximal GlcNAc residues. The 
authors demonstrated that the HIV-1 Env glycan shield comprises prominent ridges of 
hydrogen-bonded oligosaccharides, which are ordered by glycan clustering and 
protrude 20Å above the Env glycoprotein surface88. 
 
Due to the difficulties surrounding the determination of the structural characteristics of 
glycans with regards to their impact on various Env functions, studies commonly 
include computational approaches to complement experimental-based studies53,95,102–
113. For these Env-focussed studies, the structures of the respective Env glycoproteins 
were either undetermined, or additional structural characteristics were sought. The 
computational approaches that were used include molecular dynamics simulations, 
which are particularly well suited for glycan and glycoprotein systems, i.e. systems 
that are either experimentally undetermined or poorly resolved. While molecular 
dynamics simulation studies have provided valuable insights on Env and its glycans, 
few analytical approaches exist in the context of the Env glycans, with the majority of 
studies focussing on the protein only103–113, or on the overlap, or binding, of glycans to 
antibodies88,113. Only two studies86,89 to date investigated glycans in more detail using, 
as measure, a solvent accessible surface area (SASA) calculation (with a probe of 0-
10Å86 or 10Å89), network analysis (based on distances89 or hydrogen bonds86), glycan-
antibody overlap86,89, glycan volumes86,89, and SASA when a glycan is removed89. 
Given the variation between the glycan shields of different viral isolates, as well as the 
glycoform micro-heterogeneity at different glycosylated sites, the application of 
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analytical techniques to investigate the HIV-1 Env glycan shield in a novel way is 
essential.  
 
1.2 Glycans and glycoform heterogeneity 
 
As introduced in section 1.1.1, the glycans of HIV-1 Env are diverse in their glycoforms 
and distribution, and characterising this diversity remains a challenge for HIV-1 Env 
research. A detailed investigation and comparison between different HIV-1 glycan 
shields is presented in Chapter 2-4 of this thesis, and background on the composition 
and conformational features of glycans is provided below.  
 
Glycans, or carbohydrates, are biomolecules consisting of chains of monosaccharides 
and follow the general formula ) ∙ +,- . from which their name, hydrates of carbon, 
is derived114. They are also referred to as sugars or, specifically, glycans when they 
are attached to other biomolecules such as lipids or proteins. 
 
1.2.1 Monosaccharides 
 
Monosaccharides, the most basic unit of carbohydrates, have a linear and unbranched 
carbon skeleton with one carbonyl (C=O) group on the first carbon atom and hydroxyl 
(OH) groups on all the remaining carbon atoms114 (Figure 1.4 A). The carbon atoms 
are numbered from 1 to n along the backbone, starting from the end that is closest to 
the carbonyl (C=O) group114 (Figure 1.4 A). Two monosaccharides, with the same 
molecular formula and location of the carbonyl group, can still be distinct in their 3D 
arrangements of the bonds of certain atoms114. For example, monosaccharides are 
classified as a member of either the D- or L-series, depending on the orientation of the 
hydroxyl furthest from the carbonyl group (Figure 1.4 B). Most naturally occurring 
monosaccharides belong to the D-series114. 
 
Monosaccharides can exist in a linear or cyclic form; the latter results from an intra-
molecular interaction between the oxygen atom of a hydroxyl group and the carbonyl 
carbon114 (Figure 1.4 C). Several ring-forms are possible depending on which hydroxyl 
interacts with the carbonyl carbon. For example, monosaccharides can form five-
https://etd.uwc.ac.za
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membered (furanoses) or six membered (pyranoses) rings, provided that there are the 
appropriate number of carbons114. The pyranose form is the most common for the 
majority of monosaccharides114. Furthermore, monosaccharides are classified as 
either (  or / , based on two alternative hydroxyl configurations at the carbonyl 
carbon114 (Figure 1.4 D). Monosaccharides combine to form more complex molecules 
such as disaccharides, polysaccharides and glycans114.  
 
 
Figure 1.4: Monosaccharide configurations 
Representations of the (A) linear carbon skeleton, (B) distinction between D- and L-
series, (C) cyclic form, and (D) (  and /  classifications of monosaccharides. This 
figure was adapted from a book by Collins et al.114 
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1.2.2 Glycan conformations 
 
Disaccharides, and eventually glycans, are formed when the hydroxyl groups of two 
monosaccharides form a C-O-C bond, which releases a water molecule114. The C-O-
C bond is called the glycosidic linkage and occurs between carbon 1 (the first carbon) 
of one monosaccharide and either carbon 2, 3, 4, or 6 of another monosaccharide, 
forming a 1-2, 1-3, 1-4 or 1-6 linkage114. The dihedral angles, formed by four linked 
atoms, of these linkages are called 0	 (H1-C1-O-Cx) and 2 (C1-O-Cx-Hx)114 (Figure 
1.5 A). The 1-6 linkage has an additional dihedral angle called 3 (O-C6’-C5’-H5’)114 
(Figure 1.5 B). Glycosidic linkages and dihedral angles determine the overall glycan 
conformations.  
 
 
Figure 1.5: The dihedral angles of glycosidic linkages 
3D representations of sections of a Man-9 glycan, demonstrating the (A) 0, 2 and  
(B)	0, 2 and 3 dihedral angles. 
 
For example, and in this thesis, the majority of analyses were performed using Man-9 
glycans with the specific form: Manα1-2Manα1-6[Manα1-2Manα1-3]Manα1-6[Manα1-
2Manα1-2Manα1-3]Manβ1-4GlcNAcβ1-4GlcNAcβ1. During attachment of the glycans 
to the protein structures, these dihedral angles were adjusted, within reason, to 
facilitate glycan attachment, which is discussed in section 2.2.2. 
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1.2.3 The HIV-1 Env glycan shield 
 
The HIV-1 Env glycoprotein trimer is characterised by an unusually high abundance 
of glycans46,47. As detailed in section 1.1.1, these glycans shield the underlying Env 
surface from the immune system and continue to do so over the course of 
infection42,44,53–56. The HIV-1 Env glycans are, therefore, key features during 
investigations on structural and antigenic properties of Env, and while recent 
experimentally determined structures have greatly extended our knowledge of the 
interlocking glycan networks of the Env glycans, these cryo-electron microscopy115–117 
and X-ray crystallography87,88,91,92 studies can only capture a single static state of any 
individual glycan (as described in section 1.1.1). However, the potential glycan 
conformational heterogeneity and movement can be illustrated and described using a 
computational method of generating molecular dynamics simulations. As example, 
Lemmin et al.86 used a molecular dynamics approach and observed that neutralising 
antibodies generally bind at the interface between stable patches of glycans.  
 
1.3 Molecular Dynamics Simulations 
 
Molecular dynamics is a computational approach that simulates the physical 
movement of atoms in a given system. Atoms are typically represented as single point 
masses inside van der Waals potentials, i.e. they mostly act as hard spheres, and 
bond- and angle restraints are represented as harmonic oscillations118–120. Atoms can 
transfer both energy and momentum to one another via electrostatics and van der 
Waals interactions118–120. Atomic movements are determined by numerically solving 
Newton’s equations of motion for the system of 4  interacting atoms118–120. By 
Newton’s second law, the force (#) on an object, in this case an atom, is equal to the 
mass ($) of that object multiplied by the acceleration (") of the object118–120: 
 # = $" (1) 
The force (# ) is further given by the negative gradient of the potential energy 6(&8, &,, … , &;)118–120: 
 # = −∇6(?) (2) 
https://etd.uwc.ac.za
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Equations (1) and (2) are solved simultaneously in small time steps (@'), and the atom 
is accelerated in the direction of the force using a leap-frog integrator to determine the 
new velocity (A) and position (&) of the atom118–120:  
 A ' + 12@' = A ' − 12@' + @'$ #(')	
   & ' + @' = & ' + @'	A ' + 8, @'  
(3) 
(4) 
 
Thus, in order to perform molecular dynamics simulations, several properties should 
be understood and specified. The potential energy 6(?) , calculated by solving a 
mathematical expression referred to as a force field, the thermodynamic ensemble 
that governs the simulation, the solvent model, and the boundary around the simulated 
system are important features that can have a large impact on the resultant molecular 
dynamics simulation118–120. Each of these features are described in further detail 
below. 
 
1.3.1 Force Fields  
 
An important consideration during the preparation of a system prior to the simulation, 
is the choice of a force field. Force fields are the mathematical equations used to 
model the interactions between atoms, and have two components, a mathematical 
expression and the parameters required by that expression118–120. The mathematical 
expression has a general form, which can be considered as comprising of the sum of 
two terms representing the bonded and non-bonded interactions118–120: 
 6 ? = 	6EF.GHG + 6;F.IEF.GHG (5) 
The bonded and non-bonded interactions are, in turn, the sum of their own respective 
terms. Bonded interactions are calculated for the interactions formed between two 
(bonds), three (angles) and four (dihedrals/torsion) atoms118–120: 
6EF.GHG = 12JKLE &KL − &KLM ,NF.GOKPL + 12 JKLQR SKLQ − SKLQM ,
T.UVHO
KPLPQ
+ 12JW(1 + cos %0 + [ )\K]HG^_VOKPLPQPV  (6) 
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Non-bonded interactions are calculated for the van der Waals and electrostatic 
interactions using a Lennard-Jones potential and Coulomb’s law, respectively118–120: 
6;F.IEF.GHG = 4aKL bKL&KL 8, − bKL&KL cd_.	GH^	e__VOKPL + fKfL4gaMh^&KLiVHjk^FOk_kKjOKPL  (7) 
The exact form of each equation (e.g. well depth and location) is determined by the 
parameters specified by the particular force field, which are derived using 
experimental data118–120. Several different force fields exist and the choice depends 
on the composition of the system and the ability of the force field to produce accurate 
results while maintaining reasonable computational efficiency118–120. The ff14SB121 
and GLYCAM06j-1122 force fields were used in this thesis for the protein and glycan 
atoms, respectively. During molecular dynamics simulations, the equation of motion is 
governed by both the force field as well as the constraints enforced by the particular 
ensemble. 
 
1.3.2 Ensemble 
 
A further consideration during the preparation of a system is the choice of statistical 
ensemble. An ensemble represents all the microstates accessible by a system during 
a simulation. For each microstate, the ensemble also provides the probability of that 
microstate118–120. For example, if the system under study is a bottle of beer, then the 
ensemble can be thought of as a huge warehouse filled with individual, non-
interacting, bottles of beer. A typical system has three intrinsic properties, number of 
atoms, volume and energy (Table 1.1) that would remain constant under an ideal 
molecular dynamics simulation118–120. Alternatively, each intrinsic property can be 
modulated by an external source, maintaining the chemical potential, pressure, and 
temperature instead (Table 1.1)118–120. For example, during a molecular dynamics 
simulation, energy is continuously lost due to rounding errors in the motion 
calculation118–120, and thus, the decision to keep the energy of a system constant 
requires that a thermostat be specified that governs when and how much energy is 
added to the system. Therefore, the selection of a statistical ensemble involves the 
decisions around which intrinsic properties remain constant and which are modulated 
by an external source. 
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Table 1.1: The intrinsic properties of a molecular dynamics system and their 
related properties. An ensemble is defined by selecting a property in each row 
that will be kept constant. 
Intrinsic property Related property 
Number of atoms (%) Chemical potential (!) 
Volume (V) Pressure (P) 
Energy (E) Temperature (T) 
 
The isobaric-isothermal ensemble (nPT) used in this thesis, is the ensemble where 
the number of atoms, pressure and temperature are held constant118–120. A thermostat 
and barostat are used to maintain the desired temperature and pressure, 
respectively118–120. Numerous thermostat and borostat algorithms exist to facilitate 
temperature and pressure control. Those available in the molecular dynamics package 
AMBER123, include the Berendsen, Andersen and Langevin thermostats, and the 
Berendsen and Monte Carlo borostats119. Of these, the Langevin thermostat and the 
Berendsen borostat were used here. 
 
1.3.3 Solvent Models 
 
While it is possible to proceed with molecular dynamics simulations after the 
specification of the force field and ensemble, it is common to include solvent molecules 
in order to better ascertain the behaviour of the biomolecule in a biologically relevant 
environment. One of two methods can be used to represent the solvent118–120. The first 
method uses a mathematical formula to approximate the influence of the solvent on 
the surface of the biomolecule, referred to as implicit solvent118–120. While an implicit 
solvent model is less computational expensive than the alternative method, the 
inability of the biomolecule to form hydrogen bonds with solvent molecules is a severe 
limitation. The alternative is to use an explicit solvent model that includes the atomic 
representation of the solvent similar to those of the biomolecule. Despite the increased 
computational burden, systems with explicit solvent offer a more accurate 
representation, and more detail, of the solvation environments of biomolecules. 
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There are various representations of the solvent molecules118–120. Each representation 
varies in the number of atoms used to represent the H2O molecules as well as the 
distances and angels between the atoms. The TIP3P solvent model (Figure 1.6 A) is 
most commonly used during molecular dynamics simulations since it is 
computationally efficient118–120. TIP3P has three interaction points corresponding to 
the three atoms of a water molecule118–120. Each atom has a point charge representing 
the electrostatic distribution around water. More complex water models add “dummy” 
atoms (also called extra points) to the TIP3P solvent model to refine the electrostatic 
distribution around the water molecules118–120. The TIP5P solvent model124 (Figure 1.6 
B), for example, augments the TIP3P solvent model with two extra points that 
represent the electron lone pairs on the oxygen124. While the TIP5P solvent model is 
more computationally expensive124, it has been shown to give the best quantitative 
agreement with experimental free energy data for small saccharides when used in 
conjunction with the GLYCAM force field125. For this reason, the TIP5P solvent model 
was used in this thesis. 
 
 
Figure 1.6: Explicit solvent models  
Diagrams of the explicit solvent models (A) TIP3P and (B) TIP5P. Each model is 
coloured according to its atom composition, with hydrogen (white), oxygen (red), and 
the dummy atom (purple) shown.   
 
1.3.4 Periodic Boundary Conditions 
 
Once the solute (biomolecule) has been placed within the solvent, a boundary must 
be defined that will prevent the solvent molecules from dispersing too far from the 
biomolecule118–120. However, when such a boundary is introduced, the solvent 
molecules that are in contact with void space along the edges give rise to calculation 
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artefacts118–120. This “edge effect” can be addressed by using periodic boundary 
conditions (PBC, Figure 1.7)118–120.  
 
 
Figure 1.7: Periodic boundary conditions 
Illustration of an HIV-1 Env system under periodic boundary conditions. As a molecule 
crosses the boundary on one side of the primary simulation, it re-enters on the 
opposite side, unaware of the boundaries. 
 
PBC essentially results in a system that is infinitely copied in all directions such that 
the edge of every system borders its opposing edge in the adjacent image118–120. 
Therefore, if a solvent molecule happens to cross the edge of the solvent box, i.e. the 
periodic boundary, it exits the system on one side and immediately re-enters on the 
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opposite side (Figure 1.7). Consequently, this kind of system requires a finite number 
of atoms to represent a fully solvated biomolecule and the problems associated with 
edge effects are eliminated118–120. 
 
There is, however, a caveat to using periodic boundary conditions, which should be 
addressed to avoid the introduction of calculation artefacts. The minimum image 
convention states that the shortest edge of the simulated system must be at least twice 
the value of the non-bonded interaction cut-off (usually 8Å)118–120. Therefore, during 
molecular dynamics simulations, the size of the water box should be large enough 
such that the biomolecule cannot interact with itself across the boundary, which would 
lead to erroneous results118–120. 
 
1.3.5 Molecular dynamics simulations of HIV-1 Env proteins 
 
Molecular dynamics simulations have been carried out on several HIV-1 Env proteins 
and recently, more studies have started including glycans. For example, Yang et al.89 
used molecular dynamics to calculate how often the glycans that are targeted by 
bNAbs, sample the bNAb-bound conformation (as determined in crystal structures). 
This “pre-organisation” is important since glycans that more frequently sample the 
conformation/s required for bNAb-binding potentially enhance the number of 
opportunities for bNAbs to do so, and are, thus, comparatively, better targets89. 
Therefore, despite the use of homogeneous, oligomannose, glycoforms in the Yang 
et al.89 study (Man5NAc2 or Man9NAc2, depending on the site), the ability to rigorously 
define the composition of the system and subsequently study its molecular details 
resulted in valuable insights that can be used in a predictive fashion to facilitate 
vaccine design.   
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Chapter 2 Variability in the HIV-1 Env glycan shield influences 
its vulnerability after the loss of a glycan 
 
As described in Chapter 1, the glycans on HIV-1 Env serve multiple functions. One 
important function is that these glycans shield epitopes from antibodies; for example, 
glycan N301 is implicated in the shielding of V3-loop and CD4-binding site epitopes. 
In this chapter, two subtype C strains are investigated, where for each of these 
isolates, the removal of glycan N301 had substantially different effects during an in 
vitro neutralisation investigation. Specifically, glycan N301 appeared to shield the 
epitopes of frequently elicited antibodies on one of the strains from recognition, but did 
not do so on the second strain. The molecular modelling of the Env glycoproteins, 
described here, suggests that the removal of glycan N301 likely exposed a greater 
surface area of specific protein residues in the V3-loop and C4 regions on one model 
compared to the other. 
 
2.1 Introduction 
 
The surface of HIV-1 Env, despite the protection afforded by the glycan shield, is 
susceptible to bNAbs. As described in section 1.1.1, there are six known sites of 
vulnerability on the Env glycoprotein that are targeted by bNAbs58–63 (Figure 1.3). Of 
these, the class of bNAbs targeting the V3 glycans may be the easiest to elicit via 
vaccination, since these are among the most widespread and potent bNAb responses 
in infected individuals126–129. There is, therefore, considerable research focussed on 
understanding the virus-antibody dynamics that enables the development of these 
bNAbs40,42,130–135. In addition, the mutations that facilitate escape from bNAbs are also 
extensively studied42,44,64,65,102,134. 
 
One potential escape pathway is the loss of a glycan targeted by a specific bNAb. As 
example, glycans N301, N332 and, to a lesser extent, N334 are targeted by the V3-
loop glycan-binding bNAbs. However, the loss of a glycan may afford an opportunity 
for strain-specific neutralising antibodies, that target the residues previously shielded 
by this lost glycan, to bind and neutralise. Since these antibodies that target the V3-
loop glycans are candidates for both passive infusion, as therapy, and induction by a 
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future vaccine, it is important to evaluate the tolerance of HIV-1 Env glycoproteins for 
the loss of the targeted glycan/s. The comparison between the resistance of mutated 
and wild-type HIV-1 Env glycan shields to frequently elicited neutralising antibodies, 
facilitates this assessment. 
 
For this reason, collaborators at the University of Cape Town (working in the CPGRb 
laboratories at the time) investigated the key glycans around the base of the V3-loop, 
at positions 301, 332 and 334, during an in vitro study of two subtype C strains, 
CAP45.2.00.G3 (further referred to as CAP45.G3) and Du156.12, which share 
approximately 90% sequence identity. During this study, the glycan shield was 
remodelled and tested against a panel of sera (%=64) from chronically HIV-1 infected 
individuals. This was done to assess whether the epitopes of frequently elicited 
neutralising antibodies were exposed on the remodelled shield. It was shown that the 
Du156.12 strain required glycan N301 for maintenance of its glycan shield, whereas 
the CAP45.G3 strain was, comparatively, less reliant on glycan N301, since it 
remained resistant to the panel of sera despite the loss of this glycan. However, the 
differences between the glycan shields that bring about the distinct tolerances of these 
strains, for the loss of a glycan, remained unknown. 
 
As described in section 1.1.1, computational analysis complements laboratory studies 
where structures are required but experimentally undetermined. For the described 
study, our research group carried out the computational analyses to predict the 
CAP45.G3 and Du156.12 Env glycoprotein trimers. In this chapter, the portion of our 
published manuscript, Moyo et al.53, focussing on the computational analyses is 
includedc and described in further detail (section 2.3). The primary focus was to 
describe the differences in the glycans shields of the CAP45.G3 and Du156.12 
models, however, several steps preceded the final analyses and are also included in 
this chapter (section 2.2.1 and 2.2.2).  
 
 
                                            
b	Center	for	Proteomic	&	Genomic	Research	(CPGR),	University	of	Cape	Town	
c	Text	adapted	from	peer	reviewed	publication	Moyo	et	al.53	
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2.2 Methods 
 
2.2.1 Protein Structural Modelling 
 
In order to determine the unknown 3D protein structures of the CAP45.G3 and 
Du156.12 protein sequences, homology modelling was performed with the computer 
program MODELLER136,137. The MODELLER algorithm predicts 3D structures of 
proteins by satisfying spatial restraints. These restraints are derived, by MODELLER, 
from known, related, structures (i.e. templates), and from the alignment between the 
template and target sequences, in this case either the CAP45.G3 or Du156.12 
sequences. These spatial restraints can be placed on distances, angles, dihedral 
angles, pairs of dihedral angles and other spatial features defined by atoms, or 
pseudo-atoms. Subsequently, a 3D structure is obtained by optimising a molecular 
probability density function. Thus, during homology modelling, MODELLER predicts 
the 3D structure by performing the following operations: 
 
1. Determine the spatial restraints on the target sequence from its alignment with 
the templates. 
a. Generate the molecular topology for the target sequence. 
b. Calculate the coordinates for atoms with equivalent atoms in the 
templates by using the average coordinates over all the templates. 
c. Build the remaining coordinates using internal coordinates from the 
CHARMM topology library. 
d. Determine the restraints (stereo-chemical, homology-derived and 
spatial). 
2. Predict a model that satisfies, to the largest extent, the restraints determined in 
step 1. 
a. Randomise the initial structure determined in 1.b. and 1.c. by adding a 
random number to the atomic coordinates. 
b. Optimise the model. 
3. Determine the remaining restraint violations. 
4. Write the violations and final model to separate files. 
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Therefore, in order to use MODELLER to predict the unknown 3D structures, a known 
related structure and its alignment with the target sequence is required.  
 
2.2.1.1 Structural templates for HIV-1 sequences 
 
Since MODELLER requires a template structure, an appropriate template or 
combination of templates for the HIV-1 Env sequences, was sought. At the time of the 
analysis (2015/05/22), there were 108 protein data bank (PDB) structures identified 
by BLAST (www.rcsb.org) that matched the HIV-1 HXB2 gp120 protein sequence. 
Most of the structures were modified Env proteins with shortened, or absent, variable 
loop sequences (see section 1.1.1). Therefore, in order to evaluate each of these 
structures, their protein sequences were aligned to HIV-1 HXB2 gp120 and the regions 
where the amino acids structures were unresolved, were highlighted (Figure 2.1). 
Furthermore, the structures were ordered based on their structural resolution, from 
highest to lowest (Figure 2.1 A). 
 
The PDB entries 2QAD138, 2B4C139, 4TVP87, 4NCO91 and 3J5M115 were the only 
structures with resolved V3-loop regions (Figure 2.1 A). Additionally, the PDB entries 
4TVP87, 4NCO91 and 3J5M115 were the only structures with resolved V1V2-loop 
regions and, of these, 4TVP87 had the highest resolution (Figure 2.1 A). Therefore, the 
4TVP87 crystal structure was the primary candidate as a homology modelling template. 
However, since there were some unresolved amino acids, a combination of 4TVP87 
with 4NCO91 and 2B4C139, that adds 3 and 11 resolved amino acids, respectively, in 
the V4-loop region of the 4TVP87 structure, was also considered (Figure 2.1 B). The 
HIV-1 Env sequences used for crystallisation, and any structures that were co-
crystallised with these proteins, are shown in Table 2.1. The co-crystallised structures 
were removed prior to modelling. 
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Figure 2.1: Overview of the HIV-1 Env crystallised structures  
Alignment of PDB protein sequences to the HIV-1 HXB2 gp120 protein sequence for 
(A) all and (B) a subset of the PDB structures (PDB ID:CHAIN) identified by BLAST. 
Regions where the amino acids structures were unresolved are highlighted (orange). 
PDB structures are ordered from highest to lowest resolution. The gp120 conserved 
(C1-C4) and variable (V1-V5) regions are labelled and shaded to indicate the borders 
of each region. 
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Table 2.1: Crystal structures considered for modelling. 
PDB ID Sequence name Co-crystallised structures 
4TVP87 BG505 SOSIP.644 PGT122 and 35O22 
4NCO91 BG505 SOSIP.644 PGT122 
2B4C139 JR-FL CD4 and X5 
 
 
2.2.1.2 Comparing template combinations  
 
In order to decide whether to use only 4TVP87 as the template, or in combination with 
4NCO91 and 2B4C139, the different template combinations were used to generate 3D 
models and the results compared. The comparison relied on the assignment of 
numerical scores to the generated structures, which are indicative of how similar the 
model is to the native structure. Generally, the native structure has the lowest free 
energy (under the native conditions, e.g. temperature and pressure), however, the 
evaluation of an accurate free energy function is computationally expensive140. An 
alternative approach, where a scoring function is constructed with a global minimum 
that corresponds to a sample of native structures deposited in the Protein Data Bank, 
is commonly used140–144. The reliance of this scoring function on known protein 
structures led to the term knowledge-based, or statistical, potentials140. The discrete 
optimised protein energy (DOPE) is such a knowledge-based scoring function140 and 
is implemented in MODELLER. Lower DOPE scores represent models that are more 
native-like and a representation of the DOPE score by residue (DOPE score profile) 
further facilitates a detailed analysis of different template combinations140. 
 
Hence, ten homology models of both wild-type protomers (CAP45.G3 and Du156.12) 
were generated for each of the three different template combinations: 4TVP87 alone; 
4TVP87, 4NCO91 and 2B4C139; and 4NCO91 and 2B4C139. The last combination, 
4NCO91 and 2B4C139, was included to evaluate a 4TVP-independent template 
combination. For the comparison between the template combinations, only the best 
(lowest DOPE score) models generated for the wild-type CAP45.G3 and Du156.12 
protomer sequences were considered. For the best models, the per residue DOPE 
scores were calculated and normalised for the number of restraints, since the model 
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generated using 4TVP87, 4NCO and 2B4C139 as templates has more restraints than 
those generated by using only 4TVP87 or 4NCO91 and 2B4C139 (Figure 2.2). 
 
 
Figure 2.2: Comparison of protein-template combinations 
The DOPE score profiles of the best (A) CAP45.G3 and (B) Du156.12 protomer 
models, using different template combinations. The total DOPE score for the best 
model is shown for each template combination. The gp160 conserved (C1-C4), 
variable (V1-V5) and gp41 sequence regions are labelled and shaded to indicate the 
borders of each region. 
 
Despite the additional structural information in the V4-loop region, provided by the 
inclusion of 4NCO91 and 2B4C139, the DOPE score profile values were similar to those 
of the models generated with 4TVP87 as the only template (Figure 2.2). Conversely, 
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including 4TVP87 as one of the templates in the combined example markedly improved 
the DOPE sore profile values for the V1V2-loop (Figure 2.2 A) and V3-loop residues 
(Figure 2.2 A and B). Furthermore, an interesting difference in the DOPE score profiles 
was observed between the V1V2-loop regions of the CAP45.G3 and Du156.12 
protomer models (Figure 2.2). The Du156.12 models had higher DOPE values for 
these regions, which was possibly due to the longer variable loop regions of the 
Du156.12 sequence and, hence, higher uncertainty in the modelling. 
 
While the models generated with only 4TVP87 as the template were the best models 
based on the DOPE scores, the addition of 4NCO91 and 2B4C139 was a more cautious 
approach as it included further information for modelling and did not substantially 
increase the DOPE scores or the DOPE score profiles (Figure 2.2). Hence, 4TVP87, 
4NCO91 and 2B4C139 were used as templates for generating the 10 models of the wild-
type CAP45.G3 and Du156.12 protomer sequences. Each protomer model was then 
individually triplicated, and the three copies were aligned to the protomers of the 4NCO 
trimer structure to generate the trimeric models. 
 
Thereafter, each of these trimeric models (20 in total) were duplicated and a 
computational mutation was introduced to the duplicated models. Specifically, the 
duplicated models of the CAP45.G3 strain were computational mutated such that the 
PNGS at position 334 was shifted to position 332. For the Du156.12 duplicated 
models, a computational mutation was introduced that shifted the PNGS at position 
332 to 334. Therefore, the final sets included 10 Env trimer models each for the 
CAP45.G3 wild-type, Du156.12 wild-type, CAP45.G3332 variant (PNGS shifted from 
position 334 to 332), and Du156.12334 variant (PNGS shifted from position 332 to 334) 
strains.   
 
2.2.2 Glycosylating the protein models 
 
In order to computationally glycosylate the 40 trimeric models, PNGSs were 
determined by identifying the Asn-X-Thr/Ser motifs, where X is any amino acid except 
a proline45. A glycan was attached, where possible, to each PNGS of the trimer protein 
models, with the exception of the second PNGS that occurred within an NNTT, or 
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similar, motif. At the start of the research project, the question was raised as to whether 
two glycans can be present within this kind of grouped N-linked glycosylation site, 
since glycans are attached in a linear fashion in the Golgi and the attachment of the 
first may exclude the enzymes from attaching the secondd. This decision was pertinent 
for the CAP45.G3 strain, since glycans N334 and N335 occurred within a NNST motif. 
However, since glycan N334 is important in the context of bNAbs42 and is relatively 
more abundant than glycan N33547, glycan N334 was glycosylated instead of glycan 
N335. Moreover, for consistency, this handling of neighbouring glycosylation sites 
within a partially shared PNGS motif was applied to all similar motifs, i.e. a glycan was 
only attached at the first Asn residue.  
 
During the computational glycosylation, glycans were attached to the protein 
structures using a prototype tool under development for the Glycam-Web suite of web 
tools145. This tool adjusts the conformation of the input glycan such that there are no 
overlaps between the glycan and any previously added glycans or protein residues. 
The tool achieves this by executing the following sequence of operations: 
 
1. Superimpose an input glycan onto the target glycoprotein structure. 
2. Determine if there are overlapping atoms between the superimposed glycan 
(step 1.) and any other atoms of the target glycoprotein: 
a. If an overlap is present, calculate the glycan residue with the greatest 
overlap. 
b. For the glycan residue with the greatest overlap, determine and trace 
the sequential glycosidic linkages back to the Asn-GlcNac linkage 
located at the base of the glycan.  
3. Find a glycan conformation, for the superimposed glycan, that has no overlap 
with any atoms of the target glycoprotein.  
a. For each glycosidic linkage identified during the trace-back (step 2.b.), 
starting with the Asn-GlcNac linkage:  
i. Determine the number of dihedral angles present in the glycosidic 
linkage. 
                                            
d	Recent	unpublished	mass	spectrometry	data	shared	by	a	collaborator,	demonstrated	that	
the	attachment	of	a	second	glycan	in	these	motifs	is	possible.	
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ii. Increment each dihedral angle by plus or minus 5°, within a 20° 
range. 
iii. Generate “new” conformations by considering all the 
permutations of these angles, for example 2 dihedral angles 
would each have 8 new angles (step 3.a.(ii)), resulting in 64 (8x8) 
new conformations. 
iv. For those conformations determined in step 3.a.(iii), proceed with 
the conformation with the least number of overlaps.  
v. Repeat steps 3.a.(i)-(iv) for the next glycosidic linkage until a 
conformation with no overlaps is found. 
4. If no solution is found proceed to the next input glycan and repeat. 
 
The input glycans required by the attachment tool were generated using the 
carbohydrate builder available on the GLYCAM web server145. The carbohydrate 
builder generates the different rotamers of the specified glycan and then creates four 
copies of each in order to, in turn, link each glycan rotamer to one of the four Asn 
rotamers. For example, the four different rotamers of a Man5GlcNAc2 glycan (Figure 
2.3) are each attached to one of the four possible Asn residue conformations, resulting 
in sixteen conformations, which are then used as input for the attachment tool. 
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Figure 2.3: The Man5GlcNac2 rotamers 
Each conformation (A-D) represents one of the four Man5GlcNac2 rotamers as well 
as its attachment to one of the four Asn rotamers (A1-4). The oxygen (red) and 
nitrogen (blue) atoms of each conformation are coloured. 
 
While the current implementation of the attachment tool is remarkably efficient at 
attaching glycans, it is still limited to rotating and calculating overlaps for a single 
glycan at a time. Therefore, to ensure that the maximum number of glycans were 
attached to the CAP45.G3 and Du156.12 trimer models, the order of attachment as 
well as different glycoforms were taken into consideration. 
 
2.2.2.1 Glycan attachment order 
 
Since only a single glycan is considered at a time, previous, successfully added 
glycans are obstacles for the addition of subsequent glycans. This is of concern when 
previously added glycans block the current glycan by occupying the available space 
around the targeted PNGS. Therefore, the order in which glycans are attached can 
impact the total number of glycans successfully attached to a protein structure. To 
computationally glycosylate the majority of sites, those PNGSs with the least space 
available to accommodate a glycan should be considered first. Here, the SASA values 
for all the PNGSs of the two models (CAP45.G3 wild-type and Du156.12 wild-type) 
with the lowest DOPE scores were determined using a 3Å probe, which approximates 
the size of a monosaccharide99 (Figure 2.4). Subsequently, the order of the 
https://etd.uwc.ac.za
http://etd.uwc.ac.za/
 35 
computational glycosylation was set by these SASA values, glycosylating those sites 
with the lowest SASA values first (Figure 2.4). 
 
 
Figure 2.4: SASA of each PNGS of the CAP45.G3 and Du156.12 models  
The SASA (Å2) for each PNGS of the (A) CAP45.G3 and (B) Du156.12 wild-type 
models. The gp160 conserved (C1-C4), variable (V1-V5) and gp41 sequence regions 
are labelled and shaded to indicate the borders of each region. 
 
2.2.2.2 Assessing the attachment efficiency of different glycoforms 
 
Apart from the attachment order, the total number of glycans attached can also be 
affected by the glycoform, i.e. the type of glycan. This is due to the size difference 
between glycoforms. Since larger glycoforms (e.g. Man9GlcNAc2) occupy more space 
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than smaller ones (e.g. Man5GlcNAc2), the proximity of HIV-1 Env glycans may result 
in more unsuccessful attachments for the larger glycoforms than for the smaller 
glycoforms. Here, three glycoforms (Man5GlcNAc2, Man8GlcNAc2 and 
Man9GlcNAc2; Figure 2.5) were attached to the CAP45.G3 and Du156.12 trimer 
models (generated using the lowest DOPE score protomer models) according to the 
attachment order detailed in section 2.2.2.1. 
 
 
Figure 2.5: Glycoforms consdered during computational glycosylation 
Representations of the (A) Man5GlcNAc2, (B) Man8GlcNAc2 and (C) Man9GlcNAc2 
glycans considered during the computational glycosylation step. Each diagram is 
annotated to show the carbon atom involved in the glycosidic linkage (2 – 6; section 
1.2.2) as well as the ( (a) and / (b) classification of each monosaccharide (section 
1.2.1). 
 
The total number of glycans attached were similar across the glycoforms for the 
Du156.12 model (Table 2.2), however, for the CAP45.G3 model, three less 
Man9GlcNAc2 glycans were attached compared to either Man5GlcNAc2 or 
Man8GlcNAc2 glycans (Table 2.2). However, Man8GlcNAc2 glycans were unsuitable 
for the primary analysis due to the ambiguity of this glycoform (Figure 2.5 B). This is 
also the case for hybrid and complex glycans. On the other hand, Man5GlcNAc2 and 
Man9GlcNAc2 are commonly used during molecular studies86,89,103–113 as there is no 
ambiguity in their glycoforms (Figure 2.5 A and C), and these glycoforms can easily 
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be imitated during in vitro studies using inhibitors of the processing enzymes that 
govern glycosylation93,94 (section 1.1.1). Here, the Man9GlcNAc2 glycan was 
preferred due its abundance as one of the predominant glycoforms identified during 
mass spectrometry studies on HIV-1 Env glycans49,95. 
 
Table 2.2: Total number of attached glycans for each glycoform. 
Sequence Total PNGSs Man5GlcNAc2 Man8GlcNAc2 Man9GlcNAc2 
CAP45.G3 81 80 80 77 
Du156.12 84 76 75 75 
 
Since multiple rotamers (Figure 2.3) of each glycoform were provided to the 
attachment tool, a further investigation to determine the exact conformations of the 
glycans that were attached to each glycoprotein model was carried out (Figure 2.6). 
This revealed that the vast majority of the attached glycans were the first glycan 
conformation (rotamer 1 with Asn rotamer 1; Figure 2.3) supplied to the attachment 
tool (Figure 2.6). This implies that the glycan conformations on these glycoproteins 
were biased towards a specific glycan conformation, which is later addressed by 
molecular dynamics simulations (Chapter 3 and Chapter 4). 
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Figure 2.6: Conformations of the attached glycans 
Histograms of the number of times a glycan with a specific conformation was attached 
to the CAP45.G3 or Du156.12 trimer models for each glycoform. The conformations 
are defined by the glycan rotamer (R1 to R4) as well as the Asn rotamer (P1 to P4). 
For example, R1-P1 indicates the first glycan rotamer (R1) combined with the first Asn 
rotamer (P1). 
 
2.2.3 Predicting the exposed surface area 
 
In order to understand the potential impact of removing glycan N301 and why the 
impact varied between the CAP45.G3 and Du156.12 strains, it was necessary to 
identify the protein residues that became exposed once glycan N301 was removed. 
The computationally glycosylated Env models (ten for each of CAP45.G3, Du156.12, 
CAP45.G3332, and Du156.12334) predicted here (sections 2.2.1 and 2.2.2), facilitated 
this analysis. By using these models, the change in the SASA of the protein residues 
were determined and, in turn, compared between Env models.  
 
Thus, for each homology model the relative SASA was calculated in the presence of 
glycan N301, and then glycan N301 was removed and the relative solvent accessible 
surface was calculated. These relative SASA calculations were carried out using 
NACCESS146 and a 1.4Å probe, which approximates the size of water. The VDW radii 
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used for glycan atoms during the solvent accessibility calculation, were based on the 
force fields published by the Complex Carbohydrate Research Center version j1122 
available online (www.glycam.com). The change in relative SASA was then calculated 
using R147. Amino acid residues that showed an increase in relative SASA of 10% or 
greater when glycan N301 was removed, were identified. The number of occurrences 
of an increase of ≥10% for each amino acid was tabulated. It should be noted that 
each amino acid is limited to a maximum of 30 occurrences, since only ten minimised 
state trimer models were determined, each of which consists of three protomers and, 
therefore, only three duplicates of each amino acid exists. All amino acid numbers 
correspond to the HXB2 gp160 position numbers (Genbank accession number 
K03455). 
 
To further visualise the potential differences in glycan clustering, each homology 
model was glycosylated a second time with glycan N301 excluded from the models. 
Here, therefore, the change in clustering when glycan N301 is absent and other 
glycans are permitted to reshuffle, was modelled. 
 
2.3 Results 
 
To gain further insight into the surface likely shielded by glycan N301 in each virus, 
the fully glycosylated Env trimer structures were modelled for the CAP45.G3 and 
Du156.12 wild-type sequences. Additionally, since each strain had a PNGS at either 
position 332 or 334 (sites known to play a role in neutralisation sensitivity), a variant 
of each was also considered during the study. These variants were denoted by 
CAP45.G3332 and Du156.12334 to indicate the variants where the PNGS, and 
consequently the glycan, was shifted from its wild-type position to either 332 or 334. 
 
For each of the four target sequences, ten energy state-minimisation conformations 
were generated, glycosylated, and analysed. For each replicate the solvent accessible 
surface area (SASA) was calculated, using a 1.4Å probe, and subsequently, 
compared to those calculated after glycan N301 was removed (section 2.2.3). The 
number of occurrences of a specific protein residue, among those with a 10% or 
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greater increase in its SASA when glycan N301 was removed, across all the protomers 
of the replicates, was determined (Table 2.3). 
 
Table 2.3: Comparison of the number of times an increase of 10% or greater was 
observed in the SASA measure after the removal of glycan N301. 
  V3 region C4 region 
  N301a T303 I323 G324 D325 E440c G441c N442 
332 
equitable 
comparators 
CAP45.G3332 
variant 
30 6 6 0 0 0 8 14 
Du156.12 
wild-type 
29 6 14 2 2 8 14 7 
334 
equitable 
comparators 
CAP45.G3 
wild-type 
30b 6 6 0 0 0 8 11 
Du156.12334 
variant 
30 5 10 0 0 5 13 12 
 
a HXB2 gp160 reference numbering 
b Number of occurrences where an increase of ≥10% was observed in the SASA 
measure. The occurrences were counted across ten replicates each with three 
protomers, i.e. max=30 
c Suspected co-receptor binding site residue 
 
This analysis revealed that several residues were more frequently shielded by glycan 
N301 on the Du156.12 wild-type models compared to the CAP45.G3 wild-type models 
(Table 2.3). Between the 332 equitable comparators e  (Du156.12 wild-type and 
CAP45.G3332 variant), access to three V3-loop residues (323, 324 and 325) and two 
C4 residues (440 and 441) were blocked by glycan N301 in a higher proportion of the 
Du156.12 wild-type models than in CAP45.12332 variant models (Table 2.3). For the 
334 equitable comparators (CAP45.G3 wild-type and Du156.12334 variant), similar 
results were observed, with the exception of residues 324 and 325, which were not 
differentially blocked (Table 2.3). On the other hand, only residue 442 (C4 region) was 
more frequently shielded by glycan N301 on the CAP45.12332 variant models 
compared to the Du156.12 wild-type models, which was not the case when comparing 
the 334 equitable comparators (CAP45.G3 wild-type model and Du156.12334 variant 
model; Table 2.3).  
                                            
e	Comparison	between	models	where	the	glycan	of	the	mutually	exclusive	PNGS	pair,	332	or	
334,	was	in	the	same	location.	
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In order to visualise the areas that were likely shielded by glycan N301, the wild-type 
and variant homology models were superimposed and the models of the equitable 
comparators, 332 (Figure 2.7) and 334 (Figure 2.8), compared. From these figures it 
is clear that the exposed protein residues are clustered around the N301A mutation 
site. Although previous reports indicated that glycan N301 often shields the CD4-
binding site from antibody binding54,66,67,69,71,148, here, these amino acids (Figure 2.7 
and Figure 2.8) did not overlap with residues known to participate in CD4 binding69,85. 
Despite this, the differences in increased SASA were consistent with the in vitro 
neutralisation results53 that demonstrated that the loss of glycan N301 resulted in 
varied resistance to neutralising antibodies for the two HIV-1 subtype C viruses. 
Specifically, the removal of glycan N301 resulted in substantial increases in 
neutralisation sensitivity of the Du156.12 viruses to sera from chronically HIV-1 
infected individuals (18/64), while comparatively few sera (3/64) exhibited a similar 
increase for the CAP45.G3 viruses. 
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Figure 2.7: Glycosylated trimer models of the glycan-N332 variants 
The predicted models of the (A-C) Du156.12 wild-type and (D-F) CAP45.G3332 variant 
sequences are superimposed to illustrate the effect of removing glycan N301 (dark 
blue) in the presence of glycan N332 (dark green) and other glycans (red). C and F 
provide further detail around glycan N301.  Amino acid residues with a relative SASA 
greater than 30% regardless of the presence or absence of glycan N301 are shown in 
orange. The backbone of the gp120 subunit and the associated partial gp41 subunit 
are shown in cyan. The amino acid residues with a change in relative SASA greater 
than 10%, when glycan N301 is removed, are shown in a purple ball representation 
(B, C, E and F). 
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Figure 2.8: Glycosylated trimer models of the glycan-N334 variants 
The predicted models of the (A-C) Du156.12334 variant and (D-F) CAP45.G3 wild-type 
sequences are superimposed to illustrate the effect of removing glycan N301 (dark 
blue) in the presence of the glycan N334 (dark green) and other glycans (red). C and 
F provide further detail around glycan N301.Amino acid residues with a relative SASA 
greater than 30% regardless of the presence or absence of glycan N301 are shown in 
orange. The backbone of the gp120 subunit and the associated partial gp41 subunit 
are shown in cyan. The amino acid residues with a change in relative SASA greater 
than 10%, when glycan N301 is removed, are shown in a purple ball representation 
(B, C, E and F). 
 
Since the above SASA results did not account for the reshuffling of glycans that 
surround position 301 after the glycan was removed, an additional analysis was 
performed where glycan N301 was excluded during the computational glycosylation 
process in order to allow the remaining glycans to “reshuffle” on the models. Visual 
inspection of these glycosylated models (without glycan N301) illustrated the influence 
that glycan clustering may have. Apart from the space created by removing glycan 
N301, no clear overall differences were observed between the glycan shields (Figure 
2.9). Additionally, there was also no clear difference in the volumes of space occupied 
by glycan N334 on the models where this glycan is present (Figure 2.9 E, F, G and 
H). However, glycan N332 on the CAP45.G3332 variant models (Figure 2.9 C) clearly 
occupied a broader spatial range than those on the CAP45.G3332 variant models 
without glycan N301 (Figure 2.9 D). This comparison supports the hypothesis that, 
after the removal of one glycan, the clustering, conformational heterogeneity, and 
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reshuffling of glycans are likely to play a role in the accessibility and formation of 
particular antibody epitopes.  
 
 
 
Figure 2.9: Taking glycan reshuffling into account 
Superimposed structures to illustrate the effect of including (A, C, E and G) or 
excluding (B, D, F and H) glycan N301 prior to glycan-attachment for the two pairs, 
332 and 334, of equitable comparators. Glycan N301 is shown in dark blue, glycans 
N332/N334 are shown in dark green, and other glycans are in red. 
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2.4 Discussion 
 
Glycans comprise approximately half of the molecular weight of the gp120 subunit of 
HIV-1 Env and substantially shield the Env trimer from recognition by antibodies56,57. 
Conversely, glycans also often form important parts of epitopes of broadly neutralising 
antibodies. While the effect of these opposing selective pressures, for and against a 
glycan, from the different categories of antibodies has been observed in HIV-1 infected 
individuals42, the phenomenon remains incompletely understood. Studying the in vitro 
changes in neutralisation sensitivity upon the removal of PNGSs (and therefore the 
glycan/s), along with structural modelling, can broaden our understanding of this 
observation. 
 
Here, the state minimisation molecular models were modelled for the strains and their 
variants considered during the in vitro analysis, i.e. the CAP45.G3 wild-type, 
CAP45.G3332 variant, Du156.12 wild-type and Du156.12334 variant strains. The 
analysis of these state minimisation molecular models revealed a notable increase in 
the SASA upon removal of glycan N301 for the Du156.12 models as compared to the 
CAP45.G3 models, irrespective of whether the models had a glycan present at 
position 332 or 334 (Table 2.3). The regions more often blocked by glycan N301 in the 
Du156.12 glycan models were in the V3-loop and C4 regions. Although no further 
laboratory experiments were carried out to determine to what extent any particular 
residue is part of frequently recognised neutralising epitopes, the models clearly 
suggest that the surface area blocked by glycan N301 is larger for the Du156.12 
models than for the CAP45.G3 models. 
 
The particular residues identified that are likely to be more exposed on the Du156.12 
models than the CAP45.G3 models upon removal of glycan N301, were residues 323–
325 (V3) and residues 440 and 441 (C4). Amino acids 440 and 441 are thought to be 
part of the co-receptor binding site149,150. None of the identified residues formed part 
of the CD4-binding site, which was partially expected based upon the in vitro results 
of the presented work, and those of other studies54,66,69,71,148. It is possible, however, 
that the exposure of the CD4-binding site once glycan N301 is removed is related to 
changes in dynamic constraints on the conformation of the V3-loop111, which may be 
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incompletely modelled here using only a state minimisation approach. Nevertheless, 
several key observations regarding the dynamic properties of HIV-1 Env glycans were 
described. Specifically, glycans adopted distinct conformations on different HIV-1 Env 
structures and reshuffling is likely to occur upon the removal of glycan N301, and both 
of these observations may affect the accessibility and formation of antibody epitopes. 
However, since the state minimisation models provided only limited information on the 
conformational heterogeneity of the modelled HIV-1 Env glycan shields, the next step 
was to carry out a more rigorous investigation, including molecular dynamics 
simulations, to analyse the spatial and temporal characteristics of these HIV-1 Env 
glycans.  
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Chapter 3 Glycans adopt distinct conformations on different HIV-
1 Envelope structures 
 
Although it is well established that the HIV-1 Env glycans form a “glycan shield” that 
protects the underlying protein from recognition by neutralising antibodies, Chapter 2 
introduced the concept of a “glycan hole”, which refers to the notion that when glycans 
are removed, an opening is created in the glycan shield that can be exploited by 
neutralising antibodies. This chapter further investigates the concept of glycan holes, 
and the work is carried out on the two HIV-1 wild-type subtype C strains, which present 
different glycan landscapes, introduced in Chapter 2. The analysis considered two 
pairs of molecular dynamics simulations, where each pair comprised a simulation of a 
wild-type model and its N301A mutant counterpart. The analysis of these simulations 
revealed distinct conformations for equivalent glycans, i.e. glycans that shared an 
aligned HXB2 sequence position, between wild-type models. These distinct, and 
potentially favoured, conformations were specifically influenced by the surrounding 
glycan landscape, and these glycan landscapes were also important in the context of 
the glycan holes, since it shaped how the removal of glycan N301 impacted each 
glycan shield uniquely on the N301A mutant models. Due to the fact that glycan 
conformation were dependent on the overall landscape, glycans adopted distinct 
conformations on different HIV-1 Env structures, even in the case where the overall 
landscape deviated by only a single glycan. 
 
3.1 Introduction 
 
As the only surface-exposed molecule of the HIV-1 virion, the Env glycoprotein trimer 
is targeted by the immune system during infection. Due to the selection pressure this 
creates, HIV-1 env is the most variable gene151–153 in an already diverse genome 
(section 1.1). This variability is demonstrated by the disparity in the lengths of gp120 
subunits between viral strains, which range from approximately 484 to 543 amino 
acids154,155. For this reason, the HIV-1 Env amino acid positions are normalised to the 
HXB2 reference sequence to enable comparison across viral strains. These 
comparisons between viral strains have demonstrated that, despite the high levels of 
sequence and length diversity, many PNGSs are conserved47. For example, the 
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PNGSs at positions 88, 156, 160, 197, 230, 234, 241, 262, 276, 289, 301, 332, 356, 
386, 392, 442 and 448 are abundant among subtype C strains47. These conserved 
PNGSs and their glycans compose wholly, or partially, the epitopes recognised by 
many of the bNAbs58,62,63,83,127,156–165 discussed previously (section 1.1.1). While the 
HIV-1 Env glycans have long been considered as a shield, it is now evident that the 
glycan shield itself can be targeted by antibodies. Therefore, understanding the 
conformational properties of the Env glycans will substantially increase our knowledge 
of bNAb epitopes, which is vitally important in guiding vaccine design. 
 
The structural investigation of HIV-1 Env and its glycans has traditionally fallen in the 
domain of X-ray crystallography87,88,91,92 and cryo-electron microscopy115–117. While 
these studies have provided important insights into the structural features of Env and 
its glycans, the single static state image these studies produce lacks information 
regarding the dynamic nature of glycans and the glycan shield they constitute. 
Computational methods that provide atomic level molecular dynamics simulations 
offer an alternative approach with great potential for further structural investigations 
as already demonstrated, in particular, by two studies86,89. Yang et al.89 showed that 
despite conformational heterogeneity of individual glycans over the course of a 
simulation, glycans can form a network of glycan-glycan interactions. In addition, the 
authors showed that the partial pre-organisation of the glycans potentially favours 
binding by bNAbs89. Similarly, Lemmin et al.86 showed that glycans and protomer 
scissoring work in unison to restrict access to the underlying protein. Furthermore, the 
authors distinguish patches of glycans that form stable microdomains, with 
neutralising antibodies generally binding at the interface between these glycan 
microdomains86. While these studies provide valuable insight into key features of the 
glycan shield, they do not compare features between simulations of different Env 
glycoprotein trimers. This important comparison is the focus of the current chapter. 
 
With the goal of defining, understanding and comparing conformational properties of 
the Env glycan shield, four molecular dynamics simulations of fully glycosylated Env 
trimers were analysed. These models included the computationally-modelled 
glycosylated Env structures of the two subtype C strains introduced in Chapter 2. The 
remaining two simulations were of the N301A mutant forms of these models. The 
N301A mutant simulations were carried out to add insight on “glycan holes”, a concept 
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that implicates the removal of a glycan in the exposure of residues of the underlying 
protein. Thus, while any glycan was comparable between a wild-type and its N301A 
mutant counterpart, only glycans that shared an aligned HXB2 sequence position (i.e. 
equivalent glycans) were comparable within type, i.e. between wild-type or between 
N301A mutant models.  
 
The comparison between a subset of wild-type equivalent glycans revealed that both 
the conformations and interaction networks of these glycan were distinct between the 
wild-type models. This was more so for some glycans (e.g. glycans N446/N448 and 
N442) than others (e.g. glycans N156 and N262). For the comparison between each 
wild-type and its N301A mutant model counterpart (paired models), at least one glycan 
neighbouring the mutation site displayed an altered conformation. However, an 
additional, expanded comparison between the paired models demonstrated that 
glycans further from the mutation site also displayed relatively large conformational 
variations. Finally, collectively, these results, and a comparison between the N301A 
mutant models, directly associated the N301A mutant glycan conformation with the 
protein residues ultimately found to be exposed, which may explain the varied 
resistance to neutralising antibodies observed, in vitro, for the two N301A mutant 
strains. 
 
3.2 Methods  
 
3.2.1 Structural modelling and molecular dynamics simulations 
 
The protomer structures were generated using MODELLER136,137 (section 2.2.1). The 
CAP45.G3 (GenBank accession number DQ435682) and Du156.12 (GenBank 
accession number DQ411852) sequences were used as the targets, and three 
reference structures (PDB IDs 4NCO91, 4TVP87 and 2B4C139) were used as starting 
templates (sections 2.2.1.1 and 2.2.1.2). The modelling was repeated ten times for 
each strain, and models were ranked according to their DOPE scores140 (section 
2.2.1.2). The models of the CAP45.G3 and Du156.12 sequences with the lowest 
DOPE scores were then selected, triplicated, and the three copies were aligned to the 
protomers of the 4NCO91 trimer structure to generate the trimeric model.  
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Thereafter, for each PNGS, where possible, a Man9GlcNAc2 glycan (Manα1-2Manα1-
6[Manα1-2Manα1-3]Manα1-6[Manα1-2Manα1-2Manα1-3]Manβ1-4GlcNAcβ1-
4GlcNAcβ1-) was attached using a prototype tool under development for the Glycam-
Web suite of web tools145 (section 2.2.2). However, for the CAP45.G3 model, no 
attempt was made to glycosylate two of the PNGSs, N335 and N678; site 335 occurs 
in an NNST motif and due to the importance of glycan N334 in the context of bNAbs42 
and since glycan N334 is relatively more abundant than glycan N33547, glycan N334 
was glycosylated instead of glycan N335 (section 2.2.2), and N678 falls outside the 
modelled domain. For the Du156.12 model, one of the PNGSs, N625, was not 
glycosylated, for consistency, since it occurs in an NNTT motif (section 2.2.2).   
 
Of the remaining 81 and 84 PNGSs for the CAP45.G3 and Du156.12 models, 79 and 
77 were computationally glycosylated, respectively. During the first round, 
glycosylation of sites N160 (CAP45.G3, protomer C as well as Du156.12, protomer 
B), N295 (Du156.12, protomer B), N339 (Du156.12 protomer A, B and C), N393 
(Du156.12 protomer A, B and C), N399 (CAP45.G3, protomer B), N386 (CAP45.G3 
protomer C) and N442 (Du156.12, protomer B) failed. However, after 30 ns 
simulations (according to the steps described below), a second glycosylation attempt 
was carried out and sites N386 (CAP45.G3, protomer C), N295 (Du156.12, protomer 
B) and N442 (Du156.12, protomer B) were successfully glycosylated, whereas sites 
N160 (CAP45.G3, protomer C and Du156.12, protomer B), N339 (Du156.12 protomer 
A, B and C), N393 (Du156.12 protomer A, B and C) and N399 (CAP45.G3, protomer 
B) remained unglycosylated. These ‘fully’ glycosylated models were then used to 
create the N301A mutant models by replacing the Asn residue at position 301 (HXB2 
numbering) with an alanine residue and removing the glycan for both the CAP45.G3 
and Du156.12 wild-type models. 
 
The systems for simulation were created using the tLEaP package contained in 
AmberTools 14123. The ff14SB121 force field was used for the protein and the 
GLYCAM06j-1122 force field for the glycans. The wild-type and N301A mutant systems 
were immersed in a truncated octahedron water box containing TIP5P124 water 
molecules (section 1.3.3), since TIP5P was found to produce the best quantitative 
agreement with experimental data125. The box size was set such that all protein and 
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glycan atoms were 15Å from the edge of the box (section 1.3.4). Chloride ions were 
added to neutralise the system. 
The molecular dynamics simulations were produced using AMBER 14123. The systems 
were minimised by running 10,000 steps of steepest descent and 10,000 steps of 
conjugate gradient minimisation. During minimisation, restraints were placed on all 
non-hydrogen protein and glycan atoms. The systems were equilibrated by running 
0.4 ns simulations under nPT (1 bar, 300 K) on a CPU cluster. During the first 
equilibration stage, Cartesian restraints (5.0 kcal/mol) were placed on all non-
hydrogen protein and glycan atoms. Thereafter, the restraints were removed, and the 
equilibration was extended by another 1 ns on a GPU cluster (to ensure stability across 
clusters) before the production run was initiated on the GPU cluster. The 520 ns 
production runs were generated on a GPU cluster using AMBER GPU acceleration 
pmemd123 and 0.002 ps time steps, with coordinates written to the trajectory file every 
10,000 steps. 
 
3.2.2 Analyses 
 
3.2.2.1 Root mean square deviation (RMSD) to investigate equilibrium states 
 
The conformational stability of each protein model was assessed by calculating the 
RMSD between the protein backbone atoms (C, C-alpha, N, O) of the starting structure 
and the structure at each time point during the production run, i.e. for each of the saved 
26,000 frames during the simulation. This analysis was carried out using the whole 
protein as well as, separately, using only the conserved and only the variable loop 
regions (section 3.3.2). Equilibrium was reached by 20 ns for each system; the first 20 
ns of each trajectory was therefore discarded, and further analyses carried out on the 
remaining 500 ns, including 25,000 frames, of each simulation (section 3.3.2).  
 
3.2.2.2 Hydrogen-bond analyses to determine and visualise the N301-glycan clusters 
 
Since glycans form dense clusters on the HIV-1 Env surface88,89, the first objective 
was to investigate the clusters surrounding position 301 of the CAP45.G3 and 
Du156.12 wild-type models. Hydrogen-bond analyses were carried out to determine 
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which glycans formed part of the N301-glycan clusters. The hbond function of 
cpptraj166 (AmberTools 14), and the default cut-off values for the distance between the 
heavy atoms (3Å) and the angle between the acceptor and donor atom (135 degrees), 
were used. For each frame in each trajectory (25,000 frames), it was noted whether 
hydrogen bonds were formed between any of the hydrogen atoms of two different 
glycans. The total number of times a hydrogen bond was formed between any two 
glycans was calculated, and thus, for each glycan pair (including inter-protomer pairs), 
the percentage time a hydrogen bond existed during the entire trajectory was 
determined. These percentages were further grouped ([0-25%), [25-50%), [50%-
75%), and [75%-100%]f) and plotted on a circular graph, using edgebundleR167 and 
R147.   
 
3.2.2.3 Glycan heterogeneity of the wild-type models 
 
The hydrogen-bond analyses revealed that the N301-glycan clusters for the 
CAP45.G3 and Du156.12 wild-type models varied in size and conformation. Since 
these differences were likely to affect the subsequent changes once glycan N301 was 
removed, it was important to first determine the heterogeneity of the wild-type model 
glycans. In order to describe the conformational differences between glycans on the 
CAP45.G3 and Du156.12 wild-type models, an “average” conformation of each glycan 
was projected, separately, onto its first principal component.  
 
The first principal component, and subsequently the projections, were determined 
using the matrix, diagmatrix and projection functions of cpptraj166. The visualisations 
of the movement along the first principal component required an average 
conformation. This average conformation was determined by first calculating the 
RMSD between all the conformations of the glycan under consideration using the 
2drms function of cpptraj166. Then, by using the upper triangular matrix this generates, 
the average RMSD of each conformation was calculated by averaging across the 
rows. The conformation with the smallest average RMSD, i.e. the conformation that 
was the most similar to all other conformations, was defined as the average 
                                            
f	Standard	interval	notation	where	square,	‘[‘	and	‘]’,	and	round,	‘(‘	and	‘)’,	brackets	indicate	
whether	the	endpoints	are	included	or	not,	respectively.	
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conformation. This method of determining the average conformation was used instead 
of the standard method (that averages coordinates across the trajectory), since the 
standard method results in a distorted glycan conformation. This is due to the relatively 
larger variability in glycan conformations over the course of the simulation compared 
to those of protein residues. Once the average conformation was determined for each 
glycan, it could be projected onto the first principal component by adding, to its 
coordinates, the projection matrix multiplied by an index value. Subsequent 
projections were, therefore, determined by altering the index value. The number, as 
well as the exact numerical values, of the indices were determined by using the lower 
and upper quartiles of the first principal component as the interval endpoints, with the 
numerical values spread within these endpoints (each incremented by one). For 
example, if the first principal component values had upper and lower quartile values 
of -1 and 5, there would be seven indices with values of -1, 0, 1, 2, 3, 4 and 5. This 
implies that a glycan with more variable conformations and, therefore, greater 
variability in its first principal component was represented by more projections of its 
average glycan conformation than a glycan with less variability. Visual representations 
of these projections were generated using UCSF Chimera168 and by setting these 
projection conformations to opaque, with the average conformation represented as a 
“solid” form. 
 
3.2.2.4 Conformational heterogeneity between wild-type and N301A mutant model 
glycans 
 
The conformational analyses of the wild-type glycans revealed several differences, 
which provided a proxy for the detailed analysis between the glycans of each wild-type 
and N301A mutant model pair. Multiple comparisons of glycan conformations, from 
various sources, i.e. different time points, protomers and models, were carried out in 
order to obtain a detailed account of the glycan conformational heterogeneity. The 
2drms function in cpptraj166, which computes the RMSD between every pair of frames 
of the supplied trajectory, was used, and pseudo-trajectories were generated 
specifically for the heterogeneity analysis. These trajectories were constructed such 
that the first frames were from the relevant wild-type simulation, starting with those 
from protomer A, followed by the frames from protomers B and C, and then followed 
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by the N301A mutant model simulation frames, protomer A through to C. All the frames 
of these pseudo-trajectories were aligned to the first frame of the applicable trajectory 
using the protein backbone atoms. Subsequently, to restrict the analysis to only the 
glycan under consideration (N156, N197, N262, N332/N334, N442 or N446/N448), all 
other atoms were removed from the trajectory. Therefore, running the 2drms routine 
on one of these trajectories resulted in an upper triangular matrix containing the RMSD 
calculated between all the atoms in the frames indicated by the row and column. For 
example, the cell in row 5 and column 10 constrained the RMSD calculated between 
all the atoms in frames 5 and 10. Therefore, by selecting certain combinations of rows 
and columns from this RMSD triangular matrix, it was possible to evaluate 
conformational differences across time, between protomers or between models. For 
example, Table 3.1 shows the RMSD matrix and the regions selected for each 
analyses, i.e across time (Table 3.1, blue), between protomers (Table 3.1, orange) 
and between the protomers of the wild-type and N301A mutant model counterparts 
(Table 3.1, pink). The box plots of these RMSD distributions were subsequently plotted 
using R147. 
 
Table 3.1: The 2drms upper triangular matrix and the sections used during the 
comparisons over time (blue), between promoters (orange), and between the 
protomer of the wild-type and N301A mutant model counterparts (pink). 
  Wild-type protomers N301A mutant protomers 
  A 
[1,25k]a 
B 
(25k,50k] 
C 
(50k,75k] 
A 
(75k,100k] 
B 
(100k,125k] 
C 
(125k,150k] 
Wild-type 
protomers 
A       
B       
C       
a Columns of the represented matrix.   
 
3.2.2.5 Extended investigation using principal component analysis (PCA) 
 
Since the initial investigation focused only on glycans that neighbour the N301A 
mutation, further analysis that would extend this initial work was required. Therefore, 
PCA was performed to investigate the conformational heterogeneity of all the glycans, 
as well as the protein, between the wild-type and N301A mutant model counterparts. 
While PCA is relatively capable of dealing with “wide” data, it is still preferable to 
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reduce the data to the minimal working set to circumvent the curse of dimensionality 
that can decay the power of the PCA. For this reason, the comparison between the 
wild-type and N301A mutant model counterparts were limited to the protomers, and 
for each protomer the protein residues and glycans were considered separately. The 
pseudo-trajectories for this analysis were assembled such that the first frames 
originated form the wild-type model simulations, followed by the frames from the 
relevant N301A mutant model simulation. These pseudo-trajectories were created, 
separately, for each protomer (A, B and C) and wild-type model (CAP45.G3 and 
Du156.12). Additionally, as before, the frames were aligned to the first frame of each 
pseudo-trajectory, using the protein backbone atoms, before the analysis was carried 
out. Thus, for the protein PCA, the glycan residues were removed and, similarly, for 
the glycan PCA, the protein residues were removed. The PCA was then performed on 
these pseudo-trajectories using the matrix, diagmatrix and projection functions of 
cpptraj166 and graphed using R147. 
 
After determining that the first principal components reasonably differentiated between 
the wild-type and N301A mutant model frames, the factor loadings of the first principal 
components were determined by squaring each value of the first eigen vector. Since 
these values represented the factor loadings of individual atoms, they were summed 
to obtain the factor loadings of the total protein residues or glycans. Given that small 
changes in the factor loadings could potentially impact which glycans, or protein 
residues, were identified during the analysis, a median factor-loading value was 
determined instead. These medians were determined using 100 moving-blocks 
bootstrap replicates. The 50 ns blocks were defined such that each block could only 
start on whole nanoseconds to ensure adequate sampling of the whole trajectory. 
There were, therefore, 450 possible blocks for each of the wild-type and N301A mutant 
simulations, with ten random blocks required for each bootstrap replicate. The pseudo-
trajectories required for each bootstrap replicate were generated by first randomly 
selecting 10 blocks from the relevant wild-type protomer simulation, followed by 10 
blocks randomly selected for the corresponding N301A mutant protomer simulation. 
Moving-blocks bootstrap was used instead of a normal bootstrap approach to 
conserve the correlation between sequential observations. 
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To address the possibility that random variation caused the observed differences 
between the wild-type models and their N301A mutant counterparts, it was necessary 
to quantify each glycans’ random variation. For this purpose, the conformational 
heterogeneity between the protomers of the same wild-type model were used to 
disqualify any protein residues, or glycans, with relatively large random variation. This 
assessment of the variation was determined in a similar way to that between the wild-
type and N301A mutant models, i.e. with 100 bootstrap replicates used to determine 
the medians. The key difference was the pseudo-trajectory used. In this instance, the 
pseudo-trajectories were assembled such that the first frames originated from 
protomer A, followed by the frames of protomers B and C. These pseudo-trajectories 
were created, separately, for each wild-type simulation.   
 
3.2.2.6 Antibody accessible surface area for protein residues 
 
Taken together, the results from the previous analyses showed that not only did each 
glycan shield respond differently to the N301A mutation, but the conformational shifts 
were distinct for each of the N301A mutant models. Therefore, to describe these 
unique responses to the N301A mutation in a meaningful way, the antibody accessible 
surface area (AASA) was calculated. This calculation was performed using a 10Å 
probe (as an approximation of the size of an antibody87) with Naccess146 for both the 
CAP45.G3, and Du156.12, wild-type and N301A mutant model simulations. The van 
der Waals radii of the glycan atoms were defined as described for the GLYCAM06j-
1122 force field. The AASA was calculated for 2,500 evenly spaced frames across the 
500 ns trajectories.  
 
Differences between the AASA values of the wild-type and N301A mutant models 
could be attributed to either the protein and/or glycan movements and, therefore, the 
AASA values were normalised to remove any changes in the AASA due to protein 
movements. This was done by determining the “base/maximum” AASA by removing 
the glycans and re-calculating the AASA for these non-glycosylated frames. The final 
AASA ratio, per frame, was the ratio of the glycosylated and non-glycosylated AASA 
values, calculated by dividing the AASA of the glycosylated protein by the AASA of 
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the non-glycosylated protein. Averages were calculated using these AASA ratios over 
time. 
 
The mean AASA ratio, per residue, of the N301A mutant model simulations were 
compared to those of their wild-type model counterparts to determine whether there 
were statistically significant increases. The AASA ratio distribution of each residue, 
under the null-hypothesis (wild-type and N301A mutant model AASA ratio means are 
equal), was assessed by using 100 moving-blocks bootstrap replicates. The AASA 
ratio datasets for each model were mean normalised to satisfy the null-hypothesis 
before bootstrap replicates were drawn. These bootstrap replicates were constructed 
similar to those of the PCA. Variance normalisation was not performed since 
numerous residues had average AASA ratios (over time) equal to zero. The significant 
residues were further filtered to include only those where the difference between the 
average AASA ratio for the wild-type and N301A mutant model over time was 10% or 
greater.  
 
3.3 Results 
 
As described in section 3.1, the main goal of this chapter was to define and compare 
conformational features of glycans of two glycosylated Env-modelled molecular 
dynamics simulations. The first step towards this goal was to establish the differences 
between the PNGS profiles of the wild-type models (section 3.3.1), which was followed 
by verifying the stability of the molecular dynamics simulations (section 3.3.2) and the 
selection of a subset of glycans for further analyses (section 3.3.3). Thereafter, the 
conformations of the glycans in this subset were compared between the wild-type 
models (section 3.3.4) as well as between each wild-type model and its N301A mutant 
counterpart (i.e. paired models, section 3.3.5). The comparison between the paired 
models was further extended to include protein residues and all the remaining glycans 
(section 3.3.6). Finally, the integrity of each N301A mutant model was evaluated and 
compared between the strains (section 3.3.7). These results offer a detailed account 
of the conformational heterogeneity, in silico, of HIV-1 Env glycans. 
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3.3.1 Overview of the PNGS profiles of the wild-type models 
 
To examine which PNGSs were contained within the modelled domains of the 
CAP45.G3 and Du156.12 strains, the locations of Asn-X-Thr/Ser motifs were 
determined (Figure 3.1). The CAP45.G3 wild-type strain contained 27 PNGSs, which 
included PNGSs at positions 334 and 446, whereas the Du156.12 wild-type strain had 
28 PNGSs, with PNGSs at positions 332 and 448. These positions (332/334 and 
446/448) represent mutually exclusive PNGSs that were inverted in the two wild-type 
strains. Both strains contained a PNGS at position 301, which was removed to create 
the N301A mutants. Although each PNGS could not be glycosylated during the 
computational glycosylation, it is known that there is variation in glycan occupancy, 
i.e. not all PNGSs are glycosylated 100% of the time49,72–82,95,169. Therefore, there are 
potentially several different glycosylated forms of Env glycoproteins, and the models 
used here (Figure 3.2) are representations of one of the possible forms of the Env 
glycoprotein of the CAP45.G3 and Du156.12 strains. 
 
 
Figure 3.1: Distribution of PNGSs 
PNGSs contained within the CAP45.G3 (blue) and Du156.12 (orange) strains in 
relation to the HIV-1 reference strain, HXB2 (pink) are shown. The gp160 conserved 
(C1-C4), variable (V1-V5) and gp41 sequence regions are labelled and shaded to 
indicate the borders of each region.  
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Figure 3.2: Glycan landscapes of the wild-type models 
3D representation of the N-linked glycosylation sites of the (A) CAP45.G3 and (B) Du156.12 Env models. The protein residues and glycans are shown as 
surfaces and the glycans are labelled according to HXB2 numbering. 
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3.3.2 Assessing the stability of the molecular dynamics simulations 
 
Molecular dynamics simulations evolve the conformation of a molecule forward in 
time. If the initial conformation is unrepresentative of an equilibrium conformation, the 
initial samples (i.e. frames) of the trajectory will correspond to the conformation in the 
tails of the equilibrium distribution. In short simulations, as analysed here, one would 
not expect to observe the initial conformations and this portion of the trajectory is 
commonly discarded. To determine which portion to exclude from the analysis, the 
RMSD was calculated between each frame and the starting frame for all backbone 
atoms (Figure 3.3; A and B). Since the HIV-1 Env variable regions (V1-V5) are 
generally more flexible than the conserved regions (C1-C5), the RMSD for the 
conserved (Figure 3.3; C and D) and variable (Figure 3.4) regions were calculated 
separately.  
 
 
Figure 3.3: RMSD calculated for all the protein residues or only those in the 
conserved regions 
The RMSD (Å), over time (ns), for each wild-type and N301A mutant model simulation, 
calculated for all backbone atoms (A and B), and only the atoms of the conserved 
regions (C and D). For each RMSD calculation, the first frame was used as reference. 
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Figure 3.4: RMSD calculated for the variable regions 
The RMSD (Å) over time (ns) for each wild-type and N301A mutant simulation, 
calculated for backbone atoms of the variable regions (V1-V5). 
 
An upward trend over time was observed for the RMSD calculated using the entire 
protein (Figure 3.3; A and B); however, this trend was far less pronounced when the 
variable regions were removed from the analysis, i.e. calculating the RMSD using only 
the residues found in the conserved regions (Figure 3.3; C and D). After the first 20 
ns, the RMSD of the conserved regions fluctuated between 1.5 and 3.5Å, suggesting 
that the conformations of the protein backbones were more stable during the latter 
portion of the simulation. In comparison, the variable regions fluctuated between 0.8 
and 6.8Å after the first 20 ns (Figure 3.4), with substantial variation between the 
individual variable regions, which is expected given the large degree of variability in 
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the sequence lengths and composition of these regions. The relative stability of the 
conserved regions after 20 ns provided an indication that an equilibrium state was 
reached; the first 20 ns of each simulation was thus discarded, and the remaining 500 
ns was used for all subsequent analyses.  
 
There was no clear difference between the RMSD results of the wild-type and N301A 
mutant models for either the conserved or variable regions (Figure 3.3 and Figure 3.4), 
which suggests that the N301A point mutation did not cause any apparent disruptions 
to the conformations of the protein backbone of either the CAP45.G3 or Du156.12 
models. 
 
In summary, the RMSD analyses demonstrated that the models had relatively stable 
conformations after the first 20 ns, and that the N301A mutation, and loss of this 
glycan, did not have a discernible influence on the conformations of the protein 
backbones. Given these results, most of the analysis was focused on comparing the 
glycan (and not protein) conformations. 
 
3.3.3 The organisation of the N301 glycan-glycan interaction networks on the wild-
type models 
 
Glycans form dense clusters on the HIV-1 Env surface88,89 and the glycan 
arrangements are therefore likely to be affected by the loss of a glycan. Here, the aim 
was to determine the composition of the N301-glycan clusters of the CAP45.G3 and 
Du156.12 wild-type models. Describing these clusters allows for the subsequent 
investigation of how each cluster changes after the removal of one of the glycans 
forming part of that cluster – in this case glycan N301. Steward et al.88 and Yang et 
al.89 defined glycan clusters using their proximity to one another. However, instead of 
using distance-based calculations that are intractable due to time constraints, glycan 
clusters were determined using the glycan-glycan interaction networks (hydrogen 
bonds). For each glycan-glycan interaction, the proportion of frames in which the 
interaction is present during the simulation was calculated. These results are 
represented on circular network graphs that illustrate both within and between 
protomer (cross-protomer) interactions (Figure 3.5 and Figure 3.6). 
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Figure 3.5: CAP45.G3 wild-type model N301 glycan-glycan interaction network 
Interaction networks between glycan N301 and any other glycan on each protomer (A, 
B and C) are depicted. Specific line types represent different interaction frequencies 
(0-100%). 
 
The interaction partners of glycan N301 on the CAP45.G3 wild-type model varied 
slightly between the protomers; in total seven glycans (N156, N197, N262, N276, 
N386, N442 and N446) were identified (Figure 3.5). Four glycans (N156, N197, N442 
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and N446) formed part of the N301-glycan cluster on all the CAP45.G3 wild-type 
protomers.   
 
 
Figure 3.6: Du156.12 wild-type model N301 glycan-glycan interaction network 
Interaction networks between glycan N301 and any other glycan on each protomer (A, 
B and C) are depicted. Specific line types represent different interaction frequencies 
(0-100%). 
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For the Du156.12 wild-type model, the N301-glycan clusters varied to a larger degree 
between protomers and in total eleven glycans (N135, N139, N145, N156, N189, 
N197, N262, N295, N332, N442 and N459b) were identified (Figure 3.6). However, 
despite the variation, glycans N156, N197, N262 and N442 were found on all the 
protomers. 
 
Taken together, the glycan-glycan interaction network analysis showed that glycans 
N156, N197 and N442 were consistently found to interact with glycan N301 on both 
the CAP45.G3 and Du156.12 wild-type models. Additionally, glycan N446 formed part 
of the N301-glycan cluster on the CAP45.G3 model, and N262 on the Du156.12 wild-
type model. Therefore, the loss of glycan N301 from the cluster is likely to have a 
pronounced effect on the conformations of each of these glycans. However, the 
glycan-glycan interaction network analysis only presents information on the interaction 
frequencies and, therefore, does not provide insight on the directionality, or shape, of 
each cluster. If the conformations of the N301-glycan clusters are irregular across 
protomers and models, the loss of glycan N301 would likely impact each cluster in a 
different way. Thus, to gain a better understanding of the conformational 
characteristics of each cluster, a preliminary analysis was carried out on the three 
glycans (N156, N197, and N442) that formed part of the N301-glycan clusters on both 
wild-type models.  
 
3.3.4 Evaluation of the conformational variance between equivalent glycans present 
on the wild-type models 
 
In section 3.3.3, the glycan-glycan interaction networks of glycan N301 were 
investigated and compared between the CAP45.G3 and Du156.12 Env wild-type 
models. Although several differences were observed, three glycans (N156, N197 and 
N442) were present in both wild-type N301-glycan interaction networks. The 
conformational differences for each of these glycans common to each distinct model 
are important considerations, since these differences are likely to impact the way the 
glycan conformations change upon removal of glycan N301. 
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Therefore, to investigate the extent of conformational heterogeneity between the 
N301-glycan clusters on each model, the extended hydrogen-bond networks of 
glycans N156, N197 and N442, were determined. The conformations of each of these 
glycans and their interaction partners were then visualised and compared between the 
wild-type models.  
 
The visual representations were obtained by determining the predominant movement 
of each glycan using principal component analysis. Each shared glycan, and its 
interaction partners, were projected onto their individual, separate, first principal 
components. These interaction partners were restricted to include only those glycans 
where interaction frequencies of 10% or greater were observed during the relevant 
simulation. This criterion meant that glycan N301 itself was not always included in the 
comparison, as its interaction frequency was lower than 10% for several protomers of 
the wild-type models during the simulations. Detailed analysis of each of these 
networks highlighted several interesting conformational differences as well as 
important contextual characteristics, i.e. how the glycan distribution and “landscape” 
varied around glycan N301. 
 
The visual representation of glycan N156 and its interaction partners illustrated that 
glycan conformations can be heterogeneous across models (Figure 3.7). For the N156 
glycans on the CAP45.G3 wild-type model, three interaction partners were present 
across protomers. Glycan N190b, which is located on the Env protein apex, and either 
glycan N197 or N301, which appear to compete as interaction partners (Figure 3.7 A, 
C and E). On the Du156.12 wild-type model, the interaction partners of the N156 
glycans, glycans N139, N160 and N189, were all on the protein apex (Figure 3.7 B, D 
and F). This distinction, where a greater number of interaction partners were available 
on the protein apex of the Du156.12 wild-type model, may be one reason for the 
differences in glycan conformations observed between the CAP45.G3 and Du156.12 
wild-type models. As can be seen in Figure 3.7, the N156 glycans on the Du156.12 
wild-type model displayed conformations that were all orientated more toward the 
protein apex than those on the CAP45.G3 wild-type model. However, the lack of apex 
interaction partners for glycan N156 on protomer B (Figure 3.7 D), that also displayed 
the distinct conformation orientated towards the protein apex, is perplexing, as it 
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implies that frequent interactions with the apex partners were not the sole cause for 
the orientation of the N156 glycans on the Du156.12 model.  
 
 
Figure 3.7: Movement and interaction networks of glycan N156 
Interaction frequencies, shown as horizontal bar graphs, and 3D movement 
representations for the glycans forming part of the N156-glycan interaction network of each 
protomer during the CAP45.G3 and Du156.12 wild-type model simulations. 
 
The next comparison, focussing on the N197-glycan interaction networks, revealed 
interesting differences in the intra- and cross-protomer interactions. For the CAP45.G3 
wild-type model, each N197 glycan had two interaction partners. One of these partners 
formed a cross-protomer interaction, either glycan N156 or N301, and the other an 
intra-protomer interaction, either glycan N133 or N386 (Figure 3.8 A, C and E). These 
interaction partners effectively confine the N197 glycans, limiting their movements. 
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However, the N197 glycans on the Du156.12 wild-type model exclusively formed 
cross-protomer interactions with glycans N156, N262 or N301, depending on the 
protomer. Consequently, the conformations of the N197 glycans on the Du156.12 wild-
type model appeared less restricted, which resulted in larger observed conformational 
differences between the protomers of this model (Figure 3.8 B, D and F). 
 
 
Figure 3.8: Movement and interaction networks of glycan N197 
Interaction frequencies, shown as horizontal bar graphs, and 3D movement 
representations for the glycans forming part of the N197-glycan interaction network of each 
protomer during the CAP45.G3 and Du156.12 wild-type model simulations. 
 
The final wild-type glycan interaction network comparison was for glycan N442 (Figure 
3.9), which appeared to move substantially on both models compared to the N156 and 
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N197 glycans. The N442 glycans on the CAP45.G3 wild-type model consistently 
displayed conformations orientated towards the protein apex for all three protomers 
(Figure 3.9 A, C and E). Furthermore, glycan N137 was consistently an interaction 
partner of the N442 glycans, which was also observed on all three protomers (Figure 
3.9 A, C and E). In contrast, the N442 glycans on the Du156.12 wild-type were 
orientated towards the gp41 region and displayed substantial interactions with the 
N301 glycans (Figure 3.9 B, D and F). These conformations may, in part, be due to 
the N301-N442 glycan interactions and in part due to structural hindrance by V1V2 
glycans (N135 or N145). 
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Figure 3.9: Movement and interaction networks of glycan N442 
Interaction frequencies, shown as horizontal bar graphs, and 3D movement 
representations for the glycans forming part of the N442-glycan interaction network of each 
protomer during the CAP45.G3 and Du156.12 wild-type simulations. 
 
Taken together, the glycan interaction network comparison between the wild-type 
models clearly illustrated how different the N301-glycan cluster formations are, despite 
including the same, shared, interaction partners. Given these conformational 
differences of the N301-glycan clusters, it would be naïve to expect that the loss of 
glycan N301 from these wild-type models would have the same impact on the 
conformations of the remaining glycans. In the following section (section 3.3.5), the 
conformational heterogeneity comparison is expanded to include further neighbouring 
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glycans and describes, in detail, the extent of glycan conformational heterogeneity 
within, and between, protomers and paired models. 
 
3.3.5 Removing glycan N301: model-specific differences between the conformations 
of neighbouring glycans 
 
Apart from glycans N156, N197, and N442, which were shared glycans for each wild-
type N301-glycan cluster, glycans N446 and N262 formed consistent interactions 
across protomers with glycan N301 on the CAP45.G3 and Du156.12 wild-type models, 
respectively (section 3.3.3). Therefore, these two glycans were included in the new 
glycan subset for the detailed conformational heterogeneity analysis. In addition, 
glycans N448, N332 and N334 were also included in the analysis; glycan N448 is the 
mutually exclusive counterpart of glycan N446, and glycans N332 and N334 (also a 
mutually exclusive pair) were key consideration during the in vitro analysis53.  
 
To adequately describe and compare the conformational heterogeneity of the glycans 
within the new glycan subset, three glycan-group terms were defined: unique glycans, 
glycan siblings, and glycan families. The unique glycan group defines each individual 
glycan and is specified by the glycan position (e.g. “N156”), a protomer (e.g. “protomer 
A”) and a model (e.g. “CAP45.G3 wild-type”). Each model includes a set of three 
unique glycans, one from each protomer, that can then further be defined as glycan 
siblings, i.e. glycans N156 of the CAP45.G3 wild-type model are “N156 glycan 
siblings”. Finally, a glycan family includes all glycans at a specific position, regardless 
of the protomer or model. The 12 glycans (3 protomers A, B and C, of 4 models) 
attached to position 156 constitute the “N156 glycan family”. As described in the 
methods section 3.2.2.4, the conformational heterogeneity of glycans was investigated 
using the 2dms routine, which calculates the RMSD between all atoms in all frames of 
the supplied trajectory. By sub-setting and concatenating specific sections of the 
simulated trajectories, it is possible to examine conformational heterogeneity, over 
time, for unique glycans (section 3.3.5.1), between siblings (section 3.3.5.2), and 
between glycans from paired models (section 3.3.5.3). 
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To further illustrate the framework for these analyses, an example of each is presented 
in Figure 3.10. For each analysis, a conformation in group 1 was compared, using 
RMSD, to a conformation in group 2.  
 
 
Figure 3.10: Framework of the conformational heterogeneity analyses 
Each schematic (A, B and C) represents one of the three conformational heterogeneity 
analyses. (A) The comparison over time for unique glycans, termed flexibility; (B) the 
comparison between glycan siblings (versatility); and (C) the comparison between 
unique glycans from the wild-type and N301A mutant paired models.  
 
For the first analysis focusing on unique glycans, group 1 and 2 are the same 
conformations (e.g. all conformations of glycan N156 on a specific protomer and 
model). Thus, the resulting RMSD distribution represents the flexibility of a unique 
glycan (Figure 3.10 A).  
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The second analysis follows on from the first, where each unique glycan is compared 
to each of its siblings, and these siblings to each other. Group 1 represents the 
conformations of a unique glycan and group 2a and 2b the confirmations of its siblings 
(Figure 3.10 B). The distributions of these RMSD values represent the versatility of a 
glycan.  
 
For the final analysis (wild-type vs N301A mutant model), group 1 contained the 
conformations of a unique glycan (without its siblings) and group 2 those of its N301A 
mutant model counterpart (Figure 3.10 C). This analysis was extended to include, in 
group 1, all the conformations of a unique glycan and its siblings from the wild-type 
model, and in group 2 the glycan conformations of the glycan siblings on the N301A 
mutant model. However, these combined results did not provide meaningful 
information due to the large interquartile ranges and low overall differences between 
the glycan families and were not included for discussion (Supplementary Figure S3.1). 
 
These three analyses are inherently related, since each expands the preceding 
analysis by including, successively, more distant (siblings) and parallel (paired 
models) glycan conformations in the analysis set. The results for each are presented 
in sub-sections 3.3.5.1-3.3.5.3. 
 
3.3.5.1 The conformational heterogeneity of glycans over time 
 
When a glycan is removed from a densely glycosylated area, one possible 
consequence is that the glycan shield’s established equilibrium is maintained. This 
implies that the observed flexibility of the glycans surrounding the space created by 
the missing glycan (vacated space), increases, without substantially altering their 
average conformations. Under this hypothesis, the glycans of the CAP45.G3 and 
Du156.12 models surrounding the N301A mutation that displayed model specific 
flexibilities were distorted, i.e. had increased/decreased flexibility, by the removal of 
glycan N301. As described above (Figure 3.10 A), the flexibilities are defined as the 
distribution of RMSD values calculated between the collective conformations of a 
unique glycan over time. Despite the observation of large discrepancies between the 
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flexibilities of several glycans at an individual protomer level, which makes conclusive 
assertions regarding model specific flexibilities difficult, there were particular glycans 
that displayed model specific flexibilities. In these cases, glycans displayed different 
flexibilities in the paired model comparison, i.e. between the wild-type and N301A 
mutant models. 
 
3.3.5.1.1 Glycan flexibilities differentiating the CAP45.G3 paired models 
 
The comparison of glycan flexibilities between the wild-type and N301A mutant model 
revealed three glycans that showed evidence of model specific flexibilities. The 
glycans at positions 446 (Figure 3.11 K and L), 334 (Figure 3.11 I and J), and 442 
(Figure 3.11 G and H), had altered flexibilities in the N301A mutant model, suggesting 
that these glycans moved to a greater, or lesser, extent as result of the vacated space. 
Only for glycan N446 was the overall flexibility reduced for all protomers on the N301A 
mutant model, whereas for glycans N334 and N442, the change in flexibility differed 
across protomers.  
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Figure 3.11: Glycan flexibilities of the CAP45.G3 paired models 
Box and whiskerg plots of the RMSD (Å) of specific glycans (N156, N197, N262, N442, 
N334 and N446) calculated for each protomer (A, B and C). The RMSD, calculated 
between all adopted conformations of a single glycan over time, represents the 
flexibility of that glycan.  
 
                                            
g	For	all	Box	and	whisker	plots,	the	horizontal	 line	within	the	box	indicates	the	median,	the	
boundaries	 of	 the	 box	 indicate	 the	 25th-	 and	 75th-percentile,	 whiskers	 indicate	 the	
lowest/highest	datum	within	1.5	of	the	inter-quartile	range	of	the	lower/upper	quartile,	and	
circles	indicate	data	outliers.	
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3.3.5.1.2 Glycan flexibilities differentiating the Du156.12 paired models 
 
Similar to the CAP45.G3 paired model comparison, there were three Du156.12 
glycans that displayed different flexibilities between the wild-type and N301A mutant 
model. Glycans N332 (Figure 3.12 I and J), N442 (Figure 3.12 G and H), and N448 
(Figure 3.12 K and L) all presented evidence of model specific flexibility, even though 
the altered flexibilities were inconsistently lower or higher for different protomers. 
Interestingly, the N301A mutant model N442 glycans were all more flexible than their 
wild-type model counterparts when comparing the median values. However, one of 
the wild-type N442 glycans also displayed relatively large flexibility (Figure 3.12 G, 
protomer C), suggesting that the range of movement of glycan N442 is not exclusively 
affected by the removal of glycan N301.  
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Figure 3.12: Glycan flexibilities of the Du156.12 paired models 
Box and whisker plots of the RMSD (Å), representing the flexibilities, of specific 
glycans N156, N197, N262, N442, N332 and N448) calculated for each protomer (A, 
B and C)  
 
In summary, the glycan flexibilities revealed insufficient evidence to differentiate the 
wild-type and N301A mutant models. However, the RMSD results nonetheless 
presented several interesting observations. Glycans N156 and N262 had the lowest 
flexibilities on all models, which suggests that the movements of these glycans were 
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restricted regardless of the presence of glycan N301. It has been reported that glycan 
N262 is buried170 and, with the models used here, glycan N156 was densely packed 
within a cluster of glycans, which provides one explanation for the low flexibilities 
observed for these two glycans. Furthermore, although there were no definitive 
directional (less/greater) differences between glycan flexibilities when comparing the 
wild-type and N301A mutant paired models, glycans N332 (Du156.12 model), N334 
(CAP45.G3 model), N442 (CAP45.G3 and Du156.12 models), N446 (CAP45.G3 
model) and N448 (Du156.12 model) had altered flexibilities. These observations 
provide a first overview of how the movements of individual glycans were altered by 
the removal of glycan N301, but also indicates that further analyses, beyond individual 
glycans, are required.  
 
3.3.5.2 The conformational heterogeneity between glycan siblings  
 
The preceding section explored the hypothesis that the flexibility of glycans allowed 
the established equilibrium of the glycan shield to be maintained. An alternative 
hypothesis concerns the formation of a “new” equilibrium, where glycans surrounding 
the N301A mutation adopt different conformations. The observation that certain 
glycans were, unexpectedly, less flexible in the N301A mutant models (where 
intuitively there was more space for movement) compared to the wild-type models, fits 
the alternative hypothesis where a new equilibrium was established. These alternate 
conformations were inconsistent among protomers; therefore, the next investigation 
focussed on the glycan siblings, i.e. the same glycan on all protomers of the same 
model. As previously described (section 3.3.5 and Figure 3.10 B), the glycan 
conformational diversity between protomers was defined as the versatility. The 
versatility represents the distribution of RMSD values calculated between the 
conformations of a unique glycan and each of its siblings, and between these siblings. 
The versatilities were then compared between paired models, and glycans 
(surrounding the N301A mutation) with model specific versatilities, that were the direct 
result of the removal of glycan N301, were identified. 
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3.3.5.2.1 Glycan versatilities of the CAP45.G3 paired models 
 
Glycans N197, N332, N442 and N446 all showed evidence of different versatilities on 
the CAP45.G3 N301A mutant model when compared to the wild-type model (Figure 
3.13). Glycans N197 (Figure 3.13 C and D) and N442 (Figure 3.13 G and H), which 
are in the immediate vicinity of glycan N301, had higher versatilities on the N301A 
mutant model, whereas glycans N334 (Figure 3.13 I and J) and N446 (Figure 3.13 K 
and L), had lower versatilities. 
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Figure 3.13: Glycan versatilities of the CAP45.G3 paired models 
Box and whisker plots of the RMSD (Å) of specific glycans (N156, N197, N262, N442, 
N334 and N448). The RMSD was calculated between the conformations of a unique 
glycan and each of its siblings, and between these siblings. 
 
3.3.5.2.2 Glycan versatilities of the Du156.12 paired models 
 
Apart from glycan N197, all the remaining glycans (N156, N262, N442, N332 and 
N448) had increased versatilities on the Du156.12 N301A mutant model (Figure 3.14). 
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This suggests that the glycans surrounding the N301A mutation were able to explore 
a larger number of equilibrium conformations than those on the wild-type model. 
However, since these RMSD results were uninformative regarding the type of 
movement, further analysis was required to determine whether these additional 
conformations were distinct from those of the wild-type model.  
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Figure 3.14: Glycan versatilities of the Du156.12 paired models 
Box and whisker plots of the RMSD (Å) of specific glycans (N156, N197, N262, N442, 
N332 and N446), which was calculated between the conformations of a unique glycan 
and each of its siblings, and between these siblings. 
 
 
 
https://etd.uwc.ac.za
http://etd.uwc.ac.za/
 83 
3.3.5.3 The difference between the conformational heterogeneity of glycans on each 
wild-type and its N301A mutant model counterpart 
 
The final conformational heterogeneity analysis focussed specifically on the 
differences between the conformations of N301A mutant glycans compared to their 
wild-type model counterparts (sections 3.3.5 and Figure 3.10 C). Hence, the RMSD 
distribution was calculated between identical glycans on the paired models (Figure 
3.10 C). When evaluating these RMSD distributions to determine which glycans have 
substantially different conformation between the wild-type and N301A mutant model, 
the cause of the difference becomes important. Conformation differences can either 
be caused by the N301A mutation or by random variation, which was observed during 
the conformational heterogeneity analysis between glycan siblings (section 3.3.5.2). 
For this reason, RMSD distributions calculated here were compared to the relevant 
versatility results (Figure 3.13 and Figure 3.14). Only glycans with conformational 
differences greater than their versatilities were considered as heterogeneous between 
the wild-type and N301A mutant models. The possibility of identifying glycans with 
conformational heterogeneity due to random variation is also reduced by the fact that 
the starting conformation of the paired glycans, and all the surrounding glycans, were 
identical, and that this analysis was limited to the glycans close to the N301A mutation. 
Despite these precautions, it is still possible that some of the glycans identified during 
this analysis were heterogeneous due to random variation instead. Therefore, the 
results should be interpreted taking this into account.  
 
3.3.5.3.1 Glycan conformations differentiating the CAP45.G3 models 
 
For three glycans (N197, N442 and N446) particular protomer/s showed noticeably 
higher conformational heterogeneity when the CAP45.G3 N301A mutant glycan 
conformations were compared to those of the wild-type model. For glycans N197 and 
N446, the larger conformational heterogeneity was observed for protomer C, while for 
glycan N442 it was observed for protomers A and B. The heterogeneity between 
paired glycans was the largest for glycan N446, followed by glycan N442 (protomer A) 
and then glycan N197. The magnitude of these conformational differences (ranging 
from 12 to 43Å) compared to those observed for random variation (between the 
https://etd.uwc.ac.za
http://etd.uwc.ac.za/
 84 
CAP45.G3 wild-type protomers; section 3.3.5.2) for each particular glycan, increases 
the confidence that these conformational differences were likely due to the N301A 
mutation as opposed to random variation. 
  
 
Figure 3.15: RMSD distribution of identical glycans on the CAP45.G3 paired 
models 
Box and whisker plots of the RMSD (Å) of specific glycans (N156, N197, N262, N442, 
N334 and N446) calculated, for each glycan, between the conformations of the wild-
type glycan and the conformation of its N301A mutant glycan counterpart. 
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3.3.5.3.2 Glycan conformations differentiating the Du156.12 models 
 
With the exception of glycan N197, all the remaining glycans (N156, N262, N442, 
N332 and N448) had at least one protomer with considerable conformational 
heterogeneity when the Du156.12 N301A mutant glycan conformations were 
compared to the wild-type glycan conformations. Unlike the CAP45.G3 comparison, 
the differences were also more consistent across the protomers for the Du156.12 
paired models, where the same glycans from multiple protomers had considerable 
conformational heterogeneity, e.g. for glycan N442 on protomers A, B and C, for 
glycan N156 on protomers A and B, and for glycan N448 on protomers B and C. 
However, the magnitude of the conformational differences still varied between the 
protomers. Despite these differences in magnitudes, even the lowest variation was still 
larger than that observed for the random variation (i.e., between the Du156.12 wild-
type protomers; section 3.3.5.2) of the particular glycan. This implies, similar to the 
CAP45.G3 paired model comparison, that these conformational differences were likely 
due to the N301A mutation rather than random variation. 
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Figure 3.16: RMSD distribution of identical glycans on the Du156.12 paired 
models 
Box and whisker plots of the RMSD (Å) of specific glycans (N156, N197, N262, N442, 
N332 and N448) calculated, for each glycan, between the conformations of the wild-
type glycan and the conformation of its N301A mutant glycan counterpart. 
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3.3.6 Altered glycan conformations extended beyond those neighbouring glycan N301  
 
In the previous section (section 3.3.5), the extent of the conformational heterogeneity 
of glycans N156, N197, N262, N332/N334, N442 and N446/N448 within, and between, 
protomers and models was described in detail. Subsequently, the next focus was to 
extend this analysis beyond only these glycans that neighbour the N301A mutation, to 
all the glycans as well as the protein residues. To achieve this goal, each glycan, or 
protein residue, was ranked based on its capability to distinguish between frames of 
the wild-type and the corresponding N301A mutant model. For example, suppose the 
conformations of glycan N442 were perfectly distinct between paired models; if 
presented with a randomly chosen frame, one merely needs to consider the 
conformation of glycan N442 to determine if the frame emerged during the N301A 
mutant or wild-type model simulation. Therefore, glycans, or protein residues, 
exceedingly capable of correctly classifying frames as wild-type or N301A mutant 
model frames, were also the most conformational heterogeneous between paired 
models. 
 
In order to determine which glycans or protein residues were the best classifiers, an 
approach capable of dealing with “wide” data, i.e. where there are more 
variables/columns than observations/rows (many more atoms than frames), is 
advantageous. Principal component analysis (PCA), already implemented to 
accommodate simulation data, was suitable for this analysis. Even though PCA is 
relatively capable of dealing with “wide” data, it is still preferable to reduce the data to 
the minimal working set. The reason for this is that the number of variables is directly 
related to the volume of the resulting space, which increases exponentially with each 
additional variable, resulting in the available data becoming sparse. This sparsity is 
detrimental for any method that requires statistical significance. Therefore, the 
comparisons between the N301A mutant models and their wild-type counterparts were 
limited to the protomers. Additionally, for each protomer-level comparison, the protein 
residues and glycans were considered separately. 
 
Once these “reduced” simulation trajectories were assembled (see Methods section 
3.2.2.5), PCA was performed on pseudo-trajectories comprising frames originating 
from both the wild-type and N301A mutant simulations of paired models. For the initial 
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analysis, focussing only on the glycans, the first principal component differentiated the 
frames of the wild-type and N301A mutant models perfectly, since a vertical line 
completely separated each group of frames on the standard PCA plots (e.g. Figure 
3.17 A and C, and Supplementary figures Figure S3.2 and Figure S3.3). The 
separation was not as clear for the protein analysis (Supplementary figures Figure 
S3.4 and Figure S3.5), but still provided an indication of the frame separation for the 
paired models and was thus sufficient for further analysis. 
 
The next step was to isolate which glycans, or protein residues, were contributing most 
to the first principal component. In this analysis, the principal components are linear 
combinations of the atom coordinates weighted by their contributions towards 
explaining the variance in a particular orthogonal dimension. Therefore, since the first 
principal component differentiates between frames of the wild-type and N301A mutant, 
the squared weights (factor loadings) rank the glycans, or protein residues, by the 
extent of their variation between the wild-type and N301A mutant models. However, 
due to small changes in the factor loadings potentially altering the rankings 
substantially, especially if glycans or protein residues were equally distinct between 
paired models, each glycan or protein residue was ultimately ranked based on its 
median factor loading. These medians were determined for the factor loadings by 
repeating each PCA on 100 moving-block bootstrap replicates of the appropriate 
pseudo-trajectories. 
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Figure 3.17: Example of the standard PCA plots for the CAP45.G3 model 
The standard PCA plots for the CAP45.G3 paired-model comparison performed on 
the glycans of protomer A. The figures demonstrate the projection of the frames onto 
the (A) first and second, (B) second and third and (C) first and third principal 
components as well as (D) the proportion of the variance explained by each principal 
component. 
 
In studying the factor loadings of the first principal components of each protomer and 
paired models, the true range and scope of conformational heterogeneity between the 
N301A mutant models and the wild-type counterparts can be appreciated (Figure 3.18, 
Figure 3.19, Figure 3.20 and Figure 3.21). Due to the factor loadings only narrowly 
distinguishing successively ranked glycans, or protein residues, it was necessary to 
specify a threshold above which a practical number of glycans, or protein residues, 
Eigenvalue 
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were identified. Since the same glycans were rarely identified for each protomer, the 
two top ranking glycans within the gp120 and gp41 region of each protomer were 
considered. For the protein analysis, the top five protein residues for each protomer 
were identified. For consistency and reference, the rankings of glycans N156, N197, 
N262, N332/N334, N442 and N446/N448, which have been discussed in detail in the 
previous sections (sections 3.3.4 and 3.3.5) are also shown (Figure 3.18 and Figure 
3.19). 
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Figure 3.18: Factor loadings of the CAP45.G3 paired-model comparison 
focussing on glycans 
Box and whisker plots of the factor loadings of all glycans for (A) protomer A, (B) 
protomer B and (C) protomer C. Blue triangles represent the factor loadings calculated 
using the simulated trajectories. The rankings based on median factor loadings are 
shown for the top two glycans as well as glycans N156, N197, N262, N334, N442 and 
N446. 
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Figure 3.19: Factor loadings of the Du156.12 paired-model comparison 
focussing on glycans 
Box and whisker plots of the factor loadings of all glycans for (A) protomer A, (B) 
protomer B and (C) protomer C. Orange triangles represent the factor loadings 
calculated using the simulated trajectories. The rankings based on median factor 
loadings are show for the top two glycans as well as glycans N156, N197, N262, N332, 
N442 and N448. 
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Figure 3.20: Factor loadings of the CAP45.G3 paired-model comparison 
focussing on protein residues 
Box and whisker plots of the factor loadings of protein residues for (A) protomer A, (B) 
protomer B and (C) protomer C with a median value above a threshold (0.013) such 
that only the top protein residues are displayed. Blue triangles represent the factor 
loadings calculated using the simulated trajectories. The rankings based on median 
factor loadings are show for the top five protein residues. 
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Figure 3.21: Factor loadings of the Du156.12 paired-model comparison 
focussing on protein residues 
Box and whisker plots of the factor loadings of protein residues for (A) protomer A, (B) 
protomer B and (C) protomer C with a median value above a threshold (0.013) such 
that only the top protein residues are displayed. Orange triangles represent the factor 
loadings calculated using the simulated trajectories. The rankings based on median 
factor loadings are show for the top five protein residues. 
 
Of these glycans, the N442 and N446 glycans were identified by the PCA as among 
the glycans with the most distinct conformations between the CAP45.G3 wild-type and 
N301A mutant models for the gp120 region (Figure 3.18). Additionally, and similarly 
located in the gp120 region, glycans N289 and N463 also had considerable 
conformational heterogeneities between the CAP45.G3 paired models (Figure 3.18 
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C). In contrast, for the Du156.12 gp120 region, the paired-model comparison showed 
that the N197 and N332 glycans (that were also considered in the previous sections 
3.3.4 and 3.3.5), were among the most distinct glycans, along with glycans N160, 
N289 and N463 (Figure 3.19).  
 
For the gp41 region, both paired-model comparisons had at least one gp41 glycan 
that was identified as distinct between the wild-type and N301A mutant models (Figure 
3.18 and Figure 3.19). Specifically, glycans N616 and N625 for the CAP45.G3, and 
glycan N624 for the Du156.12, paired-model comparisons. Given that these glycans 
are located in the gp41 region, where there are relatively fewer glycans compared to 
gp120, and consequently more space, it is plausible that these distinct conformations 
could be attributed to random variation and not the N301A mutation. Thus, these 
glycans were not of interest in the context of the N301A mutation. 
 
In addition, the analysis of the protein revealed that residues 211, 384, 579 and 665 
consistently had distinct conformations between the CAP45.G3 N301A mutant model 
and its wild-type counterpart (Figure 3.20). However, for the Du156.12 paired-model 
comparison, no protein residues were identified that consistently had distinct 
conformations between the models (Figure 3.21). Furthermore, since the difference in 
the factor loadings of successively ranked protein residues were larger for the 
CAP45.G3 model protein residues than those for Du156.12, the factor loadings of the 
CAP45.G3 paired-models readily attributed the conformational heterogeneity to 
specific residues, whereas for the Du156.12 paired-model comparison, several, 
diverse residues were identified.  
 
Taken together the PCA analysis demonstrated that glycans (and protein residues) 
were conformationally heterogeneous between the wild-type models and their N301A 
mutant counterparts, and some more so than others. Of these top ranked glycans, 
only glycans N197, N332, N442 and N446 were previously identified using a crude 
method (hydrogen-bond interaction networks, section 3.3.3). This suggests that only 
a portion of the glycans potentially impacted by the N301A mutation were in the 
immediate vicinity of the mutation. Thus, it is important to investigate glycans further 
from the N301A mutation.  
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However, as previously described (section 3.3.5.3), a reasonable level of caution 
needs to be employed when considering glycans progressively further from the N301A 
mutation, since these glycans are more likely to display conformational heterogeneity 
due to random variation rather than due to the N301A mutation. Hence, the next step 
was to address this issue by quantifying the random variation of the glycans identified 
during the PCA and considering them relative to other glycans.  
 
As described in the methods (section 3.2.2.5), to quantify the random variation of each 
glycan, the individual glycan variation between the protomers of the wild-type models 
was used as a proxy. For example, a glycan that was conformationally heterogeneous 
between the protomers of the wild-type models, i.e. displayed higher random variation, 
was also more likely to exhibit distinct conformations between the wild-type and N301A 
mutant paired models due to this random variation, and not due to the N301A 
mutation. 
 
As before, the “reduced” simulation trajectories were used, however, the pseudo-
trajectories on which the PCA was performed consisted of frames from only the wild-
type simulation. Here, the first two principal components differentiated the frames of 
the wild-type protomer models perfectly, since only a vertical and horizontal line were 
required to separate each group of frames on the standard PCA plots for the glycans 
and protein residues (e.g. Figure 3.22 and Supplementary figures Figure S3.6-Figure 
S3.8). 
 
Similar to the paired-model comparisons, the first two principal components can be 
deconstructed into their factor loadings to determine which glycans, or protein 
residues, were contributing the most to each principal component. These glycans and 
protein residues were subsequently ranked according to their contributions based on 
their median factor loadings. As before, the medians were determined by repeating 
the PCA on 100 moving-block bootstrap replicates of the appropriate pseudo-
trajectories (Methods section 3.2.2.5). 
 
Quantifying and comparing the random variation of glycans N289, N442, N446, N463, 
N616 and N625 (CAP45.G3 model), and glycans N160, N197, N289, N332 and N468 
(Du156.12 model) was of particular interest, since these glycans displayed 
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exceptionally distinct conformations during the PCA between the appropriate paired 
models (Figure 3.18 and Figure 3.19). Additionally, the rankings of the glycans 
considered during the RMSD analysis are shown for reference and consistency 
(Figure 3.23 and Figure 3.24 glycans N156, N197, N262, N332/N334, N442 and 
N446/N448). 
 
 
Figure 3.22: Example of the standard PCA plots for the Du156.12 model 
The standard PCA plots for the Du156.12 protomer comparison performed on the 
glycans. The figures demonstrate the projection of the frames onto the (A) first and 
second, (B) second and third and (C) first and third principal components as well as 
(D) the proportion of the variance explained by each principal component. 
 
Eigenvalue 
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Figure 3.23: Factor loadings of the CAP45.G3 wild-type protomer comparison 
focussing on glycans 
Box and whisker plots of the factor loadings of all glycans for the (A) first and (B) 
second principal components. Blue triangles represent the value of the factor loadings 
calculated using the simulated trajectories. The rankings based on median factor 
loadings are shown for glycans N156, N197, N262, N289, N334, N442, N446, N463, 
N616 and N625. 
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Figure 3.24: Factor loadings of the Du156.12 wild-type protomer comparison 
focussing on glycans 
Box and whisker plots of the factor loadings of all glycans for the (A) first and (B) 
second principal components. Orange triangles represent the factor loadings 
calculated using the simulated trajectories. The rankings based on median factor 
loadings are shown for glycans N156, N197, N262, N289, N332, N442, N448, N463 
and N624. 
 
None of the glycans (N289, N442, N446 and N463) identified in the gp120 region 
during the PCA for the CAP45.G3 paired-model comparison were ranked within the 
top twelve (Figure 3.23). For the gp41 region, where two glycans were identified, 
glycan N616 was ranked 7th and 14th, while glycan N625 was ranked 18th and 12th by 
the first two principal components, respectively (Figure 3.23). Interestingly, glycans 
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N156 and N262 were ranked within the top ten by one or both principal components 
(Figure 3.23). This suggests that these glycans had distinct conformations on each 
wild-type protomer but were minimally affected by the N301A mutation, since the wild-
type and N301A mutant model conformations were comparable (Figure 3.18).  
 
During the Du156.12 paired-model comparison, five glycans (N160, N197, N289, 
N332 and N463) were identified. Glycan N160 was not glycosylated on protomer B 
(section 3.2.1) and was therefore not included during the wild-type protomer model 
comparison. Of the remaining glycans, N197 and N332 were ranked 2nd and 5th by the 
second principal component (Figure 3.24 B), while glycans N289 and N463 had 
relatively low ranks (Figure 3.24 rank 22 and 21, and 19 and 19). This suggests that 
while these glycans (N197 and N332) were potentially affected by the N301A mutation, 
they also varied between the wild-type protomer models. Therefore, further analysis 
would be required to unequivocally determine whether the conformations of these 
glycans were directly affected by the N301A mutation. 
 
During the protein analysis, only the CAP45.G3 paired-model comparison revealed 
protein residues (211, 384, 579 and 665) that were identified for all protomers (A, B 
and C). However, these were also the top four ranked protein residues during the wild-
type protomer analysis (Figure 3.25), which indicates that these protein residues were 
likely distinct due to random variation and not due to the N301A mutation. 
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Figure 3.25: Factor loadings of the CAP45.G3 wild-type protomer comparison 
focussing on protein residues 
Box and whisker plots of the factor loadings of protein residues for the (A) first and (B) 
second principal components with a median value above a threshold (0.1) such that 
only the top protein residues are displayed. Blue triangles represent the factor loadings 
calculated using the simulated trajectories. The rankings based on median factor 
loadings are show for the top five protein residues. 
 
3.3.7 The locations of exposed surface regions are associated with the unique glycan 
conformational changes in response to the N301A mutation 
 
The analyses thus far have demonstrated several interesting observations regarding 
the conformational heterogeneity between the simulations. Briefly, the PNGS locations 
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of the CAP45.G3 and Du156.12 wild-type models are considerably different. 
Consequently, the members of their respective N301-glycan clusters were also 
diverse. Nevertheless, three glycans (N156, N197 and N442) were N301-glycan 
cluster members across the protomers of both wild-type models. However, further 
investigation of these glycans revealed that not only were their conformations 
heterogeneous, but also that the landscapes around each of these glycans were 
distinct for each wild-type model. Subsequently, removing glycan N301 from each 
wild-type model resulted in different altered conformations for these glycans, 
especially glycans N197 and N442, since the glycan shields of each model responded 
to the change in specific ways. Therefore, it is likely that both the conformational 
differences of these glycans on the wild-type models, as well as the landscapes 
around each of these glycans, affected the ultimate changes in the glycan shields. 
 
To assess the influence of these unique responses to the N301A mutation in a 
meaningful way across the protein, the AASA was calculated using a 10Å probe (as 
an approximation of the size of an antibody). When comparing the AASA between 
paired models, differences could be due to protein and/or glycan movement. To focus 
on the glycan changes specifically, it was therefore necessary to normalise the AASA 
values; thus, the AASA, per residue, of the glycosylated protein was divided by the 
AASA of the non-glycosylated protein, which represents the “maximum” possible 
AASA per residue. Therefore, a proportion of 20% indicates that only 20% of the 
surface area for that residue remains accessible when the glycans are present.  
 
Subsequently, the protein residues of the N301A mutant models with statistically 
significant increases in their average AASA measures compared to the wild-type 
models, were identified (Figure 3.26, blue and orange regions). Furthermore, these 
result-sets of protein residues were further classified to distinguish residues with a 
substantial increase in the average AASA measure, i.e. an average increase of 10% 
or greater (Figure 3.26, blue regions). The location, and number, of clusters of these 
residues on the protein surface were compared between the CAP45.G3 and Du156.12 
N301A mutant models. 
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Figure 3.26: AASA for the N301A mutant models 
The N301A mutant models of (A, B, C) CAP45.G3 and (D, E, F) Du156.12 with 
different orientations (A – C, 120° increments) to show each protomer (different 
shades of tan) and the residues with statistically significant increases in their average 
AASA ratios relative to their wild-type counterparts (difference in average AASA <10% 
is orange, ≥10% is blue). A statistically significant increase was evaluated at a 5% 
significance level using a bootstrap approach (see Methods). The V3-loop (pink) and 
CD4 (green) regions are outlined. 
 
Although the number of statistically significant residues with a substantial increase 
were roughly equal for each N301A mutant model (157 for CAP45.G3 and 187 for 
Du156.12), there were clear differences in the clustering of these residues between 
the CAP45.G3 and Du156.12 N301A mutant models (Figure 3.26, blue regions). For 
the CAP45.G3 N301A mutant model, the identified residues were relatively spread 
out, with the exception of protomer B where a cluster, in either the C1/C2, V3 or C3/V4 
regions, was observed. On the Du156.12 N301A mutant model, however, the 
identified residues were clustered in the C3/V1/V4 regions on all the protomers. This 
https://etd.uwc.ac.za
http://etd.uwc.ac.za/
 104 
suggests that removing a glycan from the glycan shield not only uniquely impacted the 
conformations of the surrounding glycans, but that these differences may have further 
implications regarding the specific regions exposed after the N301A mutation was 
introduced. This is an important point, since predicting the regions exposed after the 
removal of a glycan may offer clues on where antibodies can bind. Moreover, the 
location of these regions may further indicate the relative ease with which antibodies 
can bind, since some regions on Env are generally more accessible than others 
(Supplementary Figure S3.9). 
 
3.4 Discussion 
 
Traditionally, detailed inspection of crystallised glycoprotein structures has allowed for 
certain observations regarding the conformations of N-linked glycans. However, apart 
from the protein-proximal GlcNAc residues, it is difficult to resolve the conformations 
of HIV-1 N-linked glycans unless the glycans are stabilised83–92 (section 1.1.1). This is 
thought to be due to the conformational heterogeneity of glycans83–92. Molecular 
dynamics simulations present an alternative approach for studying glycan 
conformations, since a converged simulation provides an ensemble of 3D structures 
from which it is possible to compute the relative populations of each conformational 
state observed120. These simulations further allow comparison between different 
glycoprotein structures, and, therefore, a comparison between HIV-1 strains, which 
was the focus of this chapter.  
 
In order to understand whether the conformations of equivalent glycans (i.e. shared 
HXB2 numbering) vary between wild-type models, and additionally if these 
conformations were impacted by the removal of a glycan, the conformational 
differences during the molecular dynamics simulations of four models, two wild-type 
and two N301A mutant models, were investigated in detail. 
 
The comparison between the wild-type models revealed that equivalent glycans had 
a wide range of conformational differences and diverse glycan-glycan interactions 
(sections 3.3.3 and 3.3.4). Since glycan conformations are constrained by 
neighbouring glycans, variation in the locations of neighbouring glycans led to this 
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observed diversity of glycan conformations and glycan-glycan interactions. This 
finding is in contrast to the observation from Steward et al.88, who compared the glycan 
conformations of three crystal structures and where a conserved structural motif of the 
protein-proximal GlcNAc residues was reported. Here, however, the conformational 
diversity was not restricted to the mannose branches, but also observed for the 
protein-proximal GlcNAc residues. This difference is likely attributable to the relatively 
larger disparity between the locations of neighbouring glycans between the sequences 
considered here compared to the Steward et al.88 study, where strains with more 
similar PNGS profiles were investigated. The differences, and similarities, between 
PNGS profiles, which provide an overview of potential glycan neighbours, is therefore 
an important factor when extrapolating information about glycan conformations to 
other HIV-1 Env glycoprotein structures (and thus HIV-1 strains). Importantly, 
equivalent HXB2 numbering does not necessarily translate to equivalent 
conformational characteristics. 
 
The next part of the investigating focused on the paired-model comparison, where the 
wild-type models were each compared to their N301A mutant model counterparts. 
This analysis revealed that at least one of the glycans neighbouring glycan N301 
displayed altered conformations when comparing the wild-type and N301A mutant 
models. Due to the extra space generated by removing a glycan, it was expected that 
the glycan conformations of the N301A mutant models would exhibit greater overall 
differences compared to those of the wild-type models. However, this was not always 
the case since certain glycans established “new” equilibrium positions, which were 
less flexible and more consistent across the protomers (e.g. glycan N446, section 
3.3.5.1.1, Figure 3.11). Extending the analysis using a different approach, beyond only 
the neighbouring glycans, revealed that while glycans around the N301A mutation 
were among those with relatively greater variation between paired models, further 
glycans also displayed relatively large variations. This suggests that there were farther 
reaching consequences to removing a glycan than were initially expected. 
 
Altogether, the results from the wild-type and paired-model comparisons established 
that the distinct wild-type conformations, and implicitly the landscapes, were linked to 
the observed changes and differences after removing a glycan. This was 
demonstrated by distinct glycan conformations not only emerging between paired 
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models, but also between the N301A mutant models. The distinct glycan 
conformations, in turn, impacted the location of the areas likely to be exposed, if any, 
due to the N301A mutation. Thus, these results again demonstrated that equivalent 
glycans are not as equivalent as implied by the identical HXB2 numbering, and that 
the landscape surrounding each glycan is an important consideration. Therefore, HIV-
1 Env glycans should not be considered in isolation, but in their glycan shield “context”. 
 
A caveat for the comparison of glycan conformations from molecular dynamics 
simulations is that the observed differences may be due to distinct equilibrium glycan 
conformations sampled on relatively short time scales, whereas the average 
properties of glycan conformations across an unlimited time scale are the same. This 
“random” variation was clearly seen when glycans were compared between the 
protomers of the same models. In this case, observed variations in glycan 
conformations were due to glycans occupying different equilibrium conformations and 
one would expect, given a long enough time scale, that these glycans would exhibit 
similar average properties due to their near identity. However, observing enough of 
the sample space during molecular dynamics simulations, i.e. a long enough 
trajectory, is a key, and ongoing, problem for molecular dynamics research of large 
structures. Since extending the simulations to an indefinite time scale was impractical, 
an alternative approach was considered here, i.e. using the variation between 
protomers as proxy for quantifying random variation (sections 3.3.5.3 and 3.3.6). 
Therefore, only where the variations between models exceeded that which was 
observed between protomers, were these variations considered as substantial 
differences. While this may have excluded glycans with small, yet statistically 
significant differences, the aforementioned, more cautious, approach was preferred 
during this investigation. 
 
Several studies have focussed on the changes to exposed HIV-1 Env surface areas 
when different mutations are introduced53–55,66–71. While this remains an important 
question, a further consideration relates to how the changes in glycan conformations 
impact the efficacy of glycan-binding antibodies. This particular line of enquiry was 
previously investigated by Kwong et al.51 using crystal structures of HIV-1 Env bound 
to different glycan-binding antibodies; these crystal structures contained a number of 
resolved glycans conformations that were compared. The authors speculated that the 
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initial orientation of an entire glycan might not be critical for glycan-binding antibodies 
that bind and recognise only a contiguous region on a single glycan51. However, for 
glycan-binding antibodies that bind multiple glycans, or multiple glycans and the 
protein surface, the initial orientation of the entire glycan, including its degree of 
flexibility, may be important51. This is due to the additional constraints on the angle of 
approach that is required for successfully binding to occur between the glycan-binding 
antibody and its target51,162. Therefore, the conformations of glycans can play a 
notable part in the ability of glycan-binding antibodies to recognise a glycan and are 
also likely to affect the elicitation of the particular antibodies51. Thus, the glycan 
conformations should be considered along with the glycan-binding antibody. Unlike 
the antibody-bound crystal structures studied by Kwong et al.51, the glycan 
conformations during the molecular dynamics simulations described here, allow for 
the additional investigation of the conformations of these glycans when unbound to 
the glycan-binding antibody. 
 
Thus, this chapter demonstrates that equivalent glycans can adopt conformations 
distinct to specific wild-type Env models, in this case the CAP45.G3 and Du156.12 
models. Moreover, these model-specific conformations also emerged when only a 
single glycan was removed from the glycan shield, and these differences were not 
limited to glycans in the immediate vicinity of the removed glycan. Additionally, the 
model-specific glycan conformations that emerged after glycan N301 was removed, 
were unique to each of the N301A mutant models, which was consequently directly 
related to whether certain protein residues were exposed. However, due to random 
variation implicit to macromolecular structures, there remained a degree of uncertainty 
as to whether the conformational heterogeneity observed for glycans located farther 
from the N301A mutation were a direct result of the mutation. Therefore, associating 
the conformational heterogeneity of a glycan to the original mutation was the focus for 
the subsequent investigation (Chapter 4). 
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Chapter 4 Structural Rearrangements Maintain the Glycan 
Shield of an HIV-1 Envelope Trimer After the Loss of a Glycanh 
 
As highlighted in Chapter 1, the HIV-1 Env glycans shield the underlying protein from 
the immune system and by removing a glycan, a hole, or gap, is created in the glycan 
shield. However, as described in Chapter 3, distinct glycan conformations were 
observed for the two HIV-1 Env wild-type subtype C isolates and their corresponding 
N301A mutant counterparts. These distinct conformations provide one potential 
explanation as to why one of these N301A mutant isolates not only remained protected 
against frequently elicited neutralising antibodies, but also exhibited increased 
resistance to a CD4-binding site broadly neutralising antibody despite the missing 
glycan. However, drawing a direct association between the conformational 
heterogeneity of any glycan and the loss of glycan N301, required a more detailed 
analysis. Therefore, in order to further investigate the resistant strain and directly 
associate the conformational heterogeneity of its glycans with the N301A mutation, a 
more detailed comparison between this wild-type model and its N301A mutant 
counterpart was carried out and is presented in this chapter, as published online in 
Scientific Reports (DOI:10.1038/s41598-018-33390-2). 
 
4.1 Abstract 
 
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune 
response and a critical vaccine candidate. However, Env is densely glycosylated and 
thereby substantially protected from neutralisation. Importantly, glycan N301 shields 
V3 loop and CD4 binding site epitopes from neutralising antibodies. Here, we use 
molecular dynamics techniques to evaluate the structural rearrangements that 
maintain the protective qualities of the glycan shield after the loss of glycan N301. We 
examined a naturally occurring subtype C isolate and its N301A mutant; the mutant 
not only remained protected against neutralising antibodies targeting underlying 
                                            
h	This	 chapter,	 from	 the	 Abstract	 onwards,	 is	 included	 verbatim	 as	 published	 in	 Scientific	
Reports	 (DOI:10.1038/s41598-018-33390-2).	 Where	 necessary,	 minor	 changes,	 e.g.	 Figure	
numbering,	were	made	to	ensure	reasonable	flow	and	consistency	between	chapters	of	this	
thesis.	
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epitopes, but also exhibited an increased resistance to the VRC01 class of broadly 
neutralising antibodies. Analysis of this mutant revealed several glycans that were 
responsible, independently or through synergy, for the neutralisation resistance of the 
mutant. These data provide detailed insight into the glycan shield’s ability to 
compensate for the loss of a glycan, as well as the cascade of glycan movements on 
a protomer, starting at the point mutation, that affects the integrity of an antibody 
epitope located at the edge of the diminishing effect. These results present key, 
previously overlooked, considerations for HIV-1 Env glycan research and related 
vaccine studies. 
 
4.2 Introduction 
 
A key scientific challenge in the field of HIV-1 vaccine development is the design of 
immunogens that elicit antibodies capable of neutralising the wide range of HIV-1 
isolates in circulation, despite its immense global diversity7. Due to immune-mediated 
selection pressure, the majority of this diversity is in the viral envelope gene that 
encodes the Env proteins on the surface of a virion171. The Env proteins facilitate viral 
entry to target cells and are formed by gp120/gp41 heterodimers that non-covalently 
associate, forming a trimer of heterodimers172,173. Even though the majority of HIV-
infected individuals mount an immune response targeting these Env trimers, within-
host diversity ensures that certain strains continue to evade recognition and 
neutralisation56,174–176.  
 
Large sections of the Env trimers are covered by dense glycosylation and roughly half 
of its molecular mass is made up by glycans177,178, which have been suggested to 
protect the virus from antibody binding and neutralisation42,44,53–55. Changes in these 
glycosylation patterns can therefore have a large impact on its ability to escape from 
immune attack. Once HIV infiltrates the host cells, it takes advantage of host cellular 
biosynthetic pathways for its own benefit, which includes protein glycosylation as one 
of the main post-translational modifications45. N-linked glycosylation occurs in the 
endoplasmic reticulum and Golgi apparatus, where glycans are attached to 
asparagine residues within an Asn-X-Ser/Thr motif (X is any amino acid except 
proline45). The attached glycans, initially assumed to be immunologically inert “self” 
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molecules, were until recently considered a largely insurmountable challenge for 
antibody recognition; hence termed, the “glycan shield”56,57. 
 
However, some HIV-1 infected individuals develop potent and broadly neutralising 
antibodies (bNAbs) that specifically target, or find ways to bypass, the glycan shield39–
43. These bNAbs are characterised by their target region, and are generally defined by 
particular monoclonal antibodies that target specific regions: the CD4 binding site59, 
the membrane proximal external region of gp4160, the glycan outer domain (typified 
by mAb 2G12)61, the V1V2 apex region around glycan N16058, the V3 base around 
glycans N301 and N33262, and the gp120/gp41 interface63. Despite the presence of 
such bNAbs in the serum of infected individuals, circulating plasma viruses generally 
escape, resulting in continued infection64,65. This escape from bNAbs has been linked 
to shifting glycosylation sites or mutations in the protein sequence surrounding specific 
glycans42,44. For example, Lynch et al.44 showed that the mutation introducing a glycan 
at position N276 lead to partial VRC01 resistance, and Moore et al.42 reported that the 
shift of glycan N332 to position N334 resulted in PGT128 resistance.  
 
To quantify the impact of glycans on the effectiveness of neutralising antibodies, 
previous in vitro studies have used targeted de-glycosylation to compare the 
neutralisation of a range of viral strains with and without a specific glycan53–55,70. For 
example, the removal of glycan N301 (HXB2 numbering throughout), which is highly 
conserved47,179 amongst HIV strains, has been shown to expose V3 loop and CD4 
binding site epitopes66–69,71. However, Moyo et al.53 described a subtype C strain, 
CAP45.2.00.G3 (referred to herein as CAP45.G3), in which removal of the glycan at 
position 301 unexpectedly did not result in increased sensitivity to to a large proportion 
of sera (61/64 panels) from chronically infected individuals53, despite its central role in 
protecting other isolates from neutralisation39,53,54,66,67,69,71. Furthermore, the N301A 
mutant had increased resistance to the CD4 binding site bNAb VRC01, and other 
VRC01-like bNAbs, when the neutralisation profile was compared to that of the wild-
type53. The authors suggested that this virus typified a subset of viruses that could 
tolerate the loss of glycan N301 while largely maintaining the protective qualities of 
the glycan shield. The mechanism of compensation for the loss of a glycan, in this 
case glycan N301, as well as the development of increased resistance to VRC01, was 
not understood.  
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Here, we explored glycan conformations in silico to explain these findings. We 
analysed two molecular dynamics simulations of glycosylated Env trimers: the 
CAP45.G3 wild-type and the CAP45.G3 N301A mutant, which removes the 
glycosylation site at residue 301, to establish whether the models replicated the in vitro 
compensation of the glycan shield observed previously53. Subsequently we describe, 
in detail, the structural changes of glycans N442, N446 and N262 that bear the burden 
of compensation, how this burden is distributed, and the differences observed 
between the protomers of each model. We show that by determining the glycan 
nearest to each protein residue over time, we can clearly illustrate how changes in 
glycan conformations impact their ability to protect certain residues of the underlying 
protein. Finally, our study demonstrates how a cascade of events could contribute 
towards the increased resistance to antibodies targeting an epitope distal to the point 
mutation, in this case the N301A mutation and the VRC01 epitope. These in silico data 
provide a detailed investigation of the glycan shield’s ability to compensate for the loss 
of a glycan as well as the associated cascade of events that affect a distal epitope, 
which provides further important considerations and avenues of exploration for 
vaccine studies focussing on the HIV-1 Envelope. 
 
4.3 Methods 
 
4.3.1 Structural modelling and molecular dynamics simulations: 
System preparation 
 
We used MODELLER136,137 to generate the protomer structures. The CAP45.G3 
(Genbank accession number DQ435682) sequence was used as the target, and three 
reference structures, PDB IDs 4NCO91, 4TVP87 and 2B4C139 were used as starting 
templates. The modelling was repeated ten times and models were ranked according 
to their DOPE scores140. The model with the lowest DOPE score was then selected, 
triplicated, and the three copies were aligned to the protomers of the 4NCO trimer 
structure to generate the trimeric model. Potential N-linked glycosylation sites 
(PNGSs) were determined by identifying the NXT/S motifs, where X is any amino acid 
except a proline. For each PNGS on the trimer homology model, we attempted to 
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attach a Man9GlcNAc2 glycan (Manα1-2Manα1-6[Manα1-2Manα1-3]Manα1-
6[Manα1-2Manα1-2Manα1-3]Manβ1-4GlcNAcβ1-4GlcNAcβ1-). The glycans were 
generated using the carbohydrate builder available at Glycam-Web145 and were 
attached using a prototype tool under development for the Glycam-Web suite of web 
tools that explores the most populated rotamers of the Asn-GlcNac linkage180 and 
then, if clashes are observed between previously added glycans or the protein, 
iteratively rotates the Asn sidechain and glycosidic linkages within reasonable bounds. 
Two of the glycosylation sites, N335 and N678, were not glycosylated; site N335 
occurs in an NNST motif and we were specifically interested in the positioning of 
glycan N334 in the context of bNAbs42 and due to its relative abundance compared to 
N33547, and N678 falls outside the modelled domain. For the remaining 81 PNGSs, 
79 were computationally glycosylated. During the first round, glycosylation of sites 
N160 (protomer C), N399 (protomer B), and N386 (protomer C) failed. However, after 
a 30 ns simulation (according to the steps described below), we retried glycosylating 
these three sites; only site N386 (protomer C) was successfully glycosylated, whereas 
sites N160 (protomer C) and N399 (protomer B) remained unglycosylated. It is 
unknown whether, but unlikely that, the three protomers of an Env trimer will always 
have matching glycosylation profiles; although position N160 is widely known as a 
conserved PNGS, researchers have used mass spectrometry to quantify the presence 
of glycans at PNGSs of 94 cross-clade HIV-1 gp120 proteins and the results show that 
glycosylation at N160 is not absolute169. Furthermore, the dependence of a glycan at 
this position for effective neutralisation has been shown to be variable42, and the 
particular binding characteristics of bNAb PG9 and PG16 to glycan N160 does not 
necessitate trimer specific glycosylation, i.e. the antibodies recognise a single N160 
glycan163. Therefore, although we could not glycosylate each PNGS of the model 
(positions N335 and N678, and positions N160 on protomer C and N399 protomer B), 
each viral clone will have varied glycosylation patterns and our ‘fully’ glycosylated 
model represents one form of the CAP45.G3 Env glycoprotein. We continued with this 
fully glycosylated model to create the N301A mutant by replacing the asparagine 
residue at position 301 (HXB2 numbering) with an alanine residue and removing the 
glycan. 
 
The systems were created using the tLEaP package contained in AmberTools 14123. 
The ff14SB121 force field was used for the protein and the GLYCAM06j-1122 force field 
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for the glycans. The wild-type and N301A mutant systems were immersed in a 
truncated octahedron water box containing TIP5P124 water molecules, since TIP5P 
was found to produce the best quantitative agreement with experimental data125. The 
box size was set such that all protein and glycan atoms were 15 Å from the edge of 
the box. Chloride ions were added to neutralise the system. 
 
4.3.2 Simulation 
 
The molecular dynamics simulations were produced using AMBER 14123. The systems 
were minimised by running 10,000 steps of steepest descent and 10,000 steps of 
conjugate gradient minimisation. During minimisation restraints were placed on all 
non-hydrogen protein and glycan atoms. The systems were equilibrated by running 
0.4 ns simulations under nPT (1 bar, 300 K) on a CPU cluster. During the first 
equilibration stage, Cartesian restraints (5.0 kcal/mol) were placed on all non-
hydrogen protein and glycan atoms. The restraints were removed, and the 
equilibration was extended by another 1 ns on a GPU cluster to ensure stability across 
clusters before the production run started on the GPU cluster. The 520 ns production 
runs were generated on a GPU cluster using AMBER GPU acceleration pmemd123 
and 0.002 ps time steps, with coordinates written to the trajectory file every 10,000 
steps. 
 
4.3.3 Analyses 
 
4.3.3.1 Root Mean Square Deviation to determine system equilibrium 
 
The conformational stability of the protein during the simulation was assessed by 
calculating the root mean squared deviation (RMSD) between the protein backbone 
atoms (C, C-alpha, N, O) and the starting structure of the production run. 
Conformational stability was achieved after 20 ns (data not shown) and this section of 
each trajectory was therefore discarded; the remaining 500 ns simulations were used 
for further analyses. 
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4.3.3.2 Antibody-accessible surface area for different regions and residues 
 
To investigate the efficiency with which the glycan shield compensates for the loss of 
glycan N301, we calculated the antibody accessible surface area (AASA) using a 10 
Å probe (as an approximation of the size of an antibody87) with Naccess146 for both 
the wild-type and N301A mutant simulations. The van der Waals radii of the glycan 
atoms were defined as described for the GLYCAM06j-122 force field. The AASA was 
calculated for 2,500 evenly spaced frames across the 500 ns trajectory. 
 
Differences between the wild-type and N301A mutant AASA values could be attributed 
to either the protein and/or glycan movements and we, therefore, normalise the values 
to remove changes in the AASA due to protein movements. To do this, we determined 
the “base/maximum” AASA by removing the glycans and re-calculating the AASA for 
these non-glycosylated frames. The final AASA ratio, per frame, is the ratio of the 
glycosylated and non-glycosylated AASA values, calculated by dividing the AASA of 
the glycosylated protein by the AASA of the non-glycosylated protein. Averages were 
calculated using these AASA ratio over time. 
 
We compared the mean AASA ratio, per residue, of the N301A mutant simulation to 
that of the wild-type to determine whether there was a statistically significant increase. 
The AASA ratio distribution of each residue under the null-hypothesis (wild-type and 
N301A mutant means are equal) was assessed by using 100 moving-blocks bootstrap 
replicates. The AASA ratio datasets for each model were mean normalised to satisfy 
the null-hypothesis before bootstrap replicates were drawn. The 50 ns blocks were 
defined such that each block could only start on whole nanoseconds for adequate 
sampling of the whole trajectory. There were, therefore, 450 possible blocks, with ten 
random blocks required for each bootstrap replicate. Variance normalisation was not 
performed due to numerous residues with average AASA ratio over time equal to zero. 
We further filtered the significant residues to include only those where the difference 
between the average AASA ratio for the wild-type and N301A mutant over time was 
10% or greater. We opted for moving-blocks bootstrap above a normal bootstrap 
approach to conserve the correlation between sequential observations. 
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4.3.3.3 Nearest glycan calculation for all protein residues 
 
Since the AASA results revealed that some residues have increased AASA ratios in 
the N301A mutant when compared to the wild-type simulation, we wanted to 
understand the shielding capacity of the surrounding glycans and determine which 
glycans are the most likely to affect the AASA ratio of particular protein residues. To 
achieve this, we calculated, for each residue, the distances between its atoms and all 
the atoms of the glycans. Each residue is subsequently assigned a nearest glycan 
based on the calculated distances. The nearest glycan for each residue was calculated 
for 25 evenly spaced frames across the 500 ns trajectory. The glycan that was most 
frequently the nearest to a particular residue throughout the trajectory, was defined as 
that residue’s “nearest glycan”. 
 
4.3.3.4 Overlap between wild-type glycans and specific glycans from the N301A 
mutant model 
 
The nearest glycan calculation revealed which glycans were nearest to the protein 
residues that had increased AASA ratios, and showed conformational changes, during 
the N301A mutant simulation compared to that of the wild-type. In order to determine 
if these conformational changes were specifically due to the additional space 
generated from the absence of glycan N301, we investigated whether the changes 
were viable when glycan N301 was present, i.e. whether or not the identified glycans 
caused large conformational clashes with any of the wild-type glycans. Hence, we 
iteratively removed the identified nearest glycans from the wild-type model trajectory 
and replaced each with the N301A mutant model trajectory equivalent. One glycan 
was analysed at a time and then restored before the next N301A mutant glycan’s 
overlap calculations were performed. All the frames of the wild-type and N301A mutant 
models were aligned to the first frame of the wild-type trajectory before the analysis 
was carried out. The overlap was calculated using UCSF Chimera168 for 2,500 evenly 
spaced frames across the 500 ns trajectory. The default values were used for the van 
der Waals overlap (0.6 Å) and potential hydrogen bonding between clashing pairs 
(subtract 0.4 Å). 
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4.3.3.5 Tree representation of hydrogen bonds between glycans to illustrate the 
cascade of events after the loss of a glycan 
 
In order to determine which further glycans were affected by the absence of glycan 
N301, but not immediately adjacent to the N301A mutation, we calculated and 
compared the hydrogen bonds that formed between glycans in the N301A mutant and 
wild-type simulations. The number of hydrogen bonds that formed between any two 
glycans was calculated for all 25,000 frames. The proportion of the total frames in 
which there was a hydrogen bond between any two glycans was calculated and 
rounded to the nearest percentage. The analysis was performed using the hbond 
function in cpptraj166 contained in AmberTools 14, using the default cut-off values for 
the distance between the heavy atoms (3 Å) and the angle between the acceptor and 
donor atom (135 degrees). The glycans that showed a change of 10% or greater in 
the frequency of the interaction between the wild-type and N301A mutant simulations 
were represented on tree graphs.  The analyses tree graphs were generated using 
R147 and, where necessary, the trajectory data was parsed into R using the Bio3D 
package181. Visual representation of the protein structures were generated using 
UCSF Chimera168. 
 
4.4 Results 
 
The CAP45.G3 subtype C virus was used to model the wild-type and N301A mutant 
trimer structures, comprising of protomers A, B and C, for molecular dynamics (MD) 
simulations. The CAP45.G3 Env sequence has 29 potential N-linked glycosylation 
sites (PNGSs, Figure 4.1) and although we could not computationally glycosylate each 
PNGS, given the extent of variation seen during glycan occupancy studies49,72–82,95, the 
generated model represents one possible form of the wild-type glycosylated model 
(Figure 4.2). The N301A mutant model matched the wild-type model, except the 
asparagine at position 301 was replaced with alanine and the glycan excluded. The 
systems were equilibrated for the first 20 ns of the simulation and analyses were 
performed on the remaining 500 ns. 
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Figure 4.1: Distribution of PNGSs of the CAP45.G3 strain  
Distribution of PNGSs for the CAP45.G3 strain (blue) relative to the PNGSs of the 
HIV-1 reference strain, HXB2 (orange). The gp160 conserved (C1-C4), variable (V1-
V5) and gp41 sequence regions are labelled and shaded to indicate the borders of 
each region. 
 
 
Figure 4.2: The CAP45.G3 computationally determined model vs. a crystal 
structure 
3D representation of the N-linked glycosylation sites of the (a) CAP45.G3 strain 
(computationally determined) and the (b) clade A BG505 strain88 (crystal structure). 
The protein and glycan residues are shown as surfaces and the glycans are labelled 
according to HXB2 numbering. The depicted orientation is such that the lipid 
membrane is located at the top and the V1/V2-loop regions are at the bottom of the 
figure.	
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4.4.1 Region-specific changes in the average antibody-accessible surface area 
(AASA) between the wild-type and N301A mutant viruses 
 
To investigate how the glycan shield compensates for the loss of glycan N301 in 
CAP45.G3, we calculated the antibody accessible surface area (AASA) of the wild-
type and N301A mutant models using a 10 Å probe (as an approximation of the size 
of an antibody87) with Naccess146. When directly comparing AASA values between the 
wild-type and mutant simulations, there are differences due to underlying protein 
movement (particularly in the loop regions) and as a result of the loss of a glycan. In 
order to isolate the effect of the glycan loss, we divided the AASA of each residue by 
its AASA when all glycans are removed from the same simulation. The non-
glycosylated value represents the “maximum” possible AASA for a residue. We next 
compared these AASA ratios between the wild-type and N301A mutant simulations 
using a bootstrap approach (see Methods section) to calculate which residues 
displayed a statistically significant (5% significance level) increase in the average 
AASA ratios between the wild-type and N301A mutant simulations.  
 
From the statistically significant subset (Figure 4.3, blue and orange residues), we 
distinguished those residues with a considerable increase in their AASA ratios, i.e. an 
average increase of 10% or greater, which we define as ‘substantial’ (Figure 4.3, blue 
residues), to further isolate those residues that were most affected by the loss of 
glycan N301. Residues identified in this manner were observed across all protomers 
and a total of 14, 42 and 18 residues were found for protomers A, B and C, 
respectively. Two clusters, one within the V3 region (Figure 4.3, pink and outlined) and 
one within the CD4 binding site region (Figure 4.3, green and outlined), were apparent. 
 
These clusters (Figure 4.3 (a) and (b), blue clusters) with a substantial increase in their 
AASA ratios (average increase of 10% or greater) surround the N301A mutant site, 
and since the clusters fall within the V3 loop and CD4 binding site regions, we defined 
each cluster as the “V3 sub-region” (including residues 303-305, 321-322, 323, and 
440) and “CD4 sub-region” (including residues 198, 365, 367, 368, 460, 462, and 464) 
(Table 4.1). 
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Figure 4.3: AASA for the CAP45.G3 N301A mutant model 
N301A mutant model with different orientations (A – C, 120° increments) to show each 
protomer (different shades of tan) and the residues with statistically significant 
increases in their average AASA ratios relative to the wild-type simulation (difference 
in average AASA <10% is orange, ≥10% is blue). A statistically significant increase 
was evaluated at a 5% significance level using a bootstrap approach (see Methods). 
The V3 (pink) and CD4 (green) regions are outlined. 
 
Table 4.1: Residues with significantly different AASA values between the wild-
type and N301A mutant simulations.  
SUB-REGION [ENV REGION] RESIDUES 
V3  [V3] 303-305, 321-322, 323, [C4] 440 
CD4  [C2] 198, [C3] 365, 367, 368, [V5] 460, 462, 464 
 
For these V3 and CD4 sub-regions, we calculated the average AASA ratios over time 
(glycosylated region total, over non-glycosylated total averaged over time) for the 
protomers of the wild-type and N301A mutant models ((Table 4.2). Apart from the CD4 
sub-region on protomer A, the average AASA values are substantially higher for the 
N301A mutant sub-regions on protomer B (33% for the CD4 sub-region and 14% for 
the V3 sub-region, N301A mutant virus) than for the other N301A mutant or wild-type 
protomers. 
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Table 4.2: Average AASA ratios (%) of the residues for the wild-type (WT) and 
N301A mutant (M) viruses that form part of the CD4 sub-region and V3 sub-
region.  
 Protomers 
 A B C 
 WT M WT M WT M 
CD4 sub-region 30 30 8 33 20 4 
V3 sub-region <1 0 <1 14 <1 <1 
 
Because the laboratory study showed that the N301A mutant strain had increased 
resistance to VRC01, and VRC01-like, antibodies compared to the wild-type strain, we 
also calculated the AASA ratios for the residues that form part of this epitope (residues 
[C1] 123, 128, 129, [C2] 276, 278-283, [C3] 365-368, 371, [C4] 427-430, 455-459, [V5] 
460-461, 463, 465-467, 469, 471, [C5] 472, 474, 476182). Apart from protomer C, 
where there was a substantial decrease in the AASA ratio for the N301A mutant model 
(wild-type: 11% and N301A mutant: 2%), the wild-type and N301A mutant ratios 
remained relatively unchanged for protomers A (wild-type: 11% and N301A mutant: 
16%) and B (wild-type: 10% and N301A mutant: 14%). 
 
4.4.2 Glycan conformational changes around the N301A mutation 
 
As shown in previous studies42,44,53–55, and evident from the AASA ratio results 
focussing on glycan N301, glycosylation shields the underlying protein. To fully 
understand the shielding capacity of any glycan, it is important to establish which 
glycans are capable, and most likely given their proximity, to affect the AASA of a 
particular protein residue. To achieve this, we determined the nearest glycan to each 
protein residue by calculating the distances between its atoms and all the atoms of 
each of the glycans for the wild-type and N301 mutant trimer models. Since the 
systems are dynamic, the nearest glycan can vary between frames and we defined 
each glycan’s ‘neighbourhood’ as the region that includes all the protein residues 
nearest to that glycan in the majority of the frames. For example, the protein residues 
surrounding glycan N442 form the neighbourhood of glycan N442 and can be 
represented on the 3D structure. These calculations allow us to determine which 
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glycans shield the residues of the sub-regions identified during the AASA calculations 
(Table 4.1).  
 
We specifically focus on comparing the neighbourhoods of the N301A mutant 
protomers to their wild-type counterparts, since the starting structures are identical 
and thus the differences in glycan neighbourhoods are likely to be due to the loss of 
glycan N301. To further visualise and interpret the 3D representation of the glycan 
neighbourhoods, we also calculate the average centre of mass position (to illustrate 
the directionality of the change), throughout the simulation, for each glycan. The 
results are described for the two sub-regions surrounding the N301A mutation, CD4 
and V3, identified during the AASA calculations. 
 
CD4 sub-region:  Our neighbourhood calculation determined which glycans were 
nearest to each of the residues within each sub-region. For the C3 residues (CD4 sub-
region, Table 1), glycan N386 was the nearest to these residues for all wild-type 
protomers, as well as for protomers A and B of the N301A mutant, whereas glycan 
N197 was the nearest on protomer C of the N301A mutant (Table 4.3). To further 
investigate how glycan N197 replaces glycan N386 as nearest glycan to the C3 
residues, we represent their 3D neighbourhoods on all protomers (Figure 4.4). There 
is a clear difference in the conformation of glycan N197 (protomer C; N301A mutant) 
when compared to its wild-type counterpart, and this conformational change results in 
a shift in the residues contained in its neighbourhood (Figure 4.4 (a) and (b), protomer 
C). A large proportion (29%) of the neighbourhood of the wild-type glycan N197 
(protomer C) contains residues from the V3 region of protomer B. However, the 
neighbourhood of glycan N197 of the N301A mutant includes a large proportion (31%) 
of CD4 binding residues from protomer C and five fewer V3 residues of protomer B 
than the wild-type. 
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Table 4.3: The glycans nearest to the two protein clusters, with a statistically 
significant and substantial (≥10%) increase in their average AASA ratio (CD4 
and V3 sub-region), for the three protomers (A, B and C). 
 Protomers 
 A B C 
CD4 sub-region:    
Wild-type N386, N463 N386, N355 N276, N386, N463 
N301A mutant N276, N386 N386, N463 N197, N276, N463 
    
V3 sub-region:    
Wild-type N156, N262, N442 
N156, N197, N301, 
N442 
N156, N197, N262, 
N301 
N301A mutant N156, N262, N442 N156, N442 N156, N262 
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Figure 4.4: Neighbourhood of the CD4 sub-region 
Neighbourhoods of the (A) wild-type and (B) N301A mutant glycans nearest to the 
CD4 sub-region for the three protomers (A, B, and C): glycans N197 (orange), N301 
(blue, only present in the wild-type), and N386 (pink). Horizontal lines represent 
residues that are in different neighbourhoods when comparing the wild-type and 
N301A mutant. The arrows originate from the Cα atom of the Asn and end at the 
average centre of mass position for the selected glycans. The representations are 
cropped around the CD4-binding site of each protomer and the surface representation 
of residues on adjacent protomers are shown as opaque. 
 
Also, for protomer C of the N301A mutant, a change in the conformation of glycan 
N386 is associated with the change in conformation of glycan N197 (Figure 4.4 (b) 
protomer C), which causes the exclusion of any CD4 binding residues from glycan 
N386’s neighbourhood. Conversely, glycan N386 of the N301A mutant protomer A 
also undergoes a conformational change (Figure 4.4 (b) protomer A), but this change 
results in the inclusion of an equivalent number of CD4 binding residues as its wild-
type counterpart. 
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V3 sub-region:  The neighbourhoods of the glycans nearest to the V3 sub-region, 
N156, N262 and N442 (Table 4.3), are shown in Figure 4.5. Additionally, the 
neighbourhood of glycan N446 is included because its neighbourhood is itself 
enclosed by the abovementioned V3 sub-region glycan neighbourhoods (Figure 4.5 
(a) protomer B). There are marked differences between the conformations of glycans 
N442 and N446 of the N301A mutant model on protomer A, and to a lesser extent 
those on protomers B and C, when compared to their wild-type counterparts (Figure 
4.5).  
 
 
Figure 4.5: Neighbourhood of the V3 sub-region 
Neighbourhoods of the (A) wild-type and (B) N301A mutant glycans nearest to the V3 
sub-region for the three protomers (A, B, C): glycans N156 (orange), N262 (yellow), 
N301 (blue, only present in the wild-type), N442 (pink), and N446 (green). Horizontal 
lines represent residues that are in different neighbourhoods when comparing the wild-
type and N301A mutant. The arrows originate from the Cα atom of the Asn and end 
at the average centre of mass position for the selected glycans. The representations 
are cropped around the V3 region of each protomer and the surface representation of 
residues on adjacent protomers are shown as opaque. 
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Glycan N442 (N301A mutant) re-orientates towards the N301A site in all the protomers 
to varying degrees, with the largest shift occurring on protomer A (Figure 4.5 (b) 
protomer A) and only a slight movement on protomer C (Figure 4.5 (b) protomer C). 
Comparatively, glycan N446 (N301A mutant) re-orientates towards the N301A site on 
protomers A and C only (Figure 4.5 (b) protomers A and C), while for protomer B, the 
glycan shifts away from the N301A site (Figure 4.5 (b) protomer B). Finally, glycan 
N262 on protomer C (N301A mutant) also re-orientates towards the N301A site 
(Figure 4.5 (b) protomer C). 
 
4.4.2.1 Protomer-specific glycan conformational changes that compensate for the loss 
of glycan N301 
 
Since glycans N197, N262, N386, N442 and N446 were identified as the glycans 
nearest to the protein residues that had increased AASA ratios and showed 
conformational changes, we investigated whether these conformations were viable 
when glycan N301 was present, i.e. whether or not they caused large conformational 
clashes with any of the wild-type glycans, which would imply that the N301A mutant 
glycan conformations are impossible in the wild-type model. Hence, we superimposed 
the N301A mutant glycan conformations of each protomer onto its wild-type 
counterpart and directly compared each time point. For each of these N301A mutant 
glycans, we calculated the proportion of frames where an atomic overlap was 
observed with any of the wild-type glycans, as well as the average number of atoms 
with an atomic overlap with wild-type glycans (Table 4.4). Due to differences between 
the results, each protomer is described separately. 
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Table 4.4: Overlap calculations between the N301A mutant glycan substitute 
and any wild-type glycan.  
N301A mutant 
glycan 
substitute 
Wild-type glycans 
 that clash with  
the N301A substitute 
Protomers 
A B C 
N197 
N133  53%a; 45b  
N156c 86%; 58 68%; 46 <1%; 2 
N160  33%; 30  
N301 21%; 37 10%; 25 12%; 27 
N386 55%; 25 <1%; 6 94%; 115 
     
N262 
N301 77%; 22 3%; 7 97%; 58 
N334  <1%; 1 16%; 6 
N442 90%; 42 12%; 13 67%; 26 
N446 6%; 9 99%; 175 85%; 23 
     
N386 
N137 9%; 5 17%; 67  
N197 11%; 13 1%; 14 6%; 7 
N463 13%; 33 22%; 20 8%; 43 
     
N442 
N133   34%; 14 
N137  13%; 49 59%; 43 
N156 21%; 33 7%; 43  
N262 52%; 9 2%; 13 1%; 6 
N301 99%; 226 29%; 28 19%; 14 
N446  31%; 45 36%; 19 
     
N446 
N137 15%; 13  1%; 12 
N262 >99%; 80 88%; 86 24%; 9 
N301 22%; 18 <1%; 16 66%; 36 
N334  24%; 56 3%; 49 
N442 95%; 148 6%; 16 96 %; 125 
aThe proportion of frames with a overlap (%).  
bThe average number of overlapping atoms in those frames with a overlap. Wild-type glycans are 
omitted if the proportion of frames with an overlap is below 10% on all protomers. 
cWild-type glycans on a different protomer from that of the N301A mutant glycan are shown in bold.  
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Protomer A:  The glycan with the largest and most frequent overlap with glycan N301 
(protomer A; wild-type) was glycan N442 (N301A mutant). In 99% of the frames, 
glycan N442 occupies the same space as glycan N301 does in the wild-type simulation 
with an average of 226 overlapping atoms per frame (Table 4.4). A Man-9 glycan 
(described in the Methods section) has a total of 244 atoms; 226 clashes therefore 
imply that almost all of the atoms overlap with glycan N301 and that glycan N442 
(N301A mutant) occupies most of the space vacated by glycan N301 for practically 
the entire duration of the trajectory. Similarly, glycan N262 (protomer C; N301A 
mutant) occupies some (22 clashes per frame) of the space vacated by glycan N301 
for a large (77%) proportion of the trajectory (Table 4.4).  
 
Concurrently, the space vacated by glycans N442 and N262, is in turn occupied by 
glycan N446 (N301A mutant). This is evident from the large proportion of frames with 
an atomic overlap, as well as a large average number of overlapping atoms per frame 
(Table 4.4), observed between glycan N446 and glycans N442 (95%, 148 overlapping 
atoms) and N262 (>99%, 80 overlapping atoms). 
 
Protomer B:  None of the glycans on protomer B have noticeably large overlap with 
glycan N301 on the wild-type protomer B, which suggests that the wild-type glycan 
conformations are maintained on the N301A mutant protomer B.  
 
Protomer C:  The largest overlap with glycan N301 were observed for glycan N262 
(N301A mutant), where 97% of the frames have an atomic overlap with glycan N301, 
with an average of 58 overlapping atoms per frame, and for glycan N446 (N301A 
mutant; 66%, 36 overlapping atoms; Table 4.4). 
 
Lastly, the nearest glycan results highlighted the conformational change of glycan 
N197 (protomer C; N301A mutant). This shifted conformation appeared to occupy the 
space where glycan N386 of the wild-type is located, which is confirmed here by the 
large overlap observed between glycan N197 (N301A mutant) and glycan N386 (wild-
type). Only a small overlap is observed for glycan N386 (protomer C; N301A mutant) 
with glycan N301, which suggests that the adjusted conformation for this glycan is 
viable in the presence of glycan N301. The conformation of glycan N197 (protomer C; 
N301A mutant), however, has moderate overlap with glycan N301 (12%, 27 
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overlapping atoms). Further investigation revealed that glycan N197 overlaps with 
glycan N301 at two specific time intervals (14-35 ns and 346-500 ns) and not 
throughout the simulations. This suggests the ‘new’ conformation for glycan N197 can 
coexist with glycan N301. 
 
4.4.3 Domino effect of glycan conformational changes: how changes propagate and 
taper off 
 
During the investigation of the protomer specific conformational changes, we observed 
that the space generated by removing glycan N301 is occupied by another glycan, 
which in turn leaves a new space that is then occupied by yet another glycan. To 
extend the investigation of glycan conformational changes beyond those glycans 
nearest to the N301A mutation site, while maintaining the relevance of the changes 
(i.e. the changes associated with the loss of the N301 glycan), we compare the 
frequency of the hydrogen bonds that form between glycans in the wild-type and 
N301A mutant. Substantial changes in the hydrogen bond network allude to changes 
in the conformations of glycans adjacent to those glycans near the N301A mutation 
site. For each of the identified glycans, we calculated the average centre of mass 
position, throughout the simulation, for the wild-type (Figure 4.6 (a), orange arrows) 
and N301A mutant (Figure 4.6 (a), blue arrows).
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Figure 4.6: Domino effect of glycan conformational changes on the three 
protomers 
(A) Structures illustrating the location of glycans. The arrows originate from the Cα 
atom of the Asn and end at the average centre of mass position for the selected wild-
type (orange) and N301A mutant (blue) glycans identified by the hydrogen bond 
analysis for protomers A, B and C. Curved arrows indicate the degree of change in 
directionality, e.g. the large movement for glycan N399 on protomer C. The 
representations are cropped around the V3 region of each protomer and the surface 
representation of residues on adjacent protomers are shown as opaque. (B) Each 
schematic – protomer A, B and C - shows the hydrogen bond network starting from 
glycan N442 (first node) on protomer A, B and C, respectively. Solid borders around 
glycan nodes and broad arrows represent glycans and interactions that form part of 
the domino effect considered, whereas dotted borders and fine arrows indicate any 
glycans and interactions outside the considered domino effect. The arrows connecting 
glycan nodes distinguish interactions that are either greater on the wild-type (WT; 
orange) or on the N301A mutant (M; blue). 
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Protomer A:  The conformational change domino effect is clear on protomer A, where 
the conformations of six glycans (N442, N446, N137, N133, N386 and N463) are 
affected. In the wild-type, these glycans are interlinked by sequential hydrogen bonds. 
However, the interlinked nature of these glycans is broken in the absence of glycan 
N301, and two glycan clusters exist on the N301A mutant. The first cluster includes 
glycans N442, N446 and N137, and the second glycans N133, N386 and N463.  
 
Glycan N442 occupies the space vacated by glycan N301 (Figure 4.6 (a) protomer A). 
In turn, the space vacated by glycan N442 is occupied by glycans N446 and N137 
(Figure 4.6 (a) protomer A). These rearrangements result in an increased interaction 
between glycans N442 and N446 (9% wild-type vs. 20% N301A mutant; Figure 4.6 (b) 
Protomer A). Glycan N137 on the other hand, no longer interacts with glycan N442 
(33% wild-type vs. 0% N301A mutant; Figure 4.6 (b) Protomer A) but instead has an 
increased interaction with glycan N446 (14% wild-type vs. 59% N301A mutant; Figure 
4.6 (b) Protomer A). The second cluster is separated from the first by the change in 
conformation of glycan N137 (Figure 4.6 (a) protomer A), which eliminates the 
interaction between glycans N137 and N133 (13% wild-type vs. 0% N301A mutant; 
Figure 4.6 (b) Protomer A). This reduced structural hindrance near glycan N133 may 
allow for its re-orientation (Figure 4.6 (a) protomer A) and subsequent increased 
interaction with glycan N386 (5% wild-type vs. 30% N301A mutant; Figure 4.6 (b) 
Protomer A), as well as with glycans N463 (2% wild-type vs. 16% N301A mutant; 
Figure 4.6 (b) Protomer A). There is also an increased interaction between glycan 
N386 and N463 (0% wild-type vs. 17% N301A mutant; Figure 4.6 (b) Protomer A). 
Other changes in the hydrogen bond network quickly taper off to glycans located at 
the protein apex (Figure 4.6 (b) Protomer A). 
 
Protomer B:  Apart from glycans N156, N197, N262, N386, N442 and N446, which 
were previously investigated on protomer B during the neighbourhood and subsequent 
overlap analyses, the hydrogen bond network further identifies interaction with glycan 
N334 (N301A mutant; Figure 4.6 (b) Protomer B). However, glycan N334 shows no 
movement when compared to its wild-type counterpart (Figure 4.6 (a) protomer B), 
which indicates that there was almost no domino effect. 
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Protomer C:  The domino effect was similar to that of protomer A, however, glycans 
N446 and N463 (N301A mutant) are not implicated, whereas glycan N399 is. The 
hydrogen bonds between glycans N137 and N133 persist, although at a reduced scale 
compared to the wild-type (76% wild-type vs. 56% N301A mutant; Figure 4.6 (b) 
Protomer C). The hydrogen bonds between glycans N133 and N386 were not present 
in the wild-type and are substantial in the N301A mutant (0% wild-type vs. 39% N301A 
mutant; Figure 4.6 (b) Protomer C). The persistent interaction between glycans N133 
and N137 results in all these interlinked glycans collectively moving closer to the gap 
left by the N301A mutation on the N301A mutant model (Figure 4.6 (a) protomer C). 
In our model, this movement, coupled with the increase in interaction between glycans 
N133 and N386, likely contributes to the ‘new’ conformation of glycan N197 (protomer 
C; N301A mutant). 
 
4.5 Discussion 
 
Here, we analysed two 500 ns molecular dynamics simulations (CAP45.G3 wild-type 
and CAP45.G3 N301A mutant) and show that the systems imitate in vitro 
neutralisation data – the glycan shield restores itself and retains its ability to protect 
key epitopes after the removal of glycan N30153. This was in contrast to a second 
isolate, Du156.12, where the laboratory results showed that this N301A mutant virus 
had increased sensitivity to a panel of sera from chronically infected individuals53, and 
where the in silico simulations of the Du156.12 wild-type and N301A mutant models 
were vastly different to that of the CAP45.G3 models (Supplementary Figure S4.1). 
The key observation during our initial, in silico, comparative analysis was that the 
conformational differences of the glycans on the wild-type models, as well as the 
landscapes around each of these glycans, likely affected the ultimate changes in the 
glycan shields. The importance of this collective behaviour of glycans on the Env 
surface was previously noted by Lemmin et al.86, describing several, relatively stable, 
glycan microdomains86. Since Moyo et al. 53 speculated that the CAP45.G3 virus 
typified a subset of viruses where the loss of glycan N301 was tolerated, i.e. the 
protective qualities of the glycan shield, or perhaps the glycan microdomain, were 
retained, the focus of our manuscript was on providing a thorough account for the 
suggested compensation. Therefore, for the CAP45.G3 modelled systems, we 
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describe, in detail, the change in the glycan landscape, and cascade of events, that 
may have contributed towards the maintenance of the glycan shield for this viral 
isolate. The only structural difference between the model simulations is the presence 
or absence of the N-linked glycan at position 301 and the stability of the distinct glycan 
interactions throughout each simulation suggests that the observed differences are 
meaningful.  
 
We observed clear evidence of compensation for two of the three N301A mutant 
protomers (A and C) within the trimeric protein structures. The antibody accessible 
surface area (AASA) ratios of these two protomers are equivalent to their wild-type 
counterparts, despite the lack of glycan N301. However, unexpectedly, there are 
differences in the particular glycans compensating for the loss. Glycan N442 bears the 
bulk of the compensation burden on protomer A, whereas glycans N446 and N262 
share the burden on protomer C. However, even though glycan N442 bears the 
compensation burden on protomer A, its ‘new’ conformation was considerably 
influenced by glycan N446 on the same protomer. The spatial pressure from glycan 
N446 resulted in a glycan N301-like conformation observed for glycan N442 (protomer 
A; N301A mutant). Therefore, this suggests that in our model, glycan N446 is essential 
for maintaining the glycan shield by not only directly bearing a part of the 
compensation burden, but also through its substantial influence on the conformation 
of glycan N442. Although we are currently unaware of studies describing the influence 
of glycan N446 on epitopes accessibility, there have been reports on glycan N442 and 
its role in shielding epitopes of the CD4 and gp41 regions55. This suggests that glycan 
N446 may also influence the availability of epitopes in these regions.  
 
In contrast to protomers A and C, we found ambiguous evidence of compensation for 
protomer B (N301A mutant), where increased AASA ratios were observed for various 
residues. The apparent lack of compensation for protomer B can be, in part, attributed 
to the lack of conformational change in glycan N442, as well as the substantial change 
in the conformation of glycan N197 on protomer C (adjacent to protomer B), which is 
commonly reported as shielding the CD4 and V3 regions54,55.  
 
We also identified specific glycan conformational changes that have a direct impact 
on the accessibility of the modelled protein surface. The conformational change of 
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glycan N197 (protomer C; N301A mutant) has drastic implications for the AASA ratios 
of the residues of the CD4 sub-region and VRC01 epitope on protomer C. Both the 
residues in the CD4 sub-region (Table 4.1) and the residues of the VRC01 epitope 
show decreased AASA ratios for protomer C of the N301A mutant model. Glycan N386 
(protomer A; N301 mutant) also plays a role in maintaining the AASA ratio of residues 
that form part of the CD4 sub-region (Table 4.1); however, in comparison, the 
conformational change of glycan N386 does not lead to a decrease in the AASA ratio 
of the VRC01 epitope, but instead, the removal of glycan N301 leads to a slight 
increase in AASA for this region (protomer A). Thus, based on the AASA results, 
glycan N386 may not contribute to the increased resistance observed to the VRC01 
bNAb (unlike glycan N197), which is contrary to evidence of this glycan shielding the 
CD4 binding site70,183.  
 
Despite the popularity of calculating the AASA86,87,89,90 as a predictor of whether 
residues are accessible by antibodies, it remains to be seen whether they are useful, 
and accurate, for describing the contact between HIV-1 gp160 and antibodies. For 
example, there are considerable differences between the conformation of particular 
HIV-1 envelope glycans co-crystalised with VRC01 compared to an unliganded crystal 
structure88. Additionally, Stewart-Jones et al.88 showed that substantial overlap 
occurred between broadly neutralising antibodies and one or more glycan/s 
throughout 500 ns trajectories, suggesting that known broadly neutralising antibodies 
likely need to accommodate at least one glycan during the binding process. Given this 
evidence, the passive nature of AASA calculations is likely to result in an 
underestimation of the accessibility of residues in regions where the “shielding” 
glycans can be flexible. This may be the case for glycan N386 (protomer A; N301A 
mutant), where the flexibility of glycan N133 (protomer A; N301A mutant) increased 
the structural hindrance near glycan N386. This, in turn, reduced the freedom of 
movement of glycan N386 resulting in slightly higher AASA ratios around this glycan 
in our model, but potentially still leading to increased VRC01 resistance due to its 
reduced flexibility to accommodate the antibody. However, complete resistance to 
VRC01 was not observed for the CAP45.G3 N301A mutant53 and it is unknown if 
glycan N386 plays a role, or whether the conformation of glycan N197 is solely 
responsible for, the observed increase in VRC01 resistance.  
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Due to the potential caveats associated with AASA, we extended the analyses to 
examine the capacity for each glycan to act as a shield to its surrounding protein 
residues by determining which glycan was the nearest to each protein residue across 
time. A benefit of this analysis is the ability to generate leads in the cases where the 
binding site of a particular antibody is known and point mutations that would reduce 
resistance are sought. The analysis also provides an intuitive and easy representation 
of the glycan positions over time. For example, the large change in the conformation 
of glycan N197 (protomer C; N301A mutant) is apparent and easily related to a change 
in the conformation of glycan N386 (protomer C; N301A mutant; Figure 4.4 (b)). 
 
The nearest glycan approach also presents certain disadvantages; small differences 
are easily overlooked and, since the crowded nature of the HIV glycan shield can result 
in large conformational differences that change the glycan neighbourhood only 
slightly, small changes could be an important consideration. Additionally, the nearest 
glycan may not necessarily be the shielding glycan, which is the case when glycans 
are buried and therefore relatively inflexible. Glycan N262, where a large 
neighbourhood was observed, presents one such case. Visual inspection suggested 
that other glycans, only slightly further away, may have greater capacity to shield 
certain residues assigned to glycan N262. However, due to its static, buried, nature, 
these residues were consistently assigned to glycan N262, and therefore removing it 
prior to the analysis might be prudent.  
 
The length of the trajectory (MD simulation), which relates to the uncertainty 
associated with observing enough of the sample space during the simulation is a key, 
and ongoing, problem of molecular dynamics research of large structures. We would 
expect that, on a long enough time scale, the glycans would populate similar volumes 
across the protomers. However, the glycans of each protomer adopt distinct 
conformations that do not interconvert during our simulation. Unlike the protomer 
scissoring reported by Lemmin et al.86, we did not observe this effect for either the 
wild-type or N301 mutant model simulations, but did identify small scale, protomer 
specific, protein movements (data not shown). Nonetheless, despite the differences, 
the data for each protomer is self-consistent and stable; i.e. although the effect of 
glycosylation on the AASA is different across protomers, the effect is constant in each 
protomer throughout the simulation. A possible solution to this issue is to use replicate 
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exchange (which should explore greater proportions of the potential energy surface) 
but requires more study. Yang et al.89 used replicate exchange and described 
enhanced sampling for glycosylated Env trimers; it would be worthwhile for future 
studies to compare the degree of convergence in the observed glycan shapes 
between different protomers in the different approaches. The advantage of the 
molecular dynamic protocol used here is that it clearly shows that there are glycan-
glycan and glycan-protein interaction networks that extend across the Env surface and 
persist on at least a 500 ns timescale. Although the lack of convergence between 
protomers is concerning for drawing statistically strong conclusions, it is interesting, 
and important, to note that the interactions driving the observed differences occur at 
longer time scales than 500 ns.  
 
Finally, our modelling results suggest that the loss of a glycan, due to a point mutation, 
can result in a cascade of events on the same protomer (intra-protomer) that could 
contribute towards increased resistance to epitopes distal to the location of the initial 
sequence mutation causing the cascade of events – in this case the VRC01 epitope. 
We initially speculated that this epitope would be influenced directly by the N301A 
mutation via cross-protomer interactions (through the additional space created), since 
it has been shown that the N301 glycan overlaps with VRC01 on an Env crystal 
structure bound to this antibody88. However, here we present evidence for intra-
protomer conformational rearrangements of specific glycans, which we believe 
contributed to the increased resistance of the CAP45.G3 N301A mutant to VRC01, 
and other VRC01-like, antibodies.  
 
It is unlikely that the glycan shield of the CAP45.G3 isolate is unique in its ability to 
compensate for a loss of a glycan, however, the particular glycan distribution and 
clustering meant that the absence of glycan N301 was not crucial for the maintenance 
of its protective qualities as a whole. The further implication is that different viral Env 
glycoproteins will likely each have their own set of glycans that are, individually, either 
dispensable or indispensable in forming, and maintaining, the glycan shield. This 
argument extends to the asymmetrical effects seen across protomers; the degree of 
glycan conformity, both in terms of site occupancy and glycan type, between the three 
protomers of an Env trimer is currently unknown and largely unacknowledged in HIV-
1 Env studies. It is completely plausible that the HIV-1 glycans of Env trimers vary 
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across their protomers and that these differences affect the neutralisation efficiency of 
glycan-dependent antibodies in different ways. This ties in with the knowledge that 
antibodies are not always present on all three protomers, and that glycan 
heterogeneity is one likely cause of this finding115,184.  
 
Despite the caveats associated with molecular dynamics simulations, as well as the 
immense potential variation in the Env glycan shields of HIV-1 isolates, this study 
provides a detailed investigation of how the loss of a single HIV-1 Env glycan does not 
result in a hole, but rather results in a cascade of events that may have led to the 
maintenance of the glycan shield and increased resistance to a broadly neutralising 
antibody observed for the viral isolate. Given the focus on Env glycans within HIV-1 
vaccine research, and the importance of these glycans for bNAb binding, we hope the 
techniques and results presented here will encourage further in-depth consideration 
of the virus-specific glycan landscapes. Future investigations, both in vitro and in silico, 
focussing on different glycan point mutations and including systems composed of a 
variety of glycan forms, will demonstrate to what extent these results translate, and 
are predictive, across viral isolates and subtypes.  
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Chapter 5 Conclusion and Future Work 
 
This manuscript focussed on examining the HIV-1 Env glycan shield using molecular 
dynamics simulations. These molecular dynamics simulations were carried out on the 
computationally determined, fully glycosylated, Env structures of two wild-type HIV-1 
subtype C isolates and their paired N301A mutant variants, i.e. where glycan N301 
was removed. These particular strains were used since in vitro data showed that the 
absence of glycan N301 had a substantially different effect on the neutralisation 
sensitivity of the two strains, despite the large (~90%) identity between the sequences. 
Therefore, the project focussed on using computational techniques to describe the 
differences between the glycan shields of these two isolates and to identify the 
particular glycans that contributed toward maintaining the glycan shield of the resistant 
strain (to both frequently elicited antibodies and a bNAb), despite the missing glycan. 
However, the literature on the analysis of molecular dynamics simulations in this 
context is limited and, consequently, an additional goal for this study emerged very 
quickly, which was to determine what analyses were not only feasible, but also 
provided useful features for comparison. 
 
Initially, in order to understand the potential impact of removing glycan N301, static 
state representations of the fully glycosylated Env trimer structures were compared 
(Chapter 2). These results suggested that the removal of glycan N301 likely exposed 
a greater surface area on one model compared to the other and in that way affected 
the neutralisation sensitivity of each strain uniquely, which was in agreement with the 
in vitro study. However, since molecular molecules are dynamic and change 
conformation over time, the static state representations offered only limited information 
for carrying out comparative studies.  
 
Therefore, the next step was to carry out and compare molecular dynamics 
simulations of the modelled structures (Chapter 3). The results of these comparisons 
revealed glycan position-specific differences. For example, the N442 and N197 
glycans were more likely to vary between models than the N156 glycans, irrespective 
of which models were compared. Nevertheless, the comparisons also demonstrated 
that not only can equivalent glycans adopt distinct conformations specific to each wild-
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type model, but that model-specific conformations emerged when glycan N301 was 
removed from the glycan shield. Moreover, the N301A mutant model-specific glycan 
conformations were directly associated with the protein residues ultimately exposed. 
The difference in the locations of these exposed regions on the N301A mutant models 
may explain the varied resistant to neutralising antibodies observed, in vitro, after 
glycan N301 was removed. Furthermore, the results also demonstrated that each 
glycan shield is conformationally unique, regardless of large sequence identity (e.g. 
between the wild-type models) or where the glycan shields differ by only a single 
glycan (e.g. between a wild-type model and its N301A mutant counterpart).  
 
However, due to the random variation implicit in macromolecular structures, a degree 
of uncertainty remained regarding whether the conformational heterogeneity observed 
for glycans located farther from the N301A mutation were a direct result of the N301A 
mutation. Additionally, these result did not provide substantial insight on how one of 
the strains remained resistant to the frequently elicited neutralising antibodies and had 
increased resistance to a CD4-binding site bNAb despite the loss of glycan N301. 
Therefore, due to this remaining uncertainty, a detailed comparison between the wild-
type simulation and its N301A mutant counterpart was carried out on the resistant 
strain (Chapter 4). The results of the detailed computational analysis showed that the 
glycan shield of this strain retained its ability to shield the protein residues even after 
the removal of glycan N301. Moreover, the change in the glycan landscape, and 
cascade of events, that contributed towards the maintenance of this glycan shield and 
the increased resistance to a bNAb epitope located at the edge of the cascade, were 
discernible. 
 
This thesis therefore provides a detailed analysis of the HIV-1 Env glycans and their 
capacity to protect the underlying protein and, in some cases, shield the virus against 
frequently elicited neutralising antibodies. During the study, several key 
considerations, and important opportunities for further explorations, for vaccine and 
treatment studies focussing on HIV-1 Env were highlighted. These include: 
 
- PNGS profiles can vary substantially despite large sequence identity 
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- The conformations of equivalent glycans (glycans that share an HXB2 
reference sequence position) can be distinct between strains and, therefore, 
this should be considered during all Env glycan shield comparisons 
- The conformation of a glycan is dependent on the conformations of the 
surrounding glycans 
- Protomers may present alternate equilibrium states 
- Glycans move and adjust to accommodate changes in the surrounding 
landscape 
- Glycan adjustments, after a glycan is removed, could lead to the maintenance 
of the glycan shield 
 
These considerations came to light throughout this project where, broadly speaking, 
the analyses always focussed on one of three glycan features, i.e. the glycan’s 
surroundings, its conformation, or its function (shield and/or target). These glycan 
features are intrinsically related since a change in one likely impacts the others. For 
example, removing a glycan changes the surroundings of the neighbouring glycans, 
which themselves could change conformations as a result, and this could affect the 
region they shield. Therefore, a single change in the glycan shield can affect the region 
each glycan is capable of shielding, i.e. its fundamental function within the glycan 
shield. However, it is important to note that an altered feature does not necessarily 
imply that the glycan shield is impaired. In fact, glycans appear to be capable of 
altering their features over time, and these changes may even be distinct across 
protomers, as demonstrated in this thesis where unique glycan features were 
observed for the different protomers of the same model. Thus, it is important that 
glycan features are not considered in isolation at a single time point, but rather as an 
integrated network that changes over time. 
 
However, this type of analysis is complex, since determining a fully glycosylated HIV-
1 Env trimer structure and carrying out molecular dynamics simulations are non-trivial 
tasks. The glycosylated structures can either be obtained from deposited X-ray crystal 
structures or computationally determined, as was done here. The considerable 
differences between these types of structures (Figure 4.2) demonstrate the 
advantages of computationally determined structures, which allow the composition of 
the system to be defined in much more detail. Together, the established methods that 
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predict protein structures from template crystal structures, the higher resolution of 
available HIV-1 Env crystal structures, and the development of tools that facilitate 
computational glycosylation of these models, will inevitably streamline the creation of 
computationally-determined glycosylated models and alleviate a substantial portion of 
the burden associated with performing HIV-1 Env molecular dynamics simulations. 
 
It is important to reiterate that, although this study has offered one of the current most 
systematic analysis of the molecular dynamics simulations of HIV-1 Env and its 
glycans, it was conducted on only 500 ns simulations of glycosylated Env trimers that 
lacked the MPER regions and where the glycan shield comprised of only 
Man9GlcNAc2 glycans. In the context of a virion, however, the Env trimer is 
membrane-bound with variations in occupancy and glycoforms at N-linked glycan 
sites, as well as glycoform micro-heterogeneity at the same N-linked glycan site (i.e. 
a wide spectrum of similar, but not identical, glycoforms have been identified at the 
same site). These features give rise to additional questions regarding the differences 
between glycan characteristics of Env glycoproteins. Therefore, future work will 
include investigating glycan features over longer time scales, the effect of various 
glycoforms at the same or different positions, and models that include both MPER and 
a membrane in order to determine the impact of membrane proximity on the 
surrounding glycans.  
 
In conclusion, the current study has demonstrated that the landscape of the glycan 
shield contains immense diversity, and that glycans that share an HXB2 reference 
sequence position will not necessarily conform in shape, dynamics and function 
between different strains. These conformational differences ultimately determine 
whether or not the glycan shield can compensate for the loss of a glycan. This is a 
key, and too often ignored, detail, since it directly relates to the main function of the 
glycans in their ability to shield and protect the virus from immune surveillance. The 
results from the analysis of the simulations in this thesis further highlight the 
remarkable potential of molecular dynamics simulations, which can be used as a 
powerful predictive technique to facilitate, and direct, laboratory studies focussing on 
vaccine research.  
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Supplementary Materials 
 
Chapter 3  
 
Figure S3.1: Conformational heterogeneity between wild-type glycan siblings 
and the N301A mutant siblings. 
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Figure S3.2: Standard PCA plots for the CAP45.G3 glycans 
The standard PCA plots for the CAP45.G3 paired-model comparison performed on 
the glycans of protomer A (A), B (B) and C (C). Demonstrating the projection of the 
frames onto the (i) first and second principal components as well as (ii) the proportion 
of the variance explained by the first three principal components. 
 
 
Eigenvalue 
Eigenvalue 
Eigenvalue 
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Figure S3.3: Standard PCA plots for the Du156.12 glycans 
The standard PCA plots for the Du156.12 paired-model comparison performed on the 
glycans of protomer A (A), B (B) and C (C). Demonstrating the projection of the frames 
onto the (i) first and second principal components as well as (ii) the proportion of the 
variance explained by the first three principal components. 
	
Eigenvalue 
Eigenvalue 
Eigenvalue 
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Figure S3.4: Standard PCA plots for the CAP45. G3 protein residues 
The standard PCA plots for the CAP45.G3 paired-model comparison performed on 
the glycans of protomer A (A), B (B) and C (C). Demonstrating the projection of the 
frames onto the (i) first and second principal components as well as (ii) the proportion 
of the variance explained by the first three principal components.	
	
Eigenvalue 
Eigenvalue 
Eigenvalue 
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Figure S3.5: Standard PCA plots for the Du156.12 protein residues 
The standard PCA plots for the Du156.12 paired-model comparison performed on the 
glycans of protomer A (A), B (B) and C (C). Demonstrating the projection of the frames 
onto the (i) first and second principal components as well as (ii) the proportion of the 
variance explained by the first three principal components.	
	
Eigenvalue 
Eigenvalue 
Eigenvalue 
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Figure S3.6: Standard PCA plots for the CAP45.G3 protomer glycans  
The standard PCA plots for the CAP45.G3 protomer comparison performed on the 
glycans. Demonstrating the projection of the frames onto the first and second principal 
components as well as the proportion of the variance explained by the first three 
principal components. 
	
	
	
Figure S3.7: Standard PCA plots for the CAP45.G3 protomer protein residues  
The standard PCA plots for the CAP45.G3 protomer comparison performed on the 
protein residues. Demonstrating the projection of the frames onto the first and second 
principal components as well as the proportion of the variance explained by the first 
three principal components.	
	
Eigenvalue 
Eigenvalue 
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Figure S3.8: Standard PCA plots for the Du156.12 protomer protein residues  
The standard PCA plots for the Du156.12 protomer comparison performed on the 
protein residues. Demonstrating the projection of the frames onto the first and second 
principal components as well as the proportion of the variance explained by the first 
three principal components.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Eigenvalue 
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Figure S3.9: AASA ratios for the Env regions 
AASA ratios (%), using a 10Å probe radius, of the Env region (C1-C5, gp41, and V1-
V5) for the three protomers A, B and C. The ratios are shown for each wild-type and 
N301A mutant simulations. 	
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Chapter 4  
 
	
Figure S4.1: Residue accessibility for the CAP45.G3 and Du156.12 N301A 
mutant models. 
The surface area accessibility for each residue on the (a) CAP45.G3 and (b) Du156.12 
N301A mutant models is shown on a scale where bright red represents least 
accessible and blue indicates high accessibility. The V3-loop and CD4 binding site 
regions are circled and labelled.  
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